Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Conditions
Keywords
CLDN 18.2, gastroesophageal junction cancer, adenocarcinoma, IMAB362, oxaliplatin, HER2, claudiximab, capecitabine, gastric cancer, HER2 Negative, zolbetuximab
Brief summary
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called GEJ cancer. Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body's immune system to attack the tumor. There is an unmet medical need to treat people with advanced stomach cancer or GEJ cancer. This study will give more information about how well zolbetuximab works when given with chemotherapy in adults with advanced stomach cancer or GEJ cancer. In this study, adults with advanced stomach cancer or GEJ cancer will either be given zolbetuximab with chemotherapy or a placebo with chemotherapy. A placebo looks like zolbetuximab but doesn't have any medicine in it. Zolbetuximab with chemotherapy has already been approved to treat stomach cancer and GEJ cancer in some countries. This study is being done in countries where zolbetuximab has not yet been approved for use. If zolbetuximab becomes approved for use in those countries taking part in this study, the people taking part in those countries will leave this study and receive licensed zolbetuximab. The main aim(s) of the study is(are) to determine the efficacy of zolbetuximab combined with chemotherapy compared to a placebo combined with chemotherapy in treating adults with Claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. Adults with locally advanced unresectable or metastatic stomach cancer or GEJ cancer can take part. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. A tumor sample of their cancer will also have the Claudin 18.2 protein. They may have been previously treated with certain standard therapies but have not been treated with chemotherapy for their cancer. People cannot take part if they need to take medicines to suppress their immune system, have blockages or bleeding in their gut, have specific uncontrollable cancers such as symptomatic or untreated cancers in the nervous system, or have a specific heart condition, or infections. The study treatments are either zolbetuximab with chemotherapy or placebo with chemotherapy. People who take part will receive just one of the treatments by chance. Study treatment will be double-blinded. That means that the people in the study and the study doctors will not know who takes which of the study treatments. Study treatment will be given in cycles. The study treatment is given to people slowly through a tube into a vein. This is called an infusion. The chemotherapy is called CAPOX (capecitabine and oxaliplatin) and will be given as an infusion and also as tablets. People will have 1 infusion of either zolbetuximab or placebo together with oxaliplatin chemotherapy in 3-week (21-day) cycles. People will also take 1 tablet of capecitabine (chemotherapy) twice a day for the first 2 weeks (14 days) of each cycle. People may receive zolbetuximab or placebo until their cancer worsens, they cannot tolerate the treatment, or they need to start another cancer treatment. People will receive CAPOX for up to about 6 months (8 treatment cycles). After the 6 months, people may receive capecitabine chemotherapy only, until their cancer worsens, they cannot tolerate the study treatment, or they need to start another cancer treatment. People will visit the clinic on certain days during their treatment. The study doctors will check if people had any medical problems from zolbetuximab or the other study treatments. Also, people in the study will have health checks. On some visits, they will have scans to check for any changes in their cancer. People will have the option of giving a tumor sample after their study treatment has finished. People will visit the clinic within 7 days after they stop their study treatment. People will be asked about any medical problems and will have a health check. People who start treatment with licensed zolbetuximab will not need to attend the clinic for further visits and will receive standard of care health checks. People who continue study treatment will visit the clinic at 1 and 3 months after they stop their study treatment. They will continue to have scans every 9 or 12 weeks to check for any changes in their cancer. They will have telephone health checks every 3 months. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their treatment or not.
Detailed description
After the marketing approval in Japan on 26 Mar 2024, this study continued as "post marketing clinical study" in Japan. In the rest of the countries which participated in this study, this study continued as clinical study.
Interventions
DRUGzolbetuximab
Zolbetuximab were administered as a minimum 2-hour IV infusion.
DRUGoxaliplatin
Oxaliplatin were administered as a 2-hour IV infusion.
DRUGcapecitabine
Capecitabine were administered orally twice daily (bid).
DRUGplacebo
Placebo were administered as a minimum 2-hour IV infusion.
Sponsors
Astellas Pharma Global Development, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A female subject is eligible to participate if she is not pregnant (negative serum pregnancy test at screening; female subjects with elevated serum beta human chorionic gonadotropin (βhCG) and a demonstrated non-pregnant status through additional testing are eligible) and at least 1 of the following conditions applies: * Not a woman of childbearing potential (WOCBP) OR * WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study drugs. * Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study treatment administration. * Female subject must not donate ova starting at screening and throughout the study period, and for 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study drugs. * A male subject with female partner(s) of childbearing potential: * must agree to use contraception during the treatment period and for 6 months after the final study treatment administration. * A male subject must not donate sperm during the treatment period and for 6 months after the final study treatment administration. * Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study treatment administration. * Subject has histologically confirmed diagnosis of Gastric or GEJ adenocarcinoma. * Subject has radiologically confirmed locally advanced unresectable or metastatic disease within 28 days prior to randomization. * Subject has radiologically evaluable disease (measurable and/or non-measurable disease according to RECIST 1.1), per local assessment, ≤ 28 days prior to randomization. For subjects with only 1 evaluable lesion and prior radiotherapy ≤ 3 months before randomization, the lesion must either be outside the field of prior radiotherapy or have documented progression following radiation therapy. * Subject's tumor expresses CLDN18.2 in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central IHC testing. * Subject has a HER2-negative tumor as determined by local or central testing on a gastric or GEJ tumor specimen. (Unique to China: Subject has a known HER2-negative gastric or GEJ tumor.) * Subject has ECOG performance status 0 or 1. * Subject has predicted life expectancy ≥ 12 weeks. * Subject must meet all of the following criteria based on the centrally or locally analyzed laboratory tests collected within 14 days prior to randomization. In the case of multiple sample collections within this period, the most recent sample collection with available results should be used to determine eligibility. * Hemoglobin (Hb) ≥ 9 g/dl. Subjects requiring transfusions are eligible if they have a post-transfusion Hgb ≥ 9 g/dL. * Absolute Neutrophil Count (ANC) ≥ 1.5x10\^9/L * Platelets ≥ 100x10\^9/L * Albumin ≥ 2.5 g/dL * Total Bilirubin ≤ 1.5 x upper limit of normal (ULN) without liver metastases (or \< 3.0 x ULN if liver metastases are present) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN without liver metastases (or ≤ 5 x ULN if liver metastases are present) * Estimated creatinine clearance ≥ 30 mL/min * Prothrombin time/international normalized ratio (PT/INR) and partial thromboplastin time (PTT) ≤ 1.5 x ULN (except for subjects receiving anticoagulation therapy)
Exclusion criteria
* Subject has received prior systemic chemotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. However, subject may have received either neo-adjuvant or adjuvant chemotherapy, immunotherapy or other systemic anticancer therapies as long as it was completed at least 6 months prior to randomization. * Subject has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma ≤ 14 days prior to randomization and has not recovered from any related toxicity. * Subject has received treatment with herbal medications or other treatments that have known antitumor activity within 28 days prior to randomization. * Subject has received systemic immunosuppressive therapy, including systemic corticosteroids within 14 days prior to randomization. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use are allowed. * Subject has received other investigational agents or devices within 28 days prior to randomization. * Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibodies, including humanized or chimeric antibodies. * Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment. * Subject has prior severe allergic reaction or intolerance to any component of CAPOX. * Subject has known dihydropyrimidine dehydrogenase (DPD) deficiency. * Subject has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting. * Subject has significant gastric bleeding and/or untreated gastric ulcers that exclude the subject from participation. * Subject has a known history of a positive test for human immunodeficiency virus (HIV) infection or known active hepatitis B (positive hepatitis B surface antigen (HBs Ag)) or C infection. NOTE: Screening for these infections should be conducted per local requirements. * For subjects who are negative for HBs Ag, but hepatitis B core antibody (HBc Ab) positive, an HB deoxyribonucleic acid (DNA) test will be performed and if positive, the subject will be excluded. * Subjects with positive hepatitis C virus (HCV) serology, but negative HCV ribonucleic acid (RNA) test are eligible. * Subjects treated for HCV with undetectable viral load results are eligible. * Subject has an active autoimmune disease that has required systemic treatment within the past 3 months prior to randomization. * Subject has active infection requiring systemic therapy that has not completely resolved within 7 days prior to randomization. * Subject has significant cardiovascular disease, including any of the following: * Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, stenting, coronary artery bypass graft, cerebrovascular accident (CVA) or hypertensive crisis within 6 months prior to randomization. * History of clinically significant ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes * QTc interval \> 450 msec for male subjects; QTc interval \> 470 msec for female subjects * History or family history of congenital long QT syndrome * Cardiac arrhythmias requiring anti-arrhythmic medications (Subject with rate controlled atrial fibrillation for \> 1 month prior to randomization are eligible). * Subject has a history of central nervous system (CNS) metastases and/or carcinomatous meningitis from gastric/GEJ cancer.. * Subject has known peripheral sensory neuropathy \> grade 1 unless the absence of deep tendon reflexes is the sole neurological abnormality. * Subject has had a major surgical procedure ≤ 28 days prior to randomization. * Subject is without complete recovery from a major surgical procedure ≤ 14 days prior to randomization. * Subject has psychiatric illness or social situations that would preclude study compliance. * Subject has another malignancy for which treatment is required. * Subject has any concurrent disease, infection, or co-morbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | From the date of randomization until 61 months and 12 days | PFS was defined as the time from the date of randomization until the date of radiological progressive disease (PD) (per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 by independent review committee \[IRC\]) or death from any cause, whichever was earliest. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan-Meier estimates was used. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | From the date of randomization until 61 months and 12 days | OS was defined as the time from the date of randomization until the date of death from any cause. Kaplan-Meier estimates was used. |
| Time to Confirmed Deterioration (TTCD) Using Physical Functioning as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) | From the date of randomization until 61 months and 12 days | TTCD: time from randomization to first clinically meaning full deterioration (CMFD) that was confirmed at the next scheduled visit. The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status which are scored 1 ('very poor') to 7 ('excellent'). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. Clinically meaningful deterioration was defined if a participant's change from baseline (CFB) exceeded a pre-specified threshold (as per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used. |
| Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching Subscale | From the date of randomization until 61 months and 12 days | TTCD:time from randomization to first CMFD confirmed at next scheduled visit.OG25 evaluated gastric \& gastroesophageal junction cancer-specific symptoms,had 25 items with 6 scales:dysphagia,eating restrictions,reflux,odynophagia,pain, discomfort,anxiety,and 10 single items:trouble with(taste, swallowing saliva, coughing, talking),eating in front of others,dry mouth,body image,choked when swallowing,weight loss and hair loss. STO22: gastric cancer quality of life questionnaire with 22 questions.For OG25 and STO22,items scored on(1:not at all; 2:a little, 3:quite a bit, 4:very much) and 1 question was "yes or no" for STO22.Linear transformation was used; score ranged from 0 to 100; higher score=better level of functioning or greater degree of symptoms. An item from STO22 instrument related to belching was used with OG25. CMFD: if participant's CFB exceeded pre-specified threshold (per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used |
| Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30 | From the date of randomization until 61 months and 12 days | TTCD: time from randomization to first CMFD that was confirmed at the next scheduled visit.The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status/QoL, which are scored 1 (very poor) to 7 (excellent). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. Clinically meaningful deterioration was defined if a participant's CFB exceeded a pre-specified threshold (as per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used. |
| Objective Response Rate (ORR) | From the date of randomization until 61 months and 12 days | ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as was assessed by IRC per RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings. |
| Duration Of Response (DOR) | From first response (CR/PR) until 61 months and 12 days | DOR was defined as the time from the date of the first response (CR/PR) until the date of PD as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest.CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan-Meier estimates was used. |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | From first dose until 61 months and 12 days | An Adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.TEAE defined as an AE observed after starting administration of the study drug through 30 days after the last dose. |
| Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline, cycle (C) 1 day (D)1 through C60 D1 | ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead. |
| Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up | The EORTC-QLQ-C30 is a cancer-specific instrument consisting of 5 functional domain scales: physical, role, emotional, social and cognitive.It is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status/QoL, which are scored 1 ('very poor') to 7 ('excellent'). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. |
| Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up | OG25 evaluated gastric \& gastroesophageal junction cancer-specific symptoms,had 25 items with 6 scales:dysphagia,eating restrictions,reflux,odynophagia,pain \& discomfort,anxiety,and 10 single items:trouble with(taste, swallowing saliva, coughing, talking),eating in front of others,dry mouth,body image,choked when swallowing,weight loss and hair loss. STO22: gastric cancer quality of life questionnaire with 22 questions.For OG25 and STO22,items scored on(1:not at all; 2:a little, 3:quite a bit, 4:very much) and 1 question was "yes or no" for STO22.Linear transformation was used; score ranged from 0 to 100;higher score=better level of functioning or greater degree of symptoms. An item from STO22 instrument related to belching was used with OG25. |
| Change From Baseline in HRQoL Measured by Global Pain (GP) | Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up | The GP instrument is a single assessment of overall pain and participants were assessed in global pain according to the following response categories: 1= no pain (anymore), 2 = less pain, 3 = no change and 4 = more pain. Low pain scores are considered a better outcome than a high pain score. |
| Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up | EQ-5D-5L is a standardized instrument for use as a measure of health outcomes consisting of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale for health status. It was developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples. |
| Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough) | Predose on C2D1,C5D1,C9D1,C13D1,C17D1 | Ctrough was defined as the predose concentration at the end of dosing interval. |
| Number of Anti-drug Antibody (ADA) Positive Participants | Predose on C1D1,C2D1,C5D1,C9D1,C13D1,C17D1, 30-day follow up, 90-day Follow up | Immunogenicity will be measured by the number of participants that are ADA positive. |
Countries
Argentina, Canada, China, Croatia, Greece, Ireland, Japan, Malaysia, Netherlands, Portugal, Romania, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States
Contacts
STUDY_DIRECTORMedical Director
Astellas Pharma Global Development
Participant flow
Recruitment details
Participants with claudin (CLDN)18.2-positive, human epidermal growth factor receptor 2 (HER2) -negative locally advanced unresectable or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma
Pre-assignment details
Participants who met all inclusion criteria and none of the exclusion criteria were enrolled in the study. Randomization was stratified by region (Asia vs Non-Asia), number of organs with metastatic sites (0 to 2 vs ≥ 3) and prior gastrectomy (Yes or No)
Participants by arm
| Arm | Count |
|---|---|
| CAPOX+ Zolbetuximab Participants received an intravenous (IV) infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 milligrams per square meter (mg/m\^2) on cycle 1 day 1 (C1D1) followed by subsequent doses of 600 mg/m\^2 every 3 weeks starting from C2D1 until participant met study treatment discontinuation criteria. Participants also received up to 8 treatments of capecitabine and oxaliplatin (CAPOX) treatment. Oxaliplatin was administered 130 mg/m\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\^2 twice daily (bid) on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21 days. | 254 |
| CAPOX+ Placebo Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C2D1 until participant met study treatment discontinuation criteria. Participants also received up to 8 treatments of CAPOX. Oxaliplatin was administered 130 mg/m\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\^2 bid on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21 days. | 253 |
| Total | 507 |
Baseline characteristics
| Characteristic | CAPOX+ Zolbetuximab | CAPOX+ Placebo | Total |
|---|---|---|---|
| Age, Continuous | 58.6 Years STANDARD_DEVIATION 12.1 | 56.7 Years STANDARD_DEVIATION 13 | 57.6 Years STANDARD_DEVIATION 12.6 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 10 Participants | 7 Participants | 17 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 242 Participants | 241 Participants | 483 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants | 5 Participants | 7 Participants |
| Number of organs with metastatic sites 0-2 metastatic sites | 189 Participants | 188 Participants | 377 Participants |
| Number of organs with metastatic sites >=3 metastatic sites | 65 Participants | 65 Participants | 130 Participants |
| Prior Gastrectomy No | 179 Participants | 178 Participants | 357 Participants |
| Prior Gastrectomy Yes | 75 Participants | 75 Participants | 150 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 158 Participants | 158 Participants | 316 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 5 Participants | 7 Participants |
| Race (NIH/OMB) White | 94 Participants | 90 Participants | 184 Participants |
| Region (Asia vs Non-Asia) Asia | 157 Participants | 158 Participants | 315 Participants |
| Region (Asia vs Non-Asia) Non-Asia | 97 Participants | 95 Participants | 192 Participants |
| Sex: Female, Male Female | 95 Participants | 97 Participants | 192 Participants |
| Sex: Female, Male Male | 159 Participants | 156 Participants | 315 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 180 / 254 | 387 / 503 | 387 / 503 | 207 / 249 |
| other Total, other adverse events | 249 / 254 | 481 / 503 | 481 / 503 | 232 / 249 |
| serious Total, serious adverse events | 123 / 254 | 249 / 503 | 249 / 503 | 126 / 249 |
Outcome results
Primary
Progression Free Survival (PFS)
PFS was defined as the time from the date of randomization until the date of radiological progressive disease (PD) (per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 by independent review committee \[IRC\]) or death from any cause, whichever was earliest. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan-Meier estimates was used.
Time frame: From the date of randomization until 61 months and 12 days
Population: FAS
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| CAPOX+ Zolbetuximab | Progression Free Survival (PFS) | 8.21 Months |
| CAPOX+ Placebo | Progression Free Survival (PFS) | 6.80 Months |
p-value: 0.000595% CI: [0.552, 0.86]Log Rank
Secondary
Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire
The EORTC-QLQ-C30 is a cancer-specific instrument consisting of 5 functional domain scales: physical, role, emotional, social and cognitive.It is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status/QoL, which are scored 1 ('very poor') to 7 ('excellent'). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state.
Time frame: Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up
Population: FAS with available data was analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C37D1 | 7.27 Unit on a scale | Standard Deviation 17.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C35D1 | 7.18 Unit on a scale | Standard Deviation 18.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C36D1 | 6.67 Unit on a scale | Standard Deviation 17.98 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C25D1 | 0.00 Unit on a scale | Standard Deviation 22.22 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C38D1 | 6.67 Unit on a scale | Standard Deviation 21.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C39D1 | 2.96 Unit on a scale | Standard Deviation 10.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning 30 day follow up | -8.65 Unit on a scale | Standard Deviation 22.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning 90 day follow up | -10.16 Unit on a scale | Standard Deviation 20.28 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning Baseline | 83.20 Unit on a scale | Standard Deviation 22.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C2D1 | -2.64 Unit on a scale | Standard Deviation 20.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C3D1 | -2.38 Unit on a scale | Standard Deviation 21.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C4D1 | -2.37 Unit on a scale | Standard Deviation 20.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C5D1 | -0.94 Unit on a scale | Standard Deviation 20.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C6D1 | -3.69 Unit on a scale | Standard Deviation 22.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C7D1 | -2.08 Unit on a scale | Standard Deviation 20.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C14D1 | -1.21 Unit on a scale | Standard Deviation 21.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C15D1 | -0.65 Unit on a scale | Standard Deviation 21.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C16D1 | 1.74 Unit on a scale | Standard Deviation 23.12 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C17D1 | 3.10 Unit on a scale | Standard Deviation 22.5 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C18D1 | -3.25 Unit on a scale | Standard Deviation 20.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C26D1 | -0.64 Unit on a scale | Standard Deviation 20.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C27D1 | 0.00 Unit on a scale | Standard Deviation 17.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C28D1 | 1.59 Unit on a scale | Standard Deviation 18.18 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C29D1 | -1.52 Unit on a scale | Standard Deviation 24.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C30D1 | 3.33 Unit on a scale | Standard Deviation 19.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C31D1 | 7.50 Unit on a scale | Standard Deviation 21.27 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C32D1 | 5.56 Unit on a scale | Standard Deviation 23.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C33D1 | 6.67 Unit on a scale | Standard Deviation 20.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C34D1 | 9.72 Unit on a scale | Standard Deviation 24.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C35D1 | 7.69 Unit on a scale | Standard Deviation 21.1 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C36D1 | 9.72 Unit on a scale | Standard Deviation 21.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C37D1 | 12.12 Unit on a scale | Standard Deviation 23.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C38D1 | 13.33 Unit on a scale | Standard Deviation 21.94 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C39D1 | 7.41 Unit on a scale | Standard Deviation 22.22 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning 30 day follow up | -13.16 Unit on a scale | Standard Deviation 27.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning Baseline | 90.95 Unit on a scale | Standard Deviation 14.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C3D1 | -1.47 Unit on a scale | Standard Deviation 14.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C4D1 | -0.59 Unit on a scale | Standard Deviation 13.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C9D1 | -1.96 Unit on a scale | Standard Deviation 14.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C11D1 | -1.23 Unit on a scale | Standard Deviation 14.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C36D1 | 8.33 Unit on a scale | Standard Deviation 19.46 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C37D1 | 9.09 Unit on a scale | Standard Deviation 21.56 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning 30 day follow up | -2.63 Unit on a scale | Standard Deviation 18.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status Baseline | 68.83 Unit on a scale | Standard Deviation 18.94 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C2D1 | 0.04 Unit on a scale | Standard Deviation 17.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C3D1 | 1.47 Unit on a scale | Standard Deviation 17.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C4D1 | 2.61 Unit on a scale | Standard Deviation 18.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C5D1 | 0.89 Unit on a scale | Standard Deviation 20.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C6D1 | 0.84 Unit on a scale | Standard Deviation 19.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C7D1 | 1.94 Unit on a scale | Standard Deviation 18.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C8D1 | 0.77 Unit on a scale | Standard Deviation 16.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C13D1 | 3.47 Unit on a scale | Standard Deviation 24.22 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C14D1 | 1.52 Unit on a scale | Standard Deviation 18.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C15D1 | 2.94 Unit on a scale | Standard Deviation 22.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C16D1 | 3.65 Unit on a scale | Standard Deviation 22.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C17D1 | 6.01 Unit on a scale | Standard Deviation 19.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C18D1 | 3.66 Unit on a scale | Standard Deviation 21.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C19D1 | 4.17 Unit on a scale | Standard Deviation 17.5 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C20D1 | 1.50 Unit on a scale | Standard Deviation 17.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C21D1 | 4.17 Unit on a scale | Standard Deviation 18.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C22D1 | 4.03 Unit on a scale | Standard Deviation 19.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C23D1 | 4.03 Unit on a scale | Standard Deviation 16.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status 30 day follow up | -8.63 Unit on a scale | Standard Deviation 25.1 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status 90 day follow up | -5.46 Unit on a scale | Standard Deviation 21.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning Baseline | 83.79 Unit on a scale | Standard Deviation 16.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C2D1 | -0.93 Unit on a scale | Standard Deviation 14.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C3D1 | -1.76 Unit on a scale | Standard Deviation 14.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C7D1 | -1.78 Unit on a scale | Standard Deviation 16.05 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C8D1 | -3.27 Unit on a scale | Standard Deviation 15.51 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C9D1 | -3.20 Unit on a scale | Standard Deviation 17.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C11D1 | -0.82 Unit on a scale | Standard Deviation 15 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C14D1 | 0.12 Unit on a scale | Standard Deviation 15.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C15D1 | 0.39 Unit on a scale | Standard Deviation 14.2 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C17D1 | 2.33 Unit on a scale | Standard Deviation 14.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning Baseline | 79.42 Unit on a scale | Standard Deviation 22.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C19D1 | 1.33 Unit on a scale | Standard Deviation 10.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C8D1 | 4.94 Unit on a scale | Standard Deviation 20.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C8D1 | 0.31 Unit on a scale | Standard Deviation 29 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C9D1 | -4.90 Unit on a scale | Standard Deviation 29.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C12D1 | -0.89 Unit on a scale | Standard Deviation 24.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C13D1 | -3.70 Unit on a scale | Standard Deviation 25.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C14D1 | -2.22 Unit on a scale | Standard Deviation 19.99 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C15D1 | -3.27 Unit on a scale | Standard Deviation 21.12 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C16D1 | -4.63 Unit on a scale | Standard Deviation 21.6 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C17D1 | -2.07 Unit on a scale | Standard Deviation 18.98 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C18D1 | -0.81 Unit on a scale | Standard Deviation 17.1 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C19D1 | -1.11 Unit on a scale | Standard Deviation 17.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C20D1 | 0.57 Unit on a scale | Standard Deviation 16.51 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C34D1 | -12.04 Unit on a scale | Standard Deviation 18.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C35D1 | -10.26 Unit on a scale | Standard Deviation 12.39 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C36D1 | -12.04 Unit on a scale | Standard Deviation 10 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C37D1 | -12.12 Unit on a scale | Standard Deviation 14.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C38D1 | -12.22 Unit on a scale | Standard Deviation 21.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C39D1 | -7.41 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue 30 day follow up | 11.50 Unit on a scale | Standard Deviation 23.09 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue 90 day follow up | 11.84 Unit on a scale | Standard Deviation 21.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting Baseline | 10.49 Unit on a scale | Standard Deviation 18.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C2D1 | 6.41 Unit on a scale | Standard Deviation 19.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C3D1 | 5.86 Unit on a scale | Standard Deviation 19.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C4D1 | 4.73 Unit on a scale | Standard Deviation 20.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C6D1 | 6.04 Unit on a scale | Standard Deviation 20.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C7D1 | 1.25 Unit on a scale | Standard Deviation 19.94 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C8D1 | 3.09 Unit on a scale | Standard Deviation 20.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C29D1 | -3.79 Unit on a scale | Standard Deviation 21.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C30D1 | -3.33 Unit on a scale | Standard Deviation 21.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C31D1 | -4.17 Unit on a scale | Standard Deviation 23.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C34D1 | -8.33 Unit on a scale | Standard Deviation 25.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C35D1 | -6.41 Unit on a scale | Standard Deviation 25.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C36D1 | -6.94 Unit on a scale | Standard Deviation 25.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C37D1 | -9.09 Unit on a scale | Standard Deviation 20.23 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C38D1 | -6.67 Unit on a scale | Standard Deviation 14.05 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C39D1 | -5.56 Unit on a scale | Standard Deviation 8.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting 90 day follow up | 7.38 Unit on a scale | Standard Deviation 21.2 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain Baseline | 21.67 Unit on a scale | Standard Deviation 22.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C2D1 | -4.17 Unit on a scale | Standard Deviation 22.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C3D1 | -5.40 Unit on a scale | Standard Deviation 21.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C5D1 | -4.82 Unit on a scale | Standard Deviation 22.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C6D1 | -3.13 Unit on a scale | Standard Deviation 19.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C7D1 | -6.39 Unit on a scale | Standard Deviation 22.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C17D1 | -5.04 Unit on a scale | Standard Deviation 19.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C18D1 | -1.63 Unit on a scale | Standard Deviation 18.18 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C19D1 | -2.50 Unit on a scale | Standard Deviation 18.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C20D1 | -0.85 Unit on a scale | Standard Deviation 16.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C21D1 | -2.31 Unit on a scale | Standard Deviation 19.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C22D1 | -2.69 Unit on a scale | Standard Deviation 18.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C23D1 | -3.76 Unit on a scale | Standard Deviation 18.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C24D1 | -4.02 Unit on a scale | Standard Deviation 18.18 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C39D1 | -9.26 Unit on a scale | Standard Deviation 16.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain 30 day follow up | 4.97 Unit on a scale | Standard Deviation 27.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain 90 day follow up | 4.37 Unit on a scale | Standard Deviation 22.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea Baseline | 9.74 Unit on a scale | Standard Deviation 17.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C2D1 | 2.24 Unit on a scale | Standard Deviation 15.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C5D1 | -0.42 Unit on a scale | Standard Deviation 19.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C6D1 | 1.12 Unit on a scale | Standard Deviation 19.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C8D1 | 1.85 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C11D1 | 0.41 Unit on a scale | Standard Deviation 20.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C12D1 | -1.33 Unit on a scale | Standard Deviation 20.09 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C19D1 | 0.00 Unit on a scale | Standard Deviation 16.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C20D1 | 2.56 Unit on a scale | Standard Deviation 19.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C22D1 | 1.08 Unit on a scale | Standard Deviation 20.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C27D1 | 2.67 Unit on a scale | Standard Deviation 16.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C16D1 | 0.00 Unit on a scale | Standard Deviation 25.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C3D1 | -0.55 Unit on a scale | Standard Deviation 28.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C4D1 | -4.73 Unit on a scale | Standard Deviation 28.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C5D1 | 1.40 Unit on a scale | Standard Deviation 23.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C24D1 | 0.00 Unit on a scale | Standard Deviation 17.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C34D1 | -2.78 Unit on a scale | Standard Deviation 22.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C35D1 | 0.00 Unit on a scale | Standard Deviation 23.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C39D1 | 7.41 Unit on a scale | Standard Deviation 22.22 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia 30 day follow up | 6.43 Unit on a scale | Standard Deviation 30.5 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia 90 day follow up | 6.56 Unit on a scale | Standard Deviation 22.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C2D1 | 3.69 Unit on a scale | Standard Deviation 31.97 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C3D1 | 0.73 Unit on a scale | Standard Deviation 34.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C9D1 | -3.92 Unit on a scale | Standard Deviation 36.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C10D1 | -3.92 Unit on a scale | Standard Deviation 31.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C11D1 | -7.82 Unit on a scale | Standard Deviation 31.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C23D1 | -10.75 Unit on a scale | Standard Deviation 30.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C20D1 | 0.00 Unit on a scale | Standard Deviation 24.18 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C21D1 | 1.85 Unit on a scale | Standard Deviation 25.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C22D1 | -3.23 Unit on a scale | Standard Deviation 21.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C26D1 | -12.82 Unit on a scale | Standard Deviation 35.37 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C27D1 | -8.00 Unit on a scale | Standard Deviation 30.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C39D1 | -18.52 Unit on a scale | Standard Deviation 37.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C5D1 | -2.73 Unit on a scale | Standard Deviation 25.97 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C8D1 | -4.63 Unit on a scale | Standard Deviation 27.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C10D1 | -6.27 Unit on a scale | Standard Deviation 26.97 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C11D1 | -4.94 Unit on a scale | Standard Deviation 28.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C14D1 | -6.06 Unit on a scale | Standard Deviation 25.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C15D1 | -4.58 Unit on a scale | Standard Deviation 27.5 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C17D1 | -3.88 Unit on a scale | Standard Deviation 27.42 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C18D1 | -5.69 Unit on a scale | Standard Deviation 25.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C19D1 | -5.83 Unit on a scale | Standard Deviation 23.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C20D1 | 0.00 Unit on a scale | Standard Deviation 31.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C21D1 | 0.00 Unit on a scale | Standard Deviation 26.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C22D1 | -2.15 Unit on a scale | Standard Deviation 32.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C23D1 | -3.23 Unit on a scale | Standard Deviation 27.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C24D1 | -3.45 Unit on a scale | Standard Deviation 22.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C25D1 | -3.57 Unit on a scale | Standard Deviation 24.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C26D1 | -5.13 Unit on a scale | Standard Deviation 26.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C27D1 | -6.67 Unit on a scale | Standard Deviation 25.46 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C28D1 | -4.76 Unit on a scale | Standard Deviation 19.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C29D1 | 0.00 Unit on a scale | Standard Deviation 20.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C30D1 | -3.33 Unit on a scale | Standard Deviation 21.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C31D1 | 0.00 Unit on a scale | Standard Deviation 18.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C33D1 | -6.67 Unit on a scale | Standard Deviation 18.69 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C35D1 | -7.69 Unit on a scale | Standard Deviation 14.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C36D1 | -8.33 Unit on a scale | Standard Deviation 15.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C37D1 | -12.12 Unit on a scale | Standard Deviation 16.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C38D1 | -6.67 Unit on a scale | Standard Deviation 14.05 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C39D1 | -3.70 Unit on a scale | Standard Deviation 11.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation 30 day follow up | -2.34 Unit on a scale | Standard Deviation 30.12 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation 90 day follow up | 1.09 Unit on a scale | Standard Deviation 27.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea Baseline | 8.09 Unit on a scale | Standard Deviation 16.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C2D1 | 2.56 Unit on a scale | Standard Deviation 20.56 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C3D1 | 2.93 Unit on a scale | Standard Deviation 21.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C4D1 | 1.38 Unit on a scale | Standard Deviation 21 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C5D1 | 1.47 Unit on a scale | Standard Deviation 20.66 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C6D1 | 2.91 Unit on a scale | Standard Deviation 24.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C7D1 | 1.94 Unit on a scale | Standard Deviation 24.17 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C8D1 | 1.23 Unit on a scale | Standard Deviation 21.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C9D1 | 1.31 Unit on a scale | Standard Deviation 23.42 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C10D1 | 1.18 Unit on a scale | Standard Deviation 19.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C12D1 | -1.33 Unit on a scale | Standard Deviation 17.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C13D1 | -3.89 Unit on a scale | Standard Deviation 16.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C14D1 | -3.03 Unit on a scale | Standard Deviation 17.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C15D1 | -1.31 Unit on a scale | Standard Deviation 19.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C16D1 | -1.39 Unit on a scale | Standard Deviation 16.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C17D1 | -0.78 Unit on a scale | Standard Deviation 19.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C18D1 | -1.63 Unit on a scale | Standard Deviation 16.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C19D1 | -2.50 Unit on a scale | Standard Deviation 15.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C20D1 | -1.71 Unit on a scale | Standard Deviation 17.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C21D1 | -0.93 Unit on a scale | Standard Deviation 18.66 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C22D1 | 0.00 Unit on a scale | Standard Deviation 14.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C23D1 | 1.08 Unit on a scale | Standard Deviation 16.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C24D1 | 2.30 Unit on a scale | Standard Deviation 12.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C25D1 | 0.00 Unit on a scale | Standard Deviation 15.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C26D1 | 0.00 Unit on a scale | Standard Deviation 13.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C27D1 | 1.33 Unit on a scale | Standard Deviation 15.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C28D1 | 0.00 Unit on a scale | Standard Deviation 14.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C29D1 | 3.03 Unit on a scale | Standard Deviation 17.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C30D1 | 1.67 Unit on a scale | Standard Deviation 17.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C31D1 | -1.67 Unit on a scale | Standard Deviation 13.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C32D1 | 5.56 Unit on a scale | Standard Deviation 17.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C33D1 | 0.00 Unit on a scale | Standard Deviation 17.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C34D1 | -5.56 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C35D1 | 2.56 Unit on a scale | Standard Deviation 16.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C36D1 | 0.00 Unit on a scale | Standard Deviation 14.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C37D1 | 0.00 Unit on a scale | Standard Deviation 21.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C38D1 | 6.67 Unit on a scale | Standard Deviation 21.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C39D1 | 3.70 Unit on a scale | Standard Deviation 20.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea 30 day follow up | -0.58 Unit on a scale | Standard Deviation 18.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea 90 day follow up | 2.73 Unit on a scale | Standard Deviation 20.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties Baseline | 20.71 Unit on a scale | Standard Deviation 25.99 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C2D1 | -0.64 Unit on a scale | Standard Deviation 25.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C3D1 | -0.92 Unit on a scale | Standard Deviation 25.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C4D1 | -2.17 Unit on a scale | Standard Deviation 23.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C11D1 | 0.00 Unit on a scale | Standard Deviation 27.39 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C14D1 | -0.61 Unit on a scale | Standard Deviation 29.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C37D1 | -6.06 Unit on a scale | Standard Deviation 13.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties 30 day follow up | 4.09 Unit on a scale | Standard Deviation 26.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties 90 day follow up | 3.28 Unit on a scale | Standard Deviation 24.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C26D1 | -2.56 Unit on a scale | Standard Deviation 20.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C28D1 | -4.76 Unit on a scale | Standard Deviation 21.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C29D1 | 3.03 Unit on a scale | Standard Deviation 17.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C36D1 | -2.78 Unit on a scale | Standard Deviation 17.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C17D1 | 5.81 Unit on a scale | Standard Deviation 15.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C19D1 | 5.00 Unit on a scale | Standard Deviation 15.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C20D1 | 3.85 Unit on a scale | Standard Deviation 15.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C22D1 | 4.30 Unit on a scale | Standard Deviation 14.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C6D1 | -1.45 Unit on a scale | Standard Deviation 14.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C17D1 | 0.78 Unit on a scale | Standard Deviation 12.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C18D1 | 1.63 Unit on a scale | Standard Deviation 13.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C19D1 | 0.42 Unit on a scale | Standard Deviation 16.66 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C27D1 | 2.67 Unit on a scale | Standard Deviation 17.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C32D1 | 2.78 Unit on a scale | Standard Deviation 21.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C35D1 | 6.41 Unit on a scale | Standard Deviation 24.09 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C39D1 | 1.85 Unit on a scale | Standard Deviation 13.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning 90 day follow up | -7.65 Unit on a scale | Standard Deviation 17.37 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C2D1 | 0.88 Unit on a scale | Standard Deviation 21.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C4D1 | 0.79 Unit on a scale | Standard Deviation 23.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C6D1 | -0.78 Unit on a scale | Standard Deviation 25.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C8D1 | -0.93 Unit on a scale | Standard Deviation 27.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C12D1 | 3.33 Unit on a scale | Standard Deviation 23.09 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C17D1 | 5.43 Unit on a scale | Standard Deviation 18.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C20D1 | 2.56 Unit on a scale | Standard Deviation 21.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C21D1 | 2.31 Unit on a scale | Standard Deviation 21.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C31D1 | 3.33 Unit on a scale | Standard Deviation 27.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C32D1 | 0.93 Unit on a scale | Standard Deviation 29.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C33D1 | 3.33 Unit on a scale | Standard Deviation 34.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C35D1 | 2.56 Unit on a scale | Standard Deviation 32.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C36D1 | 5.56 Unit on a scale | Standard Deviation 33.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C38D1 | 13.33 Unit on a scale | Standard Deviation 31.23 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning 30 day follow up | -4.09 Unit on a scale | Standard Deviation 28.22 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning 90 day follow up | 0.27 Unit on a scale | Standard Deviation 24.05 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue Baseline | 26.29 Unit on a scale | Standard Deviation 22 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C3D1 | 3.17 Unit on a scale | Standard Deviation 21.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C4D1 | 1.05 Unit on a scale | Standard Deviation 21.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C21D1 | 1.23 Unit on a scale | Standard Deviation 16.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C19D1 | 0.00 Unit on a scale | Standard Deviation 20.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C27D1 | -4.67 Unit on a scale | Standard Deviation 20.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C28D1 | -0.79 Unit on a scale | Standard Deviation 23.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C4D1 | 0.00 Unit on a scale | Standard Deviation 16.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C9D1 | 0.65 Unit on a scale | Standard Deviation 18.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C10D1 | 1.18 Unit on a scale | Standard Deviation 20.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C18D1 | 1.63 Unit on a scale | Standard Deviation 16.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C23D1 | 0.00 Unit on a scale | Standard Deviation 14.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C24D1 | 0.00 Unit on a scale | Standard Deviation 17.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C25D1 | 0.00 Unit on a scale | Standard Deviation 20.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C26D1 | -3.85 Unit on a scale | Standard Deviation 14.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea 30 day follow up | 3.51 Unit on a scale | Standard Deviation 16.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C5D1 | -2.73 Unit on a scale | Standard Deviation 28.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C6D1 | -5.15 Unit on a scale | Standard Deviation 28.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C17D1 | 1.55 Unit on a scale | Standard Deviation 25.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C22D1 | -5.38 Unit on a scale | Standard Deviation 17.42 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C23D1 | -3.23 Unit on a scale | Standard Deviation 15.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C27D1 | -4.00 Unit on a scale | Standard Deviation 17.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C30D1 | -1.67 Unit on a scale | Standard Deviation 17.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C31D1 | 1.67 Unit on a scale | Standard Deviation 17.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C7D1 | -4.44 Unit on a scale | Standard Deviation 37.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C12D1 | -8.00 Unit on a scale | Standard Deviation 31.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C13D1 | -9.44 Unit on a scale | Standard Deviation 36.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C16D1 | -9.72 Unit on a scale | Standard Deviation 32.22 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C20D1 | -7.69 Unit on a scale | Standard Deviation 33.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C24D1 | -13.79 Unit on a scale | Standard Deviation 28.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C25D1 | -10.71 Unit on a scale | Standard Deviation 30.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C28D1 | -14.29 Unit on a scale | Standard Deviation 32.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C32D1 | -14.81 Unit on a scale | Standard Deviation 36.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C35D1 | -17.95 Unit on a scale | Standard Deviation 35 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C38D1 | -23.33 Unit on a scale | Standard Deviation 41.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C9D1 | -4.25 Unit on a scale | Standard Deviation 22.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C30D1 | 0.00 Unit on a scale | Standard Deviation 24.18 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C32D1 | -5.56 Unit on a scale | Standard Deviation 17.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C21D1 | -0.74 Unit on a scale | Standard Deviation 13.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C22D1 | -0.22 Unit on a scale | Standard Deviation 12.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C23D1 | -0.22 Unit on a scale | Standard Deviation 14.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C24D1 | 2.30 Unit on a scale | Standard Deviation 14.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C25D1 | 0.48 Unit on a scale | Standard Deviation 17.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C26D1 | 1.28 Unit on a scale | Standard Deviation 17.28 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C27D1 | 1.07 Unit on a scale | Standard Deviation 16.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C28D1 | -1.27 Unit on a scale | Standard Deviation 16.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C29D1 | -3.33 Unit on a scale | Standard Deviation 23.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C30D1 | 1.67 Unit on a scale | Standard Deviation 16.17 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C31D1 | 2.00 Unit on a scale | Standard Deviation 16.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C32D1 | -1.11 Unit on a scale | Standard Deviation 19.97 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C33D1 | 2.22 Unit on a scale | Standard Deviation 18.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C34D1 | 6.67 Unit on a scale | Standard Deviation 17.98 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C27D1 | 1.33 Unit on a scale | Standard Deviation 17.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C18D1 | -12.20 Unit on a scale | Standard Deviation 32.28 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C21D1 | -4.63 Unit on a scale | Standard Deviation 33 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C22D1 | -10.75 Unit on a scale | Standard Deviation 32.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C33D1 | -17.78 Unit on a scale | Standard Deviation 37.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C34D1 | -27.78 Unit on a scale | Standard Deviation 34.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C36D1 | -19.44 Unit on a scale | Standard Deviation 36.12 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C37D1 | -18.18 Unit on a scale | Standard Deviation 37.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss 30 day follow up | 4.68 Unit on a scale | Standard Deviation 38.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss 90 day follow up | 3.28 Unit on a scale | Standard Deviation 38.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation Baseline | 18.11 Unit on a scale | Standard Deviation 26.09 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C4D1 | -4.73 Unit on a scale | Standard Deviation 26.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C32D1 | 1.85 Unit on a scale | Standard Deviation 17.98 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C34D1 | -8.33 Unit on a scale | Standard Deviation 15.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C11D1 | -3.29 Unit on a scale | Standard Deviation 21.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C24D1 | 1.15 Unit on a scale | Standard Deviation 22.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C33D1 | -6.67 Unit on a scale | Standard Deviation 13.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C34D1 | -5.56 Unit on a scale | Standard Deviation 12.97 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C8D1 | -5.25 Unit on a scale | Standard Deviation 21.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C9D1 | -5.39 Unit on a scale | Standard Deviation 23.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C10D1 | -3.92 Unit on a scale | Standard Deviation 24.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C11D1 | -3.50 Unit on a scale | Standard Deviation 19.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C12D1 | -3.33 Unit on a scale | Standard Deviation 23.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C13D1 | -0.83 Unit on a scale | Standard Deviation 24.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C19D1 | -0.42 Unit on a scale | Standard Deviation 20.5 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C20D1 | 1.28 Unit on a scale | Standard Deviation 20.37 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C21D1 | -0.93 Unit on a scale | Standard Deviation 20.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C22D1 | 0.54 Unit on a scale | Standard Deviation 19.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C23D1 | 0.00 Unit on a scale | Standard Deviation 18.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C24D1 | 0.00 Unit on a scale | Standard Deviation 18.37 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C25D1 | 1.79 Unit on a scale | Standard Deviation 20.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning 90 day follow up | -10.93 Unit on a scale | Standard Deviation 27.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning Baseline | 80.42 Unit on a scale | Standard Deviation 19.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C2D1 | 1.32 Unit on a scale | Standard Deviation 15.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C3D1 | 0.05 Unit on a scale | Standard Deviation 16.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C4D1 | 2.42 Unit on a scale | Standard Deviation 15.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C5D1 | 2.46 Unit on a scale | Standard Deviation 17.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C6D1 | 1.79 Unit on a scale | Standard Deviation 15.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C7D1 | 3.54 Unit on a scale | Standard Deviation 17.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C8D1 | 0.77 Unit on a scale | Standard Deviation 19.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C9D1 | 2.53 Unit on a scale | Standard Deviation 19.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C10D1 | 5.20 Unit on a scale | Standard Deviation 21.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C11D1 | 5.35 Unit on a scale | Standard Deviation 20.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C12D1 | 6.44 Unit on a scale | Standard Deviation 19.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C13D1 | 6.11 Unit on a scale | Standard Deviation 20.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C14D1 | 3.94 Unit on a scale | Standard Deviation 19.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C15D1 | 4.25 Unit on a scale | Standard Deviation 16.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C16D1 | 3.99 Unit on a scale | Standard Deviation 15.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C18D1 | 2.24 Unit on a scale | Standard Deviation 15.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C21D1 | 3.94 Unit on a scale | Standard Deviation 18.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C25D1 | 2.68 Unit on a scale | Standard Deviation 16.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C30D1 | -0.42 Unit on a scale | Standard Deviation 17.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C31D1 | 1.25 Unit on a scale | Standard Deviation 17.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C32D1 | 3.70 Unit on a scale | Standard Deviation 16.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C33D1 | 5.56 Unit on a scale | Standard Deviation 18.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C34D1 | 11.81 Unit on a scale | Standard Deviation 12.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C35D1 | 5.13 Unit on a scale | Standard Deviation 15.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C36D1 | 9.03 Unit on a scale | Standard Deviation 15.27 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C37D1 | 11.36 Unit on a scale | Standard Deviation 15.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C38D1 | 10.83 Unit on a scale | Standard Deviation 14.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C39D1 | -1.85 Unit on a scale | Standard Deviation 21.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning 30 day follow up | -5.99 Unit on a scale | Standard Deviation 26.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning 90 day follow up | -4.37 Unit on a scale | Standard Deviation 15.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C2D1 | -0.24 Unit on a scale | Standard Deviation 13.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C5D1 | -1.89 Unit on a scale | Standard Deviation 15.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C7D1 | 0.00 Unit on a scale | Standard Deviation 16.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C8D1 | -2.16 Unit on a scale | Standard Deviation 15.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C13D1 | -0.28 Unit on a scale | Standard Deviation 15.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C14D1 | 0.61 Unit on a scale | Standard Deviation 15.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C15D1 | -0.98 Unit on a scale | Standard Deviation 15.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C16D1 | 1.39 Unit on a scale | Standard Deviation 16.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C23D1 | 1.61 Unit on a scale | Standard Deviation 17.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C24D1 | 2.30 Unit on a scale | Standard Deviation 18.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C25D1 | 1.79 Unit on a scale | Standard Deviation 18.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C26D1 | 1.92 Unit on a scale | Standard Deviation 19.05 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C28D1 | 3.17 Unit on a scale | Standard Deviation 18.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C30D1 | 0.00 Unit on a scale | Standard Deviation 18.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C31D1 | 0.00 Unit on a scale | Standard Deviation 18.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C9D1 | -0.98 Unit on a scale | Standard Deviation 24.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C13D1 | 3.89 Unit on a scale | Standard Deviation 24.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C22D1 | 5.91 Unit on a scale | Standard Deviation 21.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C33D1 | 5.56 Unit on a scale | Standard Deviation 20.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C9D1 | 1.88 Unit on a scale | Standard Deviation 20.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C10D1 | 2.65 Unit on a scale | Standard Deviation 20.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C11D1 | 1.23 Unit on a scale | Standard Deviation 21.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C12D1 | 2.44 Unit on a scale | Standard Deviation 23.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C24D1 | 2.87 Unit on a scale | Standard Deviation 19.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C25D1 | 1.79 Unit on a scale | Standard Deviation 18.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C26D1 | 4.81 Unit on a scale | Standard Deviation 16.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C27D1 | 4.00 Unit on a scale | Standard Deviation 18.18 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C28D1 | 1.98 Unit on a scale | Standard Deviation 18.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C29D1 | 3.03 Unit on a scale | Standard Deviation 14.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C30D1 | 2.92 Unit on a scale | Standard Deviation 14.12 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C31D1 | 2.08 Unit on a scale | Standard Deviation 19.28 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C32D1 | 2.78 Unit on a scale | Standard Deviation 16.17 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C33D1 | 5.56 Unit on a scale | Standard Deviation 17.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C34D1 | 8.33 Unit on a scale | Standard Deviation 20.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C35D1 | 4.49 Unit on a scale | Standard Deviation 17.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C36D1 | 2.78 Unit on a scale | Standard Deviation 17.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C37D1 | 10.61 Unit on a scale | Standard Deviation 15.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C38D1 | 8.33 Unit on a scale | Standard Deviation 21.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C39D1 | 3.70 Unit on a scale | Standard Deviation 13.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C4D1 | -0.16 Unit on a scale | Standard Deviation 14.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C5D1 | -0.67 Unit on a scale | Standard Deviation 15.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C6D1 | -0.89 Unit on a scale | Standard Deviation 15.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C10D1 | -2.75 Unit on a scale | Standard Deviation 17.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C12D1 | -0.89 Unit on a scale | Standard Deviation 17.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C13D1 | -0.56 Unit on a scale | Standard Deviation 18.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C16D1 | -0.42 Unit on a scale | Standard Deviation 14.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C18D1 | -2.93 Unit on a scale | Standard Deviation 17.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C20D1 | -0.85 Unit on a scale | Standard Deviation 11.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C5D1 | 2.20 Unit on a scale | Standard Deviation 25.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C7D1 | -5.28 Unit on a scale | Standard Deviation 28.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C11D1 | -2.47 Unit on a scale | Standard Deviation 29.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C9D1 | 1.96 Unit on a scale | Standard Deviation 24.94 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C10D1 | 1.57 Unit on a scale | Standard Deviation 25.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C11D1 | -0.14 Unit on a scale | Standard Deviation 22.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C22D1 | -2.87 Unit on a scale | Standard Deviation 19.02 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C23D1 | -1.43 Unit on a scale | Standard Deviation 17.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C24D1 | -1.15 Unit on a scale | Standard Deviation 17.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C25D1 | -3.17 Unit on a scale | Standard Deviation 18.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C26D1 | -1.71 Unit on a scale | Standard Deviation 21.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C27D1 | -3.11 Unit on a scale | Standard Deviation 14.17 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C28D1 | -2.65 Unit on a scale | Standard Deviation 16.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C29D1 | -3.54 Unit on a scale | Standard Deviation 14.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C30D1 | -2.78 Unit on a scale | Standard Deviation 13.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C31D1 | -2.22 Unit on a scale | Standard Deviation 17.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C32D1 | -5.56 Unit on a scale | Standard Deviation 18.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C33D1 | -8.15 Unit on a scale | Standard Deviation 19.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C9D1 | 1.80 Unit on a scale | Standard Deviation 20.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C10D1 | 0.39 Unit on a scale | Standard Deviation 20.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C11D1 | -1.65 Unit on a scale | Standard Deviation 19.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C12D1 | -1.11 Unit on a scale | Standard Deviation 19.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C13D1 | -3.33 Unit on a scale | Standard Deviation 20.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C14D1 | -1.21 Unit on a scale | Standard Deviation 19.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C15D1 | -2.94 Unit on a scale | Standard Deviation 18.17 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C16D1 | -1.04 Unit on a scale | Standard Deviation 20.17 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C17D1 | -1.94 Unit on a scale | Standard Deviation 18.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C18D1 | 0.81 Unit on a scale | Standard Deviation 20.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C20D1 | -0.85 Unit on a scale | Standard Deviation 19.1 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C21D1 | 0.00 Unit on a scale | Standard Deviation 19.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C22D1 | -2.69 Unit on a scale | Standard Deviation 20.23 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C23D1 | -3.76 Unit on a scale | Standard Deviation 21.39 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C24D1 | -3.45 Unit on a scale | Standard Deviation 20.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C25D1 | -4.17 Unit on a scale | Standard Deviation 20.6 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C26D1 | -4.49 Unit on a scale | Standard Deviation 20.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C8D1 | -4.17 Unit on a scale | Standard Deviation 22.22 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C9D1 | -5.07 Unit on a scale | Standard Deviation 21.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C10D1 | -4.12 Unit on a scale | Standard Deviation 22.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C11D1 | -6.38 Unit on a scale | Standard Deviation 21.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C12D1 | -4.44 Unit on a scale | Standard Deviation 22.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C13D1 | -6.39 Unit on a scale | Standard Deviation 23.98 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C14D1 | -5.76 Unit on a scale | Standard Deviation 22.27 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C15D1 | -6.54 Unit on a scale | Standard Deviation 19.17 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C16D1 | -6.25 Unit on a scale | Standard Deviation 19.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C25D1 | -1.19 Unit on a scale | Standard Deviation 21.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C26D1 | -3.85 Unit on a scale | Standard Deviation 19.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C27D1 | -4.00 Unit on a scale | Standard Deviation 20.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C28D1 | -4.76 Unit on a scale | Standard Deviation 21.18 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C29D1 | -3.79 Unit on a scale | Standard Deviation 21.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C30D1 | -6.67 Unit on a scale | Standard Deviation 19.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C31D1 | -6.67 Unit on a scale | Standard Deviation 21.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C32D1 | -6.48 Unit on a scale | Standard Deviation 22.97 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C33D1 | -10.00 Unit on a scale | Standard Deviation 22.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C34D1 | -13.89 Unit on a scale | Standard Deviation 21.12 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C35D1 | -10.26 Unit on a scale | Standard Deviation 22.09 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C36D1 | -12.50 Unit on a scale | Standard Deviation 21.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C37D1 | -12.12 Unit on a scale | Standard Deviation 23.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C38D1 | -5.00 Unit on a scale | Standard Deviation 24.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C13D1 | -0.56 Unit on a scale | Standard Deviation 23.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C14D1 | -0.61 Unit on a scale | Standard Deviation 20.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C15D1 | 0.00 Unit on a scale | Standard Deviation 17.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C16D1 | -0.69 Unit on a scale | Standard Deviation 16.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C17D1 | 0.00 Unit on a scale | Standard Deviation 16.27 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C28D1 | -1.59 Unit on a scale | Standard Deviation 16.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C30D1 | 0.00 Unit on a scale | Standard Deviation 18.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C31D1 | -1.67 Unit on a scale | Standard Deviation 22.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C32D1 | 0.00 Unit on a scale | Standard Deviation 22.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C33D1 | 2.22 Unit on a scale | Standard Deviation 23.46 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C36D1 | -5.56 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C37D1 | -9.09 Unit on a scale | Standard Deviation 21.56 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C38D1 | -3.33 Unit on a scale | Standard Deviation 18.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C39D1 | -3.70 Unit on a scale | Standard Deviation 20.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea 90 day follow up | 2.73 Unit on a scale | Standard Deviation 15.27 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C13D1 | -3.33 Unit on a scale | Standard Deviation 24.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C14D1 | 0.61 Unit on a scale | Standard Deviation 27.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C15D1 | 5.23 Unit on a scale | Standard Deviation 23.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C25D1 | -2.38 Unit on a scale | Standard Deviation 20.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C26D1 | -2.56 Unit on a scale | Standard Deviation 18.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C28D1 | -1.59 Unit on a scale | Standard Deviation 19.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C29D1 | 1.52 Unit on a scale | Standard Deviation 21.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C32D1 | 0.00 Unit on a scale | Standard Deviation 22.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C33D1 | -2.22 Unit on a scale | Standard Deviation 19.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C5D1 | -2.94 Unit on a scale | Standard Deviation 36.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C6D1 | -0.22 Unit on a scale | Standard Deviation 34.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C8D1 | -1.23 Unit on a scale | Standard Deviation 31.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C17D1 | -8.53 Unit on a scale | Standard Deviation 32.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C19D1 | -14.17 Unit on a scale | Standard Deviation 30.09 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C23D1 | 3.23 Unit on a scale | Standard Deviation 23.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C6D1 | 2.83 Unit on a scale | Standard Deviation 21.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C7D1 | 1.11 Unit on a scale | Standard Deviation 20.99 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C29D1 | -16.67 Unit on a scale | Standard Deviation 28.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C30D1 | -10.00 Unit on a scale | Standard Deviation 32.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C31D1 | -16.67 Unit on a scale | Standard Deviation 31.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C2D1 | -0.64 Unit on a scale | Standard Deviation 24.94 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C3D1 | -2.38 Unit on a scale | Standard Deviation 26.23 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C6D1 | -5.82 Unit on a scale | Standard Deviation 26.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C7D1 | -7.78 Unit on a scale | Standard Deviation 26.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C12D1 | -6.22 Unit on a scale | Standard Deviation 25.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C13D1 | -7.78 Unit on a scale | Standard Deviation 25.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C16D1 | -2.78 Unit on a scale | Standard Deviation 26.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C5D1 | -0.63 Unit on a scale | Standard Deviation 28.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C6D1 | -0.89 Unit on a scale | Standard Deviation 27.66 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C7D1 | 0.56 Unit on a scale | Standard Deviation 24.05 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C8D1 | -0.62 Unit on a scale | Standard Deviation 26.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C9D1 | 2.29 Unit on a scale | Standard Deviation 24.94 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C10D1 | -2.75 Unit on a scale | Standard Deviation 27.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C12D1 | -0.89 Unit on a scale | Standard Deviation 30 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C13D1 | -3.33 Unit on a scale | Standard Deviation 27.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C15D1 | 0.00 Unit on a scale | Standard Deviation 29.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C16D1 | -2.08 Unit on a scale | Standard Deviation 25.18 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C17D1 | -2.33 Unit on a scale | Standard Deviation 23.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C18D1 | 3.25 Unit on a scale | Standard Deviation 22.12 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C19D1 | -2.50 Unit on a scale | Standard Deviation 21.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C38D1 | -6.67 Unit on a scale | Standard Deviation 14.05 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C39D1 | -3.70 Unit on a scale | Standard Deviation 20.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C31D1 | 0.00 Unit on a scale | Standard Deviation 21.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C35D1 | -2.56 Unit on a scale | Standard Deviation 16.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C23D1 | 2.42 Unit on a scale | Standard Deviation 11.42 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C24D1 | 2.59 Unit on a scale | Standard Deviation 14.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C26D1 | 4.17 Unit on a scale | Standard Deviation 16.37 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C27D1 | 3.00 Unit on a scale | Standard Deviation 18.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C28D1 | 0.79 Unit on a scale | Standard Deviation 19.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C29D1 | 2.65 Unit on a scale | Standard Deviation 17.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C10D1 | -0.59 Unit on a scale | Standard Deviation 17.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C12D1 | -0.22 Unit on a scale | Standard Deviation 13.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C20D1 | 0.85 Unit on a scale | Standard Deviation 17.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C21D1 | 0.93 Unit on a scale | Standard Deviation 19.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C22D1 | 2.69 Unit on a scale | Standard Deviation 18.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C29D1 | 0.76 Unit on a scale | Standard Deviation 21.5 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C34D1 | 6.94 Unit on a scale | Standard Deviation 21.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C38D1 | 8.33 Unit on a scale | Standard Deviation 23.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C3D1 | -1.47 Unit on a scale | Standard Deviation 23.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C7D1 | -0.97 Unit on a scale | Standard Deviation 26.22 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C10D1 | 2.55 Unit on a scale | Standard Deviation 25.39 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C11D1 | 3.29 Unit on a scale | Standard Deviation 23.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C14D1 | 2.12 Unit on a scale | Standard Deviation 20.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C15D1 | 1.63 Unit on a scale | Standard Deviation 22.42 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C16D1 | 4.86 Unit on a scale | Standard Deviation 20.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C18D1 | 0.81 Unit on a scale | Standard Deviation 22.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C19D1 | 5.42 Unit on a scale | Standard Deviation 19.02 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C23D1 | 4.30 Unit on a scale | Standard Deviation 24.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C24D1 | 4.02 Unit on a scale | Standard Deviation 23.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C25D1 | 4.76 Unit on a scale | Standard Deviation 21.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C26D1 | 5.77 Unit on a scale | Standard Deviation 23.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C27D1 | 4.00 Unit on a scale | Standard Deviation 25.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C28D1 | 4.76 Unit on a scale | Standard Deviation 29.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C29D1 | 3.03 Unit on a scale | Standard Deviation 26.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C30D1 | 3.33 Unit on a scale | Standard Deviation 28.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C34D1 | 5.56 Unit on a scale | Standard Deviation 35.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C37D1 | 6.06 Unit on a scale | Standard Deviation 36.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C39D1 | 0.00 Unit on a scale | Standard Deviation 33.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C2D1 | 1.66 Unit on a scale | Standard Deviation 19.69 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C5D1 | 4.93 Unit on a scale | Standard Deviation 21.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C32D1 | -2.78 Unit on a scale | Standard Deviation 25.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C33D1 | -8.89 Unit on a scale | Standard Deviation 21.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting 30 day follow up | 4.39 Unit on a scale | Standard Deviation 19.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C4D1 | -7.10 Unit on a scale | Standard Deviation 21.18 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C3D1 | -0.37 Unit on a scale | Standard Deviation 16.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C7D1 | 1.67 Unit on a scale | Standard Deviation 20.2 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C21D1 | 0.93 Unit on a scale | Standard Deviation 16.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C29D1 | 7.58 Unit on a scale | Standard Deviation 27.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C34D1 | -8.33 Unit on a scale | Standard Deviation 20.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C35D1 | -2.56 Unit on a scale | Standard Deviation 21.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia Baseline | 20.99 Unit on a scale | Standard Deviation 27.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C2D1 | -1.44 Unit on a scale | Standard Deviation 27.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C10D1 | -5.49 Unit on a scale | Standard Deviation 29.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C12D1 | -0.89 Unit on a scale | Standard Deviation 27.39 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C18D1 | 0.00 Unit on a scale | Standard Deviation 24.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C19D1 | 0.00 Unit on a scale | Standard Deviation 21.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C20D1 | -0.85 Unit on a scale | Standard Deviation 17.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C21D1 | 0.00 Unit on a scale | Standard Deviation 19.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C36D1 | -2.78 Unit on a scale | Standard Deviation 17.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C37D1 | 3.03 Unit on a scale | Standard Deviation 23.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C38D1 | 6.67 Unit on a scale | Standard Deviation 34.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss Baseline | 26.20 Unit on a scale | Standard Deviation 29.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C4D1 | -3.55 Unit on a scale | Standard Deviation 34.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C14D1 | -12.12 Unit on a scale | Standard Deviation 31.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C15D1 | -9.80 Unit on a scale | Standard Deviation 30.03 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C27D1 | -6.67 Unit on a scale | Standard Deviation 14.05 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning 90 day follow up | 0.21 Unit on a scale | Standard Deviation 21.88 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning Baseline | 87.81 Unit on a scale | Standard Deviation 18.01 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C22D1 | 2.45 Unit on a scale | Standard Deviation 18.58 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C16D1 | 6.45 Unit on a scale | Standard Deviation 26.41 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C23D1 | 3.65 Unit on a scale | Standard Deviation 23.56 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C14D1 | -4.17 Unit on a scale | Standard Deviation 21 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C24D1 | -0.69 Unit on a scale | Standard Deviation 23.96 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C25D1 | -0.69 Unit on a scale | Standard Deviation 20.24 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C5D1 | 2.22 Unit on a scale | Standard Deviation 15.13 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C26D1 | -3.70 Unit on a scale | Standard Deviation 18.69 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C6D1 | 0.91 Unit on a scale | Standard Deviation 16.81 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C28D1 | -9.09 Unit on a scale | Standard Deviation 21.56 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C28D1 | -3.79 Unit on a scale | Standard Deviation 19.85 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C15D1 | -5.56 Unit on a scale | Standard Deviation 20.31 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C12D1 | 1.17 Unit on a scale | Standard Deviation 16.62 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C27D1 | 5.00 Unit on a scale | Standard Deviation 15.81 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C18D1 | 2.38 Unit on a scale | Standard Deviation 16.06 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C19D1 | 3.33 Unit on a scale | Standard Deviation 11.6 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C13D1 | 0.69 Unit on a scale | Standard Deviation 22 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C20D1 | 1.75 Unit on a scale | Standard Deviation 21.44 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C16D1 | -5.91 Unit on a scale | Standard Deviation 20.43 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C14D1 | 0.00 Unit on a scale | Standard Deviation 19.02 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C22D1 | 4.90 Unit on a scale | Standard Deviation 20.21 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C5D1 | -0.81 Unit on a scale | Standard Deviation 23.52 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C15D1 | -1.39 Unit on a scale | Standard Deviation 19.67 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C17D1 | 2.67 Unit on a scale | Standard Deviation 13.33 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning 90 day follow up | -2.32 Unit on a scale | Standard Deviation 20.28 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C2D1 | -1.61 Unit on a scale | Standard Deviation 20.88 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C21D1 | 6.67 Unit on a scale | Standard Deviation 18.26 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C5D1 | 0.20 Unit on a scale | Standard Deviation 22.31 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C6D1 | -1.37 Unit on a scale | Standard Deviation 22.53 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C12D1 | 3.51 Unit on a scale | Standard Deviation 22.44 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C8D1 | -2.12 Unit on a scale | Standard Deviation 23.58 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C23D1 | 6.25 Unit on a scale | Standard Deviation 17.08 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C18D1 | -4.76 Unit on a scale | Standard Deviation 11.95 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C12D1 | -1.75 Unit on a scale | Standard Deviation 28.12 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C24D1 | 0.00 Unit on a scale | Standard Deviation 15.89 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C14D1 | 1.52 Unit on a scale | Standard Deviation 24.86 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C19D1 | -4.17 Unit on a scale | Standard Deviation 11.94 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C25D1 | 1.39 Unit on a scale | Standard Deviation 19.41 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C16D1 | 1.08 Unit on a scale | Standard Deviation 19.21 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C17D1 | 3.33 Unit on a scale | Standard Deviation 15.96 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C6D1 | 0.91 Unit on a scale | Standard Deviation 25.25 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C18D1 | 2.38 Unit on a scale | Standard Deviation 16.9 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C20D1 | -4.39 Unit on a scale | Standard Deviation 12.22 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C19D1 | 8.33 Unit on a scale | Standard Deviation 20.59 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C28D1 | -3.03 Unit on a scale | Standard Deviation 14.56 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C23D1 | 8.33 Unit on a scale | Standard Deviation 18.26 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C5D1 | 0.81 Unit on a scale | Standard Deviation 19.81 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C24D1 | -1.39 Unit on a scale | Standard Deviation 15.01 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C21D1 | -3.33 Unit on a scale | Standard Deviation 11.6 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C25D1 | -2.78 Unit on a scale | Standard Deviation 15.62 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C7D1 | -1.06 Unit on a scale | Standard Deviation 23.11 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C26D1 | 3.70 Unit on a scale | Standard Deviation 24.69 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C9D1 | -0.32 Unit on a scale | Standard Deviation 24.47 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C22D1 | -5.88 Unit on a scale | Standard Deviation 13.1 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C28D1 | 3.03 Unit on a scale | Standard Deviation 16.36 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C21D1 | 4.17 Unit on a scale | Standard Deviation 17.83 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C29D1 | 0.00 Unit on a scale | Standard Deviation 21.32 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue Baseline | 27.55 Unit on a scale | Standard Deviation 22.43 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C22D1 | 4.90 Unit on a scale | Standard Deviation 15.33 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C23D1 | -7.29 Unit on a scale | Standard Deviation 12.12 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C8D1 | 4.32 Unit on a scale | Standard Deviation 20.31 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning 90 day follow up | -8.23 Unit on a scale | Standard Deviation 26.4 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C24D1 | -16.67 Unit on a scale | Standard Deviation 33.33 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C3D1 | 0.96 Unit on a scale | Standard Deviation 21.26 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C12D1 | 0.00 Unit on a scale | Standard Deviation 23.19 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C26D1 | 0.00 Unit on a scale | Standard Deviation 11.11 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue 30 day follow up | 13.68 Unit on a scale | Standard Deviation 27.15 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C9D1 | 3.32 Unit on a scale | Standard Deviation 20.89 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C24D1 | -1.39 Unit on a scale | Standard Deviation 11.14 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C10D1 | 3.48 Unit on a scale | Standard Deviation 22.23 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C27D1 | -10.00 Unit on a scale | Standard Deviation 31.62 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C2D1 | -4.61 Unit on a scale | Standard Deviation 20.08 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C11D1 | 3.99 Unit on a scale | Standard Deviation 23.18 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C6D1 | -6.85 Unit on a scale | Standard Deviation 26.09 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C25D1 | -6.94 Unit on a scale | Standard Deviation 13.22 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C18D1 | 4.76 Unit on a scale | Standard Deviation 24.23 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C14D1 | -4.55 Unit on a scale | Standard Deviation 19.81 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C24D1 | 9.72 Unit on a scale | Standard Deviation 21.86 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C22D1 | -9.80 Unit on a scale | Standard Deviation 22.87 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C24D1 | -5.56 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C25D1 | -5.56 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C7D1 | -7.67 Unit on a scale | Standard Deviation 22.57 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C25D1 | 10.42 Unit on a scale | Standard Deviation 24.39 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C6D1 | 0.00 Unit on a scale | Standard Deviation 21.8 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea 90 day follow up | 2.53 Unit on a scale | Standard Deviation 24.33 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C26D1 | 3.70 Unit on a scale | Standard Deviation 19.59 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia Baseline | 24.79 Unit on a scale | Standard Deviation 26.66 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C8D1 | -5.61 Unit on a scale | Standard Deviation 24.96 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C2D1 | -1.54 Unit on a scale | Standard Deviation 27.55 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C9D1 | -4.21 Unit on a scale | Standard Deviation 27.88 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C27D1 | 6.67 Unit on a scale | Standard Deviation 11.65 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C11D1 | 0.94 Unit on a scale | Standard Deviation 30.33 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C12D1 | -0.58 Unit on a scale | Standard Deviation 29.87 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C28D1 | 5.30 Unit on a scale | Standard Deviation 14.08 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C18D1 | 4.76 Unit on a scale | Standard Deviation 24.23 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C9D1 | -8.09 Unit on a scale | Standard Deviation 24.46 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C19D1 | 6.67 Unit on a scale | Standard Deviation 38.39 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C29D1 | 4.86 Unit on a scale | Standard Deviation 14.42 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C20D1 | 7.02 Unit on a scale | Standard Deviation 23.78 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C13D1 | 4.17 Unit on a scale | Standard Deviation 25.38 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C21D1 | 8.33 Unit on a scale | Standard Deviation 30.35 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C10D1 | -6.33 Unit on a scale | Standard Deviation 25.5 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C13D1 | 1.39 Unit on a scale | Standard Deviation 33.66 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C11D1 | -6.34 Unit on a scale | Standard Deviation 26.78 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C7D1 | 0.26 Unit on a scale | Standard Deviation 24.76 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss Baseline | 24.66 Unit on a scale | Standard Deviation 29.17 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C12D1 | -7.02 Unit on a scale | Standard Deviation 24.99 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C14D1 | -0.76 Unit on a scale | Standard Deviation 33.32 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C14D1 | -11.36 Unit on a scale | Standard Deviation 30.45 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C13D1 | -7.64 Unit on a scale | Standard Deviation 24.54 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C2D1 | -2.76 Unit on a scale | Standard Deviation 25.1 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C18D1 | -9.52 Unit on a scale | Standard Deviation 35.19 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C14D1 | -6.06 Unit on a scale | Standard Deviation 24.14 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C21D1 | -10.00 Unit on a scale | Standard Deviation 34.37 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C17D1 | 1.33 Unit on a scale | Standard Deviation 20.37 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C23D1 | -14.58 Unit on a scale | Standard Deviation 40.31 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C26D1 | -14.81 Unit on a scale | Standard Deviation 17.57 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C28D1 | 0.00 Unit on a scale | Standard Deviation 29.81 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C29D1 | -11.11 Unit on a scale | Standard Deviation 29.59 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C4D1 | 1.07 Unit on a scale | Standard Deviation 15.38 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C15D1 | -7.41 Unit on a scale | Standard Deviation 21.25 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C5D1 | 0.24 Unit on a scale | Standard Deviation 16.29 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C25D1 | 2.78 Unit on a scale | Standard Deviation 22.29 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C8D1 | -1.33 Unit on a scale | Standard Deviation 17.08 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss 30 day follow up | 6.41 Unit on a scale | Standard Deviation 29.94 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C9D1 | -0.84 Unit on a scale | Standard Deviation 18.26 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C24D1 | -8.33 Unit on a scale | Standard Deviation 29.73 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C3D1 | -5.25 Unit on a scale | Standard Deviation 23.58 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C11D1 | -0.09 Unit on a scale | Standard Deviation 17.11 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C13D1 | -3.47 Unit on a scale | Standard Deviation 33.85 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C8D1 | 3.33 Unit on a scale | Standard Deviation 23.87 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C12D1 | -0.70 Unit on a scale | Standard Deviation 19.18 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C25D1 | -11.11 Unit on a scale | Standard Deviation 29.59 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C23D1 | 4.17 Unit on a scale | Standard Deviation 23.96 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C15D1 | 0.00 Unit on a scale | Standard Deviation 13.62 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C24D1 | 2.78 Unit on a scale | Standard Deviation 26.43 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C28D1 | -3.03 Unit on a scale | Standard Deviation 17.98 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C29D1 | 0.00 Unit on a scale | Standard Deviation 14.21 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C26D1 | 3.70 Unit on a scale | Standard Deviation 20.03 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C16D1 | 0.86 Unit on a scale | Standard Deviation 12.14 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C7D1 | -0.66 Unit on a scale | Standard Deviation 24.71 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C7D1 | -0.79 Unit on a scale | Standard Deviation 23.74 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C26D1 | -9.26 Unit on a scale | Standard Deviation 18.84 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C8D1 | -5.61 Unit on a scale | Standard Deviation 26.16 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C18D1 | 3.49 Unit on a scale | Standard Deviation 15.44 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C9D1 | -2.59 Unit on a scale | Standard Deviation 23.89 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C19D1 | 4.00 Unit on a scale | Standard Deviation 13.4 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C10D1 | -3.59 Unit on a scale | Standard Deviation 26.91 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C15D1 | 4.63 Unit on a scale | Standard Deviation 24.11 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C11D1 | -3.29 Unit on a scale | Standard Deviation 28.4 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C8D1 | 0.10 Unit on a scale | Standard Deviation 23.05 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C12D1 | -2.63 Unit on a scale | Standard Deviation 26.69 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C27D1 | -6.67 Unit on a scale | Standard Deviation 23.83 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C13D1 | -0.35 Unit on a scale | Standard Deviation 27.39 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C28D1 | 15.15 Unit on a scale | Standard Deviation 27.34 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C19D1 | 6.67 Unit on a scale | Standard Deviation 17.44 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C8D1 | -4.85 Unit on a scale | Standard Deviation 25.48 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C20D1 | 10.53 Unit on a scale | Standard Deviation 22.37 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C10D1 | -0.42 Unit on a scale | Standard Deviation 28.49 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C21D1 | 6.67 Unit on a scale | Standard Deviation 23.82 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C28D1 | -3.03 Unit on a scale | Standard Deviation 19.46 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C22D1 | 8.82 Unit on a scale | Standard Deviation 24.38 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C7D1 | -2.12 Unit on a scale | Standard Deviation 32.32 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C23D1 | 9.37 Unit on a scale | Standard Deviation 30.41 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C9D1 | -0.86 Unit on a scale | Standard Deviation 23.06 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C24D1 | 6.94 Unit on a scale | Standard Deviation 27.02 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C29D1 | -11.11 Unit on a scale | Standard Deviation 23.92 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C10D1 | -0.42 Unit on a scale | Standard Deviation 24.81 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning 90 day follow up | -9.49 Unit on a scale | Standard Deviation 30.39 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C29D1 | 8.33 Unit on a scale | Standard Deviation 25.13 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning Baseline | 78.79 Unit on a scale | Standard Deviation 19.41 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C8D1 | -3.03 Unit on a scale | Standard Deviation 31.13 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C2D1 | 4.42 Unit on a scale | Standard Deviation 16.49 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C22D1 | -3.27 Unit on a scale | Standard Deviation 18.33 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C3D1 | 3.00 Unit on a scale | Standard Deviation 18.84 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C9D1 | -5.50 Unit on a scale | Standard Deviation 29.19 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C4D1 | 2.51 Unit on a scale | Standard Deviation 19.52 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C23D1 | -4.17 Unit on a scale | Standard Deviation 22.18 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C5D1 | 3.69 Unit on a scale | Standard Deviation 17.81 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C3D1 | -2.71 Unit on a scale | Standard Deviation 27.43 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C6D1 | 3.77 Unit on a scale | Standard Deviation 19.18 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C24D1 | -3.70 Unit on a scale | Standard Deviation 19.73 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C7D1 | 2.12 Unit on a scale | Standard Deviation 21.24 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C9D1 | 1.94 Unit on a scale | Standard Deviation 21.3 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C8D1 | 2.20 Unit on a scale | Standard Deviation 18.08 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C25D1 | -0.93 Unit on a scale | Standard Deviation 17.38 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C9D1 | 2.59 Unit on a scale | Standard Deviation 19.07 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C5D1 | -4.44 Unit on a scale | Standard Deviation 33.03 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C10D1 | 1.79 Unit on a scale | Standard Deviation 20.62 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C12D1 | -1.17 Unit on a scale | Standard Deviation 26.7 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C11D1 | 2.58 Unit on a scale | Standard Deviation 20.97 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C27D1 | 2.22 Unit on a scale | Standard Deviation 15.54 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C12D1 | 2.05 Unit on a scale | Standard Deviation 21.49 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C7D1 | -6.88 Unit on a scale | Standard Deviation 31.36 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C13D1 | 1.91 Unit on a scale | Standard Deviation 21.42 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C28D1 | 8.08 Unit on a scale | Standard Deviation 13.23 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C14D1 | -1.33 Unit on a scale | Standard Deviation 18.76 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties 30 day follow up | 9.40 Unit on a scale | Standard Deviation 24.56 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C15D1 | -1.85 Unit on a scale | Standard Deviation 21.19 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C29D1 | 5.56 Unit on a scale | Standard Deviation 18.65 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C16D1 | -0.27 Unit on a scale | Standard Deviation 23.22 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C17D1 | 5.33 Unit on a scale | Standard Deviation 16.12 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C13D1 | -12.50 Unit on a scale | Standard Deviation 31.23 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C20D1 | 1.75 Unit on a scale | Standard Deviation 19.95 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C13D1 | -2.78 Unit on a scale | Standard Deviation 21.56 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C21D1 | 5.00 Unit on a scale | Standard Deviation 18.22 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C14D1 | -2.27 Unit on a scale | Standard Deviation 28.21 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C27D1 | -5.83 Unit on a scale | Standard Deviation 19.66 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C29D1 | -3.47 Unit on a scale | Standard Deviation 27.17 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C17D1 | -6.67 Unit on a scale | Standard Deviation 36 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C8D1 | -6.97 Unit on a scale | Standard Deviation 23.83 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C15D1 | -4.63 Unit on a scale | Standard Deviation 16.24 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C9D1 | -6.15 Unit on a scale | Standard Deviation 20.74 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C15D1 | -3.70 Unit on a scale | Standard Deviation 32.64 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C10D1 | -7.17 Unit on a scale | Standard Deviation 24.99 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C16D1 | -3.23 Unit on a scale | Standard Deviation 21.7 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C11D1 | -6.81 Unit on a scale | Standard Deviation 24.17 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C22D1 | 3.92 Unit on a scale | Standard Deviation 26.04 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C12D1 | -2.34 Unit on a scale | Standard Deviation 25.48 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C27D1 | -6.67 Unit on a scale | Standard Deviation 14.05 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning 30 day follow up | -5.02 Unit on a scale | Standard Deviation 24.15 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C13D1 | -7.99 Unit on a scale | Standard Deviation 23.82 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C25D1 | 8.33 Unit on a scale | Standard Deviation 20.72 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C21D1 | -10.00 Unit on a scale | Standard Deviation 19.04 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C26D1 | -7.41 Unit on a scale | Standard Deviation 14.7 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C22D1 | 9.31 Unit on a scale | Standard Deviation 22.99 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C15D1 | -2.78 Unit on a scale | Standard Deviation 20.12 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C23D1 | 9.38 Unit on a scale | Standard Deviation 19.69 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C26D1 | -7.41 Unit on a scale | Standard Deviation 14.7 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C18D1 | 3.97 Unit on a scale | Standard Deviation 19.65 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status 30 day follow up | -10.68 Unit on a scale | Standard Deviation 24.65 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Emotional Functioning C19D1 | 4.58 Unit on a scale | Standard Deviation 13.1 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C29D1 | 5.56 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status 90 day follow up | -4.96 Unit on a scale | Standard Deviation 22.86 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C15D1 | 1.85 Unit on a scale | Standard Deviation 30.8 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C7D1 | -1.19 Unit on a scale | Standard Deviation 17.02 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C16D1 | -2.69 Unit on a scale | Standard Deviation 20.68 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning Baseline | 83.55 Unit on a scale | Standard Deviation 17.22 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C17D1 | 2.67 Unit on a scale | Standard Deviation 14.97 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C11D1 | 4.69 Unit on a scale | Standard Deviation 22.04 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C2D1 | -0.77 Unit on a scale | Standard Deviation 13.7 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C26D1 | 0.00 Unit on a scale | Standard Deviation 16.67 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C16D1 | -3.23 Unit on a scale | Standard Deviation 13.21 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C27D1 | -1.67 Unit on a scale | Standard Deviation 14.59 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C29D1 | 0.00 Unit on a scale | Standard Deviation 14.21 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C3D1 | -0.07 Unit on a scale | Standard Deviation 14.94 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C6D1 | -0.96 Unit on a scale | Standard Deviation 17.94 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C3D1 | -2.54 Unit on a scale | Standard Deviation 28.56 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C7D1 | 0.21 Unit on a scale | Standard Deviation 17.69 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C28D1 | -6.06 Unit on a scale | Standard Deviation 20.1 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C3D1 | -1.44 Unit on a scale | Standard Deviation 22.7 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C4D1 | -5.13 Unit on a scale | Standard Deviation 27.94 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C4D1 | 1.97 Unit on a scale | Standard Deviation 21.73 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C10D1 | -2.28 Unit on a scale | Standard Deviation 18.76 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C2D1 | 0.15 Unit on a scale | Standard Deviation 19.11 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C10D1 | -0.84 Unit on a scale | Standard Deviation 27.2 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C11D1 | -2.58 Unit on a scale | Standard Deviation 25.14 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C13D1 | 0.97 Unit on a scale | Standard Deviation 13.89 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C13D1 | -0.35 Unit on a scale | Standard Deviation 23.19 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C15D1 | -2.78 Unit on a scale | Standard Deviation 23.06 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C19D1 | -3.33 Unit on a scale | Standard Deviation 18.42 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C14D1 | 1.21 Unit on a scale | Standard Deviation 13.04 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning C20D1 | 7.02 Unit on a scale | Standard Deviation 20.27 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C4D1 | -0.46 Unit on a scale | Standard Deviation 22.03 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C17D1 | -4.00 Unit on a scale | Standard Deviation 11.06 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C17D1 | 2.13 Unit on a scale | Standard Deviation 16.75 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C23D1 | 4.17 Unit on a scale | Standard Deviation 34.16 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C3D1 | 1.18 Unit on a scale | Standard Deviation 22.43 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C20D1 | 2.81 Unit on a scale | Standard Deviation 16.68 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C24D1 | 0.00 Unit on a scale | Standard Deviation 24.62 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning Baseline | 79.55 Unit on a scale | Standard Deviation 23.48 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Social Functioning 30 day follow up | -12.82 Unit on a scale | Standard Deviation 26.03 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C18D1 | -4.76 Unit on a scale | Standard Deviation 19.11 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C7D1 | -2.91 Unit on a scale | Standard Deviation 31.28 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C29D1 | -8.33 Unit on a scale | Standard Deviation 25.13 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C11D1 | -0.31 Unit on a scale | Standard Deviation 24.34 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C17D1 | -1.78 Unit on a scale | Standard Deviation 18.61 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C18D1 | -7.94 Unit on a scale | Standard Deviation 17.26 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C19D1 | -3.33 Unit on a scale | Standard Deviation 14.91 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties 90 day follow up | 3.80 Unit on a scale | Standard Deviation 20.66 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C13D1 | 0.00 Unit on a scale | Standard Deviation 20.76 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia 30 day follow up | 8.55 Unit on a scale | Standard Deviation 36.21 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C28D1 | -3.03 Unit on a scale | Standard Deviation 14.56 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C20D1 | -8.77 Unit on a scale | Standard Deviation 30.11 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C14D1 | -0.76 Unit on a scale | Standard Deviation 19.82 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C4D1 | -0.39 Unit on a scale | Standard Deviation 23.28 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation 30 day follow up | 4.70 Unit on a scale | Standard Deviation 28.29 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C15D1 | -0.62 Unit on a scale | Standard Deviation 17.2 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia 90 day follow up | 0.42 Unit on a scale | Standard Deviation 28.99 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C16D1 | -2.15 Unit on a scale | Standard Deviation 17.55 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C23D1 | -8.33 Unit on a scale | Standard Deviation 22.77 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C20D1 | -3.51 Unit on a scale | Standard Deviation 15.29 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C2D1 | -2.61 Unit on a scale | Standard Deviation 27.37 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation 90 day follow up | 5.91 Unit on a scale | Standard Deviation 31.01 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C29D1 | -11.11 Unit on a scale | Standard Deviation 21.71 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C19D1 | -4.44 Unit on a scale | Standard Deviation 15.46 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea 30 day follow up | 4.27 Unit on a scale | Standard Deviation 23.02 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea 30 day follow up | 1.71 Unit on a scale | Standard Deviation 19.29 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C5D1 | -4.44 Unit on a scale | Standard Deviation 28.16 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C20D1 | -4.68 Unit on a scale | Standard Deviation 18.64 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C6D1 | -2.51 Unit on a scale | Standard Deviation 30.35 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C16D1 | 6.45 Unit on a scale | Standard Deviation 24.97 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue C21D1 | -3.33 Unit on a scale | Standard Deviation 18.77 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C17D1 | 12.00 Unit on a scale | Standard Deviation 31.74 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C9D1 | -7.12 Unit on a scale | Standard Deviation 34.51 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C22D1 | 9.80 Unit on a scale | Standard Deviation 34.89 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea Baseline | 7.71 Unit on a scale | Standard Deviation 15.34 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C10D1 | -10.13 Unit on a scale | Standard Deviation 32.62 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Insomnia C27D1 | 6.67 Unit on a scale | Standard Deviation 21.08 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C21D1 | -3.33 Unit on a scale | Standard Deviation 14.91 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C11D1 | -12.21 Unit on a scale | Standard Deviation 33.92 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C4D1 | -5.13 Unit on a scale | Standard Deviation 33.13 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C6D1 | -2.51 Unit on a scale | Standard Deviation 33.47 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C2D1 | 5.68 Unit on a scale | Standard Deviation 22.98 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C8D1 | -6.36 Unit on a scale | Standard Deviation 32.71 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C4D1 | -1.58 Unit on a scale | Standard Deviation 22.07 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C12D1 | -11.11 Unit on a scale | Standard Deviation 30.43 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C20D1 | -1.75 Unit on a scale | Standard Deviation 20.71 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C15D1 | -11.11 Unit on a scale | Standard Deviation 29.81 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Fatigue 90 day follow up | 7.31 Unit on a scale | Standard Deviation 22 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C16D1 | -8.60 Unit on a scale | Standard Deviation 32.17 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C19D1 | -15.00 Unit on a scale | Standard Deviation 20.16 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C3D1 | 4.06 Unit on a scale | Standard Deviation 20.63 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C20D1 | -15.79 Unit on a scale | Standard Deviation 30.16 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C22D1 | -17.65 Unit on a scale | Standard Deviation 31.44 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting Baseline | 15.08 Unit on a scale | Standard Deviation 23.2 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C21D1 | 3.33 Unit on a scale | Standard Deviation 21.36 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C2D1 | -0.92 Unit on a scale | Standard Deviation 20.77 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C22D1 | -5.88 Unit on a scale | Standard Deviation 21.2 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C3D1 | 0.17 Unit on a scale | Standard Deviation 22.21 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss C25D1 | -16.67 Unit on a scale | Standard Deviation 33.33 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Appetite Loss 90 day follow up | 0.84 Unit on a scale | Standard Deviation 32.46 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation Baseline | 17.63 Unit on a scale | Standard Deviation 27.02 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C4D1 | -2.76 Unit on a scale | Standard Deviation 22.98 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C5D1 | -3.74 Unit on a scale | Standard Deviation 25.06 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C4D1 | 3.94 Unit on a scale | Standard Deviation 22.07 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C6D1 | -1.60 Unit on a scale | Standard Deviation 24.71 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C21D1 | 3.33 Unit on a scale | Standard Deviation 12.89 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea 90 day follow up | -1.27 Unit on a scale | Standard Deviation 23.54 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C22D1 | 5.49 Unit on a scale | Standard Deviation 17.52 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C7D1 | -2.91 Unit on a scale | Standard Deviation 24.59 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C23D1 | 5.83 Unit on a scale | Standard Deviation 19.3 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C5D1 | 4.44 Unit on a scale | Standard Deviation 20.34 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C24D1 | 5.56 Unit on a scale | Standard Deviation 17.71 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C26D1 | -1.85 Unit on a scale | Standard Deviation 24.22 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C25D1 | 3.89 Unit on a scale | Standard Deviation 23.35 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C27D1 | -5.00 Unit on a scale | Standard Deviation 15.81 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C26D1 | 2.96 Unit on a scale | Standard Deviation 17.36 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C4D1 | -6.90 Unit on a scale | Standard Deviation 29.07 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C27D1 | 2.00 Unit on a scale | Standard Deviation 13.72 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting C29D1 | -9.72 Unit on a scale | Standard Deviation 13.22 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C28D1 | -1.82 Unit on a scale | Standard Deviation 19.8 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C23D1 | -8.33 Unit on a scale | Standard Deviation 14.91 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning C29D1 | 1.11 Unit on a scale | Standard Deviation 18.16 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C5D1 | -4.65 Unit on a scale | Standard Deviation 26.77 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C6D1 | -4.34 Unit on a scale | Standard Deviation 29.36 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C6D1 | 3.65 Unit on a scale | Standard Deviation 21.49 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C10D1 | 1.27 Unit on a scale | Standard Deviation 24.13 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C10D1 | -7.17 Unit on a scale | Standard Deviation 30.97 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C7D1 | 5.29 Unit on a scale | Standard Deviation 19.51 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C11D1 | -3.29 Unit on a scale | Standard Deviation 33.88 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting 30 day follow up | 0.21 Unit on a scale | Standard Deviation 24.25 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C24D1 | -2.78 Unit on a scale | Standard Deviation 9.62 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Nausea and Vomiting 90 day follow up | -1.05 Unit on a scale | Standard Deviation 26.06 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C8D1 | 2.12 Unit on a scale | Standard Deviation 18.77 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning 30 day follow up | -9.91 Unit on a scale | Standard Deviation 20.29 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain Baseline | 24.10 Unit on a scale | Standard Deviation 23.71 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Physical Functioning 90 day follow up | -10.63 Unit on a scale | Standard Deviation 22.28 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C16D1 | -2.15 Unit on a scale | Standard Deviation 33.26 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning Baseline | 82.23 Unit on a scale | Standard Deviation 23.59 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties Baseline | 19.42 Unit on a scale | Standard Deviation 25.3 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C2D1 | -1.92 Unit on a scale | Standard Deviation 19.97 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C3D1 | -3.38 Unit on a scale | Standard Deviation 22.77 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C3D1 | -2.28 Unit on a scale | Standard Deviation 24.38 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C4D1 | -7.40 Unit on a scale | Standard Deviation 22.41 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C4D1 | -0.79 Unit on a scale | Standard Deviation 24.65 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C17D1 | -1.33 Unit on a scale | Standard Deviation 26.32 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C5D1 | -0.40 Unit on a scale | Standard Deviation 25.03 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C5D1 | -6.26 Unit on a scale | Standard Deviation 26.05 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C6D1 | -3.08 Unit on a scale | Standard Deviation 24.68 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C9D1 | 0.65 Unit on a scale | Standard Deviation 19.79 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C18D1 | -6.35 Unit on a scale | Standard Deviation 29.1 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C14D1 | 0.76 Unit on a scale | Standard Deviation 21.25 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C16D1 | -6.45 Unit on a scale | Standard Deviation 23.04 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C15D1 | -0.46 Unit on a scale | Standard Deviation 24.72 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C25D1 | -2.78 Unit on a scale | Standard Deviation 17.16 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C16D1 | 0.00 Unit on a scale | Standard Deviation 21.08 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C17D1 | -7.33 Unit on a scale | Standard Deviation 25.95 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C17D1 | 2.67 Unit on a scale | Standard Deviation 28.74 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C19D1 | -6.67 Unit on a scale | Standard Deviation 17.44 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C18D1 | 6.35 Unit on a scale | Standard Deviation 21.39 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C25D1 | 8.33 Unit on a scale | Standard Deviation 28.87 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C18D1 | -11.90 Unit on a scale | Standard Deviation 27.96 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C26D1 | -3.70 Unit on a scale | Standard Deviation 27.36 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C10D1 | -2.53 Unit on a scale | Standard Deviation 17.52 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C27D1 | -3.33 Unit on a scale | Standard Deviation 23.31 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C19D1 | -7.50 Unit on a scale | Standard Deviation 26.2 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C28D1 | -4.55 Unit on a scale | Standard Deviation 21.2 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C20D1 | -7.02 Unit on a scale | Standard Deviation 26.24 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning C29D1 | 2.78 Unit on a scale | Standard Deviation 19.89 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C11D1 | -0.94 Unit on a scale | Standard Deviation 18.66 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C21D1 | -11.67 Unit on a scale | Standard Deviation 29.17 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C21D1 | -5.00 Unit on a scale | Standard Deviation 31.11 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C22D1 | -12.75 Unit on a scale | Standard Deviation 30.35 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C14D1 | 0.00 Unit on a scale | Standard Deviation 23.84 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain C23D1 | -15.63 Unit on a scale | Standard Deviation 30.1 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C22D1 | 1.96 Unit on a scale | Standard Deviation 24.92 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C23D1 | 0.00 Unit on a scale | Standard Deviation 34.43 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C12D1 | -2.92 Unit on a scale | Standard Deviation 20.2 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain 30 day follow up | 8.76 Unit on a scale | Standard Deviation 26.42 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C26D1 | 0.00 Unit on a scale | Standard Deviation 16.67 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Role Functioning 30 day follow up | -16.88 Unit on a scale | Standard Deviation 31.38 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Pain 90 day follow up | 2.11 Unit on a scale | Standard Deviation 22.7 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C2D1 | 0.54 Unit on a scale | Standard Deviation 15.5 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C24D1 | 5.56 Unit on a scale | Standard Deviation 31.25 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C3D1 | 0.51 Unit on a scale | Standard Deviation 15.51 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea Baseline | 10.88 Unit on a scale | Standard Deviation 19.35 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C4D1 | 1.87 Unit on a scale | Standard Deviation 15.58 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C8D1 | 0.15 Unit on a scale | Standard Deviation 18.27 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C13D1 | -4.17 Unit on a scale | Standard Deviation 17.7 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C9D1 | 0.97 Unit on a scale | Standard Deviation 18.05 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C10D1 | -0.42 Unit on a scale | Standard Deviation 19.61 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C2D1 | -0.77 Unit on a scale | Standard Deviation 17.99 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning C11D1 | -1.41 Unit on a scale | Standard Deviation 18.42 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C3D1 | 0.51 Unit on a scale | Standard Deviation 22.2 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C25D1 | 0.00 Unit on a scale | Standard Deviation 24.62 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C5D1 | -2.22 Unit on a scale | Standard Deviation 23.03 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Cognitive Functioning 30 day follow up | -4.27 Unit on a scale | Standard Deviation 20.18 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Financial Difficulties C2D1 | -0.92 Unit on a scale | Standard Deviation 18.68 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status Baseline | 66.15 Unit on a scale | Standard Deviation 19.4 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C6D1 | 0.00 Unit on a scale | Standard Deviation 21.8 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C2D1 | 2.96 Unit on a scale | Standard Deviation 18.89 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C7D1 | -0.53 Unit on a scale | Standard Deviation 22.7 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C3D1 | 3.68 Unit on a scale | Standard Deviation 20.69 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C26D1 | 7.41 Unit on a scale | Standard Deviation 14.7 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C4D1 | 4.54 Unit on a scale | Standard Deviation 20.59 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C8D1 | 2.12 Unit on a scale | Standard Deviation 23.58 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C5D1 | 3.48 Unit on a scale | Standard Deviation 19.57 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C9D1 | -2.27 Unit on a scale | Standard Deviation 20.49 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C6D1 | 3.94 Unit on a scale | Standard Deviation 20.51 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C10D1 | -0.42 Unit on a scale | Standard Deviation 24.16 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C7D1 | 2.12 Unit on a scale | Standard Deviation 19.69 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C14D1 | -2.27 Unit on a scale | Standard Deviation 20.83 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C12D1 | 2.63 Unit on a scale | Standard Deviation 22.06 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C11D1 | -3.29 Unit on a scale | Standard Deviation 21.2 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C13D1 | 3.30 Unit on a scale | Standard Deviation 20.82 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C27D1 | 10.00 Unit on a scale | Standard Deviation 22.5 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C14D1 | 3.79 Unit on a scale | Standard Deviation 21.15 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C12D1 | -2.92 Unit on a scale | Standard Deviation 19.19 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C15D1 | 2.08 Unit on a scale | Standard Deviation 21.02 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C17D1 | -6.67 Unit on a scale | Standard Deviation 21.52 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C16D1 | 5.65 Unit on a scale | Standard Deviation 17.4 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C18D1 | -9.52 Unit on a scale | Standard Deviation 18.69 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C17D1 | 3.33 Unit on a scale | Standard Deviation 20.41 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Diarrhoea C27D1 | -3.33 Unit on a scale | Standard Deviation 18.92 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C18D1 | 3.97 Unit on a scale | Standard Deviation 31.36 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C19D1 | -11.67 Unit on a scale | Standard Deviation 19.57 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C19D1 | 10.42 Unit on a scale | Standard Deviation 15.97 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Constipation C28D1 | 12.12 Unit on a scale | Standard Deviation 22.47 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C20D1 | 3.95 Unit on a scale | Standard Deviation 19.71 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Dyspnoea C20D1 | -10.53 Unit on a scale | Standard Deviation 22.37 |
| CAPOX+ Placebo | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Global Health Status C21D1 | 2.92 Unit on a scale | Standard Deviation 18.98 |
Secondary
Change From Baseline in HRQoL Measured by Global Pain (GP)
The GP instrument is a single assessment of overall pain and participants were assessed in global pain according to the following response categories: 1= no pain (anymore), 2 = less pain, 3 = no change and 4 = more pain. Low pain scores are considered a better outcome than a high pain score.
Time frame: Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up
Population: FAS with available data was analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C4D1 | -0.63 Unit on a scale | Standard Deviation 2.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C22D1 | 0.00 Unit on a scale | Standard Deviation 2.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C12D1 | 0.08 Unit on a scale | Standard Deviation 2.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C23D1 | -0.19 Unit on a scale | Standard Deviation 2.17 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C7D1 | -0.61 Unit on a scale | Standard Deviation 2.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C24D1 | -0.45 Unit on a scale | Standard Deviation 3.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C13D1 | 0.05 Unit on a scale | Standard Deviation 3.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C25D1 | -0.86 Unit on a scale | Standard Deviation 2.17 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C3D1 | -0.74 Unit on a scale | Standard Deviation 2.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C26D1 | -0.58 Unit on a scale | Standard Deviation 2.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C14D1 | -0.95 Unit on a scale | Standard Deviation 2.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C27D1 | -1.08 Unit on a scale | Standard Deviation 2.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C8D1 | -0.59 Unit on a scale | Standard Deviation 2.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C28D1 | 0.05 Unit on a scale | Standard Deviation 2.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C15D1 | -0.80 Unit on a scale | Standard Deviation 2.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C29D1 | -0.14 Unit on a scale | Standard Deviation 2.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C5D1 | -0.37 Unit on a scale | Standard Deviation 2.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C30D1 | -0.45 Unit on a scale | Standard Deviation 2.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C31D1 | -0.45 Unit on a scale | Standard Deviation 2.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C32D1 | -0.50 Unit on a scale | Standard Deviation 2.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C33D1 | 0.07 Unit on a scale | Standard Deviation 3.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C34D1 | -0.67 Unit on a scale | Standard Deviation 3.2 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C35D1 | -0.69 Unit on a scale | Standard Deviation 2.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C36D1 | -1.42 Unit on a scale | Standard Deviation 1.56 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C37D1 | 0.18 Unit on a scale | Standard Deviation 3.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C38D1 | 0.00 Unit on a scale | Standard Deviation 3.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C39D1 | -0.89 Unit on a scale | Standard Deviation 1.27 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | 30 day follow up | 0.74 Unit on a scale | Standard Deviation 3.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C16D1 | -0.19 Unit on a scale | Standard Deviation 3.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | 90 day follow up | 0.08 Unit on a scale | Standard Deviation 3.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | Baseline | 2.45 Unit on a scale | Standard Deviation 2.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C9D1 | -0.65 Unit on a scale | Standard Deviation 2.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C17D1 | -0.74 Unit on a scale | Standard Deviation 2.46 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C2D1 | -0.60 Unit on a scale | Standard Deviation 2.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C18D1 | 0.17 Unit on a scale | Standard Deviation 3.26 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C10D1 | -0.71 Unit on a scale | Standard Deviation 2.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C19D1 | -0.20 Unit on a scale | Standard Deviation 2.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C6D1 | -0.51 Unit on a scale | Standard Deviation 2.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C20D1 | 0.05 Unit on a scale | Standard Deviation 2.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C11D1 | -0.40 Unit on a scale | Standard Deviation 2.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by Global Pain (GP) | C21D1 | -0.06 Unit on a scale | Standard Deviation 2.86 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | 90 day follow up | 0.62 Unit on a scale | Standard Deviation 2.81 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | Baseline | 2.64 Unit on a scale | Standard Deviation 2.55 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C2D1 | -0.63 Unit on a scale | Standard Deviation 2.59 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C3D1 | -0.82 Unit on a scale | Standard Deviation 2.33 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C4D1 | -0.91 Unit on a scale | Standard Deviation 2.68 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C5D1 | -0.79 Unit on a scale | Standard Deviation 2.84 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C6D1 | -0.57 Unit on a scale | Standard Deviation 3 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C7D1 | -0.38 Unit on a scale | Standard Deviation 2.74 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C8D1 | -0.36 Unit on a scale | Standard Deviation 2.48 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C9D1 | -0.36 Unit on a scale | Standard Deviation 2.63 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C10D1 | -0.71 Unit on a scale | Standard Deviation 2.65 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C11D1 | -0.61 Unit on a scale | Standard Deviation 2.55 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C12D1 | -0.53 Unit on a scale | Standard Deviation 2.41 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C13D1 | -0.63 Unit on a scale | Standard Deviation 2.44 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C14D1 | -0.34 Unit on a scale | Standard Deviation 2.12 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C15D1 | -0.44 Unit on a scale | Standard Deviation 1.81 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C16D1 | 0.10 Unit on a scale | Standard Deviation 2.23 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C17D1 | -0.20 Unit on a scale | Standard Deviation 1.32 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C18D1 | -0.48 Unit on a scale | Standard Deviation 1.29 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C19D1 | -0.25 Unit on a scale | Standard Deviation 0.97 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C20D1 | 0.21 Unit on a scale | Standard Deviation 2.9 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C21D1 | 0.50 Unit on a scale | Standard Deviation 2.96 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C22D1 | 0.00 Unit on a scale | Standard Deviation 2.92 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C23D1 | 0.69 Unit on a scale | Standard Deviation 3.22 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C24D1 | -0.33 Unit on a scale | Standard Deviation 1.72 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C25D1 | 0.17 Unit on a scale | Standard Deviation 3.21 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C26D1 | 0.22 Unit on a scale | Standard Deviation 1.86 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C27D1 | 0.80 Unit on a scale | Standard Deviation 3.29 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C28D1 | 0.18 Unit on a scale | Standard Deviation 1.33 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | C29D1 | -0.17 Unit on a scale | Standard Deviation 0.72 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by Global Pain (GP) | 30 day follow up | 0.56 Unit on a scale | Standard Deviation 2.63 |
Secondary
Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire
EQ-5D-5L is a standardized instrument for use as a measure of health outcomes consisting of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale for health status. It was developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples.
Time frame: Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up
Population: FAS with available data was analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C18D1 | 0.10 Unit on a scale | Standard Deviation 0.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities 90 day follow up | 0.41 Unit on a scale | Standard Deviation 0.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort Baseline | 1.86 Unit on a scale | Standard Deviation 0.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C2D1 | -0.17 Unit on a scale | Standard Deviation 0.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C3D1 | -0.21 Unit on a scale | Standard Deviation 0.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C4D1 | -0.26 Unit on a scale | Standard Deviation 0.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C5D1 | -0.23 Unit on a scale | Standard Deviation 0.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C6D1 | -0.18 Unit on a scale | Standard Deviation 0.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C7D1 | -0.26 Unit on a scale | Standard Deviation 0.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C8D1 | -0.23 Unit on a scale | Standard Deviation 0.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C9D1 | -0.14 Unit on a scale | Standard Deviation 0.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C10D1 | -0.19 Unit on a scale | Standard Deviation 0.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C11D1 | -0.28 Unit on a scale | Standard Deviation 0.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C12D1 | -0.19 Unit on a scale | Standard Deviation 0.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C13D1 | -0.25 Unit on a scale | Standard Deviation 0.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C14D1 | -0.36 Unit on a scale | Standard Deviation 0.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C15D1 | -0.27 Unit on a scale | Standard Deviation 0.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C16D1 | -0.35 Unit on a scale | Standard Deviation 0.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C17D1 | -0.26 Unit on a scale | Standard Deviation 0.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C18D1 | -0.15 Unit on a scale | Standard Deviation 0.69 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C19D1 | -0.15 Unit on a scale | Standard Deviation 0.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C20D1 | -0.05 Unit on a scale | Standard Deviation 0.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C21D1 | -0.22 Unit on a scale | Standard Deviation 0.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C22D1 | -0.16 Unit on a scale | Standard Deviation 0.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C23D1 | -0.16 Unit on a scale | Standard Deviation 0.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C24D1 | -0.14 Unit on a scale | Standard Deviation 0.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C25D1 | -0.14 Unit on a scale | Standard Deviation 0.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C26D1 | -0.19 Unit on a scale | Standard Deviation 0.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C27D1 | -0.16 Unit on a scale | Standard Deviation 0.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C28D1 | -0.29 Unit on a scale | Standard Deviation 0.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C29D1 | -0.14 Unit on a scale | Standard Deviation 0.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C30D1 | -0.30 Unit on a scale | Standard Deviation 0.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C31D1 | -0.40 Unit on a scale | Standard Deviation 0.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C32D1 | -0.33 Unit on a scale | Standard Deviation 0.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C33D1 | -0.40 Unit on a scale | Standard Deviation 0.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C34D1 | -0.33 Unit on a scale | Standard Deviation 0.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C35D1 | -0.23 Unit on a scale | Standard Deviation 0.6 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C36D1 | -0.42 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C37D1 | -0.27 Unit on a scale | Standard Deviation 0.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C38D1 | -0.30 Unit on a scale | Standard Deviation 0.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C39D1 | -0.44 Unit on a scale | Standard Deviation 0.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort 30 day follow up | 0.29 Unit on a scale | Standard Deviation 1.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort 90 day follow up | -0.03 Unit on a scale | Standard Deviation 0.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression Baseline | 1.65 Unit on a scale | Standard Deviation 0.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C2D1 | -0.01 Unit on a scale | Standard Deviation 0.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C3D1 | -0.05 Unit on a scale | Standard Deviation 0.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C4D1 | -0.04 Unit on a scale | Standard Deviation 0.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C5D1 | -0.08 Unit on a scale | Standard Deviation 0.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C6D1 | -0.07 Unit on a scale | Standard Deviation 0.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C7D1 | -0.04 Unit on a scale | Standard Deviation 0.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C8D1 | -0.02 Unit on a scale | Standard Deviation 0.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C9D1 | -0.05 Unit on a scale | Standard Deviation 0.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C10D1 | -0.13 Unit on a scale | Standard Deviation 0.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C11D1 | -0.11 Unit on a scale | Standard Deviation 0.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C12D1 | -0.11 Unit on a scale | Standard Deviation 0.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C13D1 | -0.12 Unit on a scale | Standard Deviation 0.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C14D1 | -0.07 Unit on a scale | Standard Deviation 0.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C15D1 | -0.02 Unit on a scale | Standard Deviation 0.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C16D1 | 0.00 Unit on a scale | Standard Deviation 0.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C17D1 | 0.05 Unit on a scale | Standard Deviation 0.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C18D1 | 0.12 Unit on a scale | Standard Deviation 0.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C19D1 | -0.10 Unit on a scale | Standard Deviation 0.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C20D1 | -0.03 Unit on a scale | Standard Deviation 0.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C21D1 | -0.03 Unit on a scale | Standard Deviation 0.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C22D1 | -0.10 Unit on a scale | Standard Deviation 0.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C23D1 | -0.03 Unit on a scale | Standard Deviation 0.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C24D1 | -0.10 Unit on a scale | Standard Deviation 0.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C25D1 | 0.11 Unit on a scale | Standard Deviation 1.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C26D1 | 0.00 Unit on a scale | Standard Deviation 0.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C27D1 | 0.00 Unit on a scale | Standard Deviation 1.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C28D1 | 0.14 Unit on a scale | Standard Deviation 1.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C29D1 | -0.09 Unit on a scale | Standard Deviation 0.97 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C30D1 | -0.10 Unit on a scale | Standard Deviation 0.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C31D1 | 0.00 Unit on a scale | Standard Deviation 1.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C32D1 | -0.17 Unit on a scale | Standard Deviation 0.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C33D1 | -0.07 Unit on a scale | Standard Deviation 0.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C34D1 | -0.42 Unit on a scale | Standard Deviation 0.51 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C35D1 | -0.23 Unit on a scale | Standard Deviation 0.6 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C36D1 | -0.25 Unit on a scale | Standard Deviation 0.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C37D1 | -0.45 Unit on a scale | Standard Deviation 0.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C38D1 | -0.60 Unit on a scale | Standard Deviation 0.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C39D1 | -0.11 Unit on a scale | Standard Deviation 0.6 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression 30 day follow up | 0.41 Unit on a scale | Standard Deviation 1.27 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression 90 day follow up | 0.10 Unit on a scale | Standard Deviation 0.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale Baseline | 71.50 Unit on a scale | Standard Deviation 19.6 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C2D1 | 3.01 Unit on a scale | Standard Deviation 15.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C3D1 | 2.17 Unit on a scale | Standard Deviation 15.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C4D1 | 3.89 Unit on a scale | Standard Deviation 16.6 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C5D1 | 1.50 Unit on a scale | Standard Deviation 17.2 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C6D1 | 1.18 Unit on a scale | Standard Deviation 17.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C7D1 | 3.21 Unit on a scale | Standard Deviation 15.6 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C8D1 | 3.22 Unit on a scale | Standard Deviation 19.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C9D1 | 0.96 Unit on a scale | Standard Deviation 17.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C10D1 | 2.88 Unit on a scale | Standard Deviation 20.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C11D1 | -1.12 Unit on a scale | Standard Deviation 18.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C12D1 | 2.89 Unit on a scale | Standard Deviation 21.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C13D1 | 4.30 Unit on a scale | Standard Deviation 17.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C14D1 | 5.68 Unit on a scale | Standard Deviation 25.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C15D1 | 4.61 Unit on a scale | Standard Deviation 23.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C16D1 | 2.40 Unit on a scale | Standard Deviation 18.26 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C17D1 | 6.07 Unit on a scale | Standard Deviation 24.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C18D1 | 8.49 Unit on a scale | Standard Deviation 24.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C19D1 | 5.08 Unit on a scale | Standard Deviation 21.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C20D1 | 2.97 Unit on a scale | Standard Deviation 25.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C21D1 | 0.69 Unit on a scale | Standard Deviation 19.39 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C22D1 | 3.55 Unit on a scale | Standard Deviation 15.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C23D1 | 3.55 Unit on a scale | Standard Deviation 14.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C24D1 | 5.17 Unit on a scale | Standard Deviation 16.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C25D1 | 1.43 Unit on a scale | Standard Deviation 20.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C26D1 | 4.15 Unit on a scale | Standard Deviation 16.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C27D1 | 0.20 Unit on a scale | Standard Deviation 20.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C28D1 | 2.90 Unit on a scale | Standard Deviation 18.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C29D1 | 3.73 Unit on a scale | Standard Deviation 15.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C30D1 | 0.75 Unit on a scale | Standard Deviation 15.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C31D1 | 1.60 Unit on a scale | Standard Deviation 16.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C32D1 | 2.00 Unit on a scale | Standard Deviation 15.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C33D1 | 6.80 Unit on a scale | Standard Deviation 17.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C34D1 | 8.33 Unit on a scale | Standard Deviation 17.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C35D1 | 5.77 Unit on a scale | Standard Deviation 16.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C36D1 | 4.17 Unit on a scale | Standard Deviation 17.2 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C24D1 | 0.07 Unit on a scale | Standard Deviation 0.26 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C37D1 | 10.73 Unit on a scale | Standard Deviation 14.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C38D1 | 7.10 Unit on a scale | Standard Deviation 17.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C39D1 | 10.22 Unit on a scale | Standard Deviation 11.42 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale 30 day follow up | -7.79 Unit on a scale | Standard Deviation 23.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale 90 day follow up | -5.24 Unit on a scale | Standard Deviation 19.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C25D1 | 0.11 Unit on a scale | Standard Deviation 0.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C26D1 | 0.12 Unit on a scale | Standard Deviation 0.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility Baseline | 1.33 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C2D1 | 0.02 Unit on a scale | Standard Deviation 0.6 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C3D1 | -0.01 Unit on a scale | Standard Deviation 0.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C4D1 | -0.01 Unit on a scale | Standard Deviation 0.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C5D1 | 0.05 Unit on a scale | Standard Deviation 0.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C6D1 | 0.04 Unit on a scale | Standard Deviation 0.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C7D1 | 0.02 Unit on a scale | Standard Deviation 0.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C8D1 | 0.20 Unit on a scale | Standard Deviation 0.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C9D1 | 0.18 Unit on a scale | Standard Deviation 0.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C10D1 | 0.08 Unit on a scale | Standard Deviation 0.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C11D1 | 0.12 Unit on a scale | Standard Deviation 0.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C12D1 | 0.08 Unit on a scale | Standard Deviation 0.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C13D1 | 0.08 Unit on a scale | Standard Deviation 0.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C14D1 | -0.05 Unit on a scale | Standard Deviation 0.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C15D1 | -0.04 Unit on a scale | Standard Deviation 0.69 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C16D1 | 0.02 Unit on a scale | Standard Deviation 0.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C17D1 | 0.00 Unit on a scale | Standard Deviation 0.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C18D1 | 0.07 Unit on a scale | Standard Deviation 0.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C19D1 | 0.03 Unit on a scale | Standard Deviation 0.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C20D1 | 0.10 Unit on a scale | Standard Deviation 0.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C21D1 | 0.03 Unit on a scale | Standard Deviation 0.51 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C22D1 | 0.03 Unit on a scale | Standard Deviation 0.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C6D1 | 0.05 Unit on a scale | Standard Deviation 0.51 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C7D1 | 0.07 Unit on a scale | Standard Deviation 0.6 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C8D1 | 0.10 Unit on a scale | Standard Deviation 0.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C23D1 | 0.00 Unit on a scale | Standard Deviation 0.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C24D1 | 0.07 Unit on a scale | Standard Deviation 0.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C25D1 | 0.21 Unit on a scale | Standard Deviation 0.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C26D1 | 0.15 Unit on a scale | Standard Deviation 0.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C27D1 | 0.08 Unit on a scale | Standard Deviation 0.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C28D1 | 0.24 Unit on a scale | Standard Deviation 0.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C29D1 | 0.05 Unit on a scale | Standard Deviation 0.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C30D1 | 0.10 Unit on a scale | Standard Deviation 0.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C31D1 | 0.00 Unit on a scale | Standard Deviation 0.56 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C32D1 | 0.06 Unit on a scale | Standard Deviation 0.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C33D1 | 0.00 Unit on a scale | Standard Deviation 0.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C34D1 | -0.08 Unit on a scale | Standard Deviation 0.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C35D1 | -0.08 Unit on a scale | Standard Deviation 0.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C36D1 | -0.08 Unit on a scale | Standard Deviation 0.51 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C37D1 | 0.00 Unit on a scale | Standard Deviation 0.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C38D1 | 0.00 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C39D1 | 0.22 Unit on a scale | Standard Deviation 0.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility 30 day follow up | 0.47 Unit on a scale | Standard Deviation 0.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility 90 day follow up | 0.32 Unit on a scale | Standard Deviation 0.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care Baseline | 1.12 Unit on a scale | Standard Deviation 0.39 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C2D1 | 0.05 Unit on a scale | Standard Deviation 0.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C3D1 | 0.02 Unit on a scale | Standard Deviation 0.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C4D1 | 0.05 Unit on a scale | Standard Deviation 0.46 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C10D1 | 0.11 Unit on a scale | Standard Deviation 0.66 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C5D1 | 0.05 Unit on a scale | Standard Deviation 0.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C9D1 | 0.15 Unit on a scale | Standard Deviation 0.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C11D1 | 0.09 Unit on a scale | Standard Deviation 0.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C12D1 | 0.09 Unit on a scale | Standard Deviation 0.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C13D1 | 0.05 Unit on a scale | Standard Deviation 0.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C14D1 | 0.04 Unit on a scale | Standard Deviation 0.5 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C15D1 | 0.00 Unit on a scale | Standard Deviation 0.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C16D1 | 0.00 Unit on a scale | Standard Deviation 0.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C17D1 | 0.02 Unit on a scale | Standard Deviation 0.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C19D1 | 0.00 Unit on a scale | Standard Deviation 0.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C20D1 | 0.00 Unit on a scale | Standard Deviation 0.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C21D1 | 0.03 Unit on a scale | Standard Deviation 0.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C22D1 | 0.00 Unit on a scale | Standard Deviation 0.37 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C23D1 | 0.06 Unit on a scale | Standard Deviation 0.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C27D1 | 0.08 Unit on a scale | Standard Deviation 0.28 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C28D1 | 0.10 Unit on a scale | Standard Deviation 0.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C29D1 | 0.14 Unit on a scale | Standard Deviation 0.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C30D1 | 0.10 Unit on a scale | Standard Deviation 0.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C31D1 | 0.10 Unit on a scale | Standard Deviation 0.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C32D1 | 0.06 Unit on a scale | Standard Deviation 0.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C33D1 | 0.13 Unit on a scale | Standard Deviation 0.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C34D1 | 0.08 Unit on a scale | Standard Deviation 0.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C35D1 | 0.08 Unit on a scale | Standard Deviation 0.28 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C36D1 | 0.08 Unit on a scale | Standard Deviation 0.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C37D1 | 0.27 Unit on a scale | Standard Deviation 0.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C38D1 | 0.20 Unit on a scale | Standard Deviation 0.42 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C39D1 | 0.22 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care 30 day follow up | 0.34 Unit on a scale | Standard Deviation 0.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care 90 day follow up | 0.30 Unit on a scale | Standard Deviation 0.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities Baseline | 1.40 Unit on a scale | Standard Deviation 0.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C2D1 | 0.08 Unit on a scale | Standard Deviation 0.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C3D1 | 0.02 Unit on a scale | Standard Deviation 0.66 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C4D1 | 0.01 Unit on a scale | Standard Deviation 0.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C5D1 | 0.10 Unit on a scale | Standard Deviation 0.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C6D1 | 0.05 Unit on a scale | Standard Deviation 0.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C7D1 | 0.05 Unit on a scale | Standard Deviation 0.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C8D1 | 0.19 Unit on a scale | Standard Deviation 0.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C9D1 | 0.19 Unit on a scale | Standard Deviation 0.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C10D1 | 0.06 Unit on a scale | Standard Deviation 0.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C11D1 | 0.11 Unit on a scale | Standard Deviation 0.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C12D1 | 0.04 Unit on a scale | Standard Deviation 0.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C13D1 | 0.02 Unit on a scale | Standard Deviation 0.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C14D1 | 0.02 Unit on a scale | Standard Deviation 0.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C15D1 | 0.10 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C16D1 | 0.04 Unit on a scale | Standard Deviation 0.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C17D1 | 0.00 Unit on a scale | Standard Deviation 0.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C18D1 | 0.15 Unit on a scale | Standard Deviation 0.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C19D1 | 0.13 Unit on a scale | Standard Deviation 0.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C20D1 | 0.13 Unit on a scale | Standard Deviation 0.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C21D1 | 0.17 Unit on a scale | Standard Deviation 0.51 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C22D1 | 0.06 Unit on a scale | Standard Deviation 0.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C23D1 | 0.06 Unit on a scale | Standard Deviation 0.51 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C24D1 | 0.17 Unit on a scale | Standard Deviation 0.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C25D1 | 0.25 Unit on a scale | Standard Deviation 0.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C26D1 | 0.12 Unit on a scale | Standard Deviation 0.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C27D1 | 0.12 Unit on a scale | Standard Deviation 0.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C28D1 | 0.29 Unit on a scale | Standard Deviation 0.56 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C29D1 | 0.14 Unit on a scale | Standard Deviation 0.56 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C30D1 | 0.15 Unit on a scale | Standard Deviation 0.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C31D1 | 0.05 Unit on a scale | Standard Deviation 0.51 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C32D1 | 0.11 Unit on a scale | Standard Deviation 0.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C33D1 | -0.07 Unit on a scale | Standard Deviation 0.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C34D1 | -0.08 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C35D1 | 0.08 Unit on a scale | Standard Deviation 0.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C36D1 | -0.08 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C37D1 | 0.00 Unit on a scale | Standard Deviation 0.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C38D1 | 0.10 Unit on a scale | Standard Deviation 0.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C39D1 | 0.22 Unit on a scale | Standard Deviation 0.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities 30 day follow up | 0.57 Unit on a scale | Standard Deviation 1.16 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C19D1 | -0.10 Unit on a scale | Standard Deviation 0.44 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C7D1 | -0.04 Unit on a scale | Standard Deviation 0.86 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C20D1 | 0.05 Unit on a scale | Standard Deviation 0.6 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C25D1 | 7.15 Unit on a scale | Standard Deviation 12.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C21D1 | -0.10 Unit on a scale | Standard Deviation 0.44 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C8D1 | 0.06 Unit on a scale | Standard Deviation 0.83 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C22D1 | 0.00 Unit on a scale | Standard Deviation 0.59 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C3D1 | 0.03 Unit on a scale | Standard Deviation 0.6 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C23D1 | -0.12 Unit on a scale | Standard Deviation 0.49 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C9D1 | 0.03 Unit on a scale | Standard Deviation 0.83 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C27D1 | -0.18 Unit on a scale | Standard Deviation 0.6 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C26D1 | 1.20 Unit on a scale | Standard Deviation 12.84 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C28D1 | -0.18 Unit on a scale | Standard Deviation 0.6 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C10D1 | 0.13 Unit on a scale | Standard Deviation 0.86 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C29D1 | -0.17 Unit on a scale | Standard Deviation 0.58 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C16D1 | 0.06 Unit on a scale | Standard Deviation 0.56 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C11D1 | 0.21 Unit on a scale | Standard Deviation 0.98 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C27D1 | 4.73 Unit on a scale | Standard Deviation 4.82 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C12D1 | 0.17 Unit on a scale | Standard Deviation 0.99 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C18D1 | -0.05 Unit on a scale | Standard Deviation 0.49 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C13D1 | 0.20 Unit on a scale | Standard Deviation 0.87 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C28D1 | 2.36 Unit on a scale | Standard Deviation 6.02 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C14D1 | 0.22 Unit on a scale | Standard Deviation 0.85 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C17D1 | 0.08 Unit on a scale | Standard Deviation 0.48 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C15D1 | 0.19 Unit on a scale | Standard Deviation 0.84 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C29D1 | 3.58 Unit on a scale | Standard Deviation 5.95 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care 30 day follow up | 0.38 Unit on a scale | Standard Deviation 0.81 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C16D1 | 0.06 Unit on a scale | Standard Deviation 0.62 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care 90 day follow up | 0.25 Unit on a scale | Standard Deviation 0.82 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C9D1 | 0.10 Unit on a scale | Standard Deviation 0.58 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities Baseline | 1.49 Unit on a scale | Standard Deviation 0.81 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C17D1 | 0.15 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C2D1 | 0.06 Unit on a scale | Standard Deviation 0.86 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C18D1 | 0.09 Unit on a scale | Standard Deviation 0.43 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C3D1 | 0.04 Unit on a scale | Standard Deviation 0.77 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C18D1 | 0.00 Unit on a scale | Standard Deviation 0.69 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C4D1 | -0.01 Unit on a scale | Standard Deviation 0.78 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C13D1 | 0.12 Unit on a scale | Standard Deviation 0.56 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C5D1 | 0.01 Unit on a scale | Standard Deviation 0.89 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C19D1 | -0.05 Unit on a scale | Standard Deviation 0.38 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C6D1 | -0.03 Unit on a scale | Standard Deviation 0.81 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C19D1 | 0.00 Unit on a scale | Standard Deviation 0.32 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C7D1 | -0.01 Unit on a scale | Standard Deviation 0.83 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C20D1 | 0.05 Unit on a scale | Standard Deviation 0.6 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C8D1 | 0.07 Unit on a scale | Standard Deviation 0.82 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C4D1 | 0.02 Unit on a scale | Standard Deviation 0.64 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C9D1 | -0.03 Unit on a scale | Standard Deviation 0.82 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C21D1 | -0.05 Unit on a scale | Standard Deviation 0.59 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C10D1 | 0.03 Unit on a scale | Standard Deviation 0.89 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C20D1 | 0.10 Unit on a scale | Standard Deviation 0.55 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C11D1 | -0.04 Unit on a scale | Standard Deviation 0.74 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C22D1 | 0.17 Unit on a scale | Standard Deviation 0.71 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C12D1 | -0.03 Unit on a scale | Standard Deviation 0.94 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C17D1 | 0.04 Unit on a scale | Standard Deviation 0.53 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C13D1 | 0.02 Unit on a scale | Standard Deviation 0.8 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C23D1 | 0.18 Unit on a scale | Standard Deviation 0.95 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C14D1 | 0.00 Unit on a scale | Standard Deviation 0.64 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C21D1 | -0.14 Unit on a scale | Standard Deviation 0.48 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C15D1 | -0.14 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C24D1 | 0.00 Unit on a scale | Standard Deviation 0.58 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C16D1 | -0.06 Unit on a scale | Standard Deviation 0.56 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C8D1 | 0.05 Unit on a scale | Standard Deviation 0.62 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C17D1 | -0.08 Unit on a scale | Standard Deviation 0.63 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C25D1 | 0.15 Unit on a scale | Standard Deviation 0.55 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C18D1 | -0.14 Unit on a scale | Standard Deviation 0.77 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C14D1 | 0.11 Unit on a scale | Standard Deviation 0.61 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C19D1 | -0.38 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C26D1 | 0.20 Unit on a scale | Standard Deviation 0.42 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C20D1 | -0.25 Unit on a scale | Standard Deviation 0.79 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C6D1 | 0.09 Unit on a scale | Standard Deviation 0.63 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C21D1 | -0.24 Unit on a scale | Standard Deviation 0.7 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C27D1 | 0.09 Unit on a scale | Standard Deviation 0.3 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C22D1 | -0.22 Unit on a scale | Standard Deviation 0.65 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C5D1 | 0.07 Unit on a scale | Standard Deviation 0.72 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C23D1 | -0.24 Unit on a scale | Standard Deviation 0.66 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C28D1 | 0.09 Unit on a scale | Standard Deviation 0.3 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C24D1 | -0.38 Unit on a scale | Standard Deviation 0.87 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale 30 day follow up | -8.63 Unit on a scale | Standard Deviation 20.32 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C25D1 | -0.15 Unit on a scale | Standard Deviation 0.99 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C29D1 | 0.25 Unit on a scale | Standard Deviation 0.45 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C26D1 | -0.30 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C7D1 | 0.02 Unit on a scale | Standard Deviation 0.7 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C27D1 | -0.36 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale 90 day follow up | -4.34 Unit on a scale | Standard Deviation 19.79 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C28D1 | -0.18 Unit on a scale | Standard Deviation 0.75 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C24D1 | -0.08 Unit on a scale | Standard Deviation 0.64 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities C29D1 | -0.33 Unit on a scale | Standard Deviation 0.65 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C10D1 | 0.10 Unit on a scale | Standard Deviation 0.65 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C25D1 | -0.08 Unit on a scale | Standard Deviation 0.64 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C22D1 | -0.11 Unit on a scale | Standard Deviation 0.58 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C26D1 | -0.20 Unit on a scale | Standard Deviation 0.63 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility 30 day follow up | 0.36 Unit on a scale | Standard Deviation 0.98 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility Baseline | 1.33 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C23D1 | -0.12 Unit on a scale | Standard Deviation 0.6 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C2D1 | 0.06 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression 30 day follow up | 0.45 Unit on a scale | Standard Deviation 1 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C16D1 | 0.09 Unit on a scale | Standard Deviation 0.59 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression 90 day follow up | 0.24 Unit on a scale | Standard Deviation 1 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities 30 day follow up | 0.40 Unit on a scale | Standard Deviation 0.93 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C3D1 | 0.05 Unit on a scale | Standard Deviation 0.65 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Usual Activities 90 day follow up | 0.29 Unit on a scale | Standard Deviation 0.94 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale Baseline | 72.65 Unit on a scale | Standard Deviation 18.73 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort Baseline | 1.84 Unit on a scale | Standard Deviation 0.84 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C24D1 | -0.15 Unit on a scale | Standard Deviation 0.69 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C2D1 | -0.13 Unit on a scale | Standard Deviation 0.88 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C2D1 | 1.67 Unit on a scale | Standard Deviation 13.6 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C3D1 | -0.16 Unit on a scale | Standard Deviation 0.75 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C4D1 | 0.02 Unit on a scale | Standard Deviation 0.76 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C4D1 | -0.29 Unit on a scale | Standard Deviation 0.91 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C3D1 | 2.07 Unit on a scale | Standard Deviation 14.7 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C5D1 | -0.26 Unit on a scale | Standard Deviation 0.9 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility 90 day follow up | 0.43 Unit on a scale | Standard Deviation 0.9 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C6D1 | -0.22 Unit on a scale | Standard Deviation 0.99 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C4D1 | 3.27 Unit on a scale | Standard Deviation 18.37 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C7D1 | -0.20 Unit on a scale | Standard Deviation 0.83 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C5D1 | 0.00 Unit on a scale | Standard Deviation 0.78 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C8D1 | -0.19 Unit on a scale | Standard Deviation 0.89 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C5D1 | 3.74 Unit on a scale | Standard Deviation 17.32 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C9D1 | -0.18 Unit on a scale | Standard Deviation 0.86 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C25D1 | -0.08 Unit on a scale | Standard Deviation 0.76 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C10D1 | -0.18 Unit on a scale | Standard Deviation 0.91 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C6D1 | 1.95 Unit on a scale | Standard Deviation 15.93 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C11D1 | -0.11 Unit on a scale | Standard Deviation 0.96 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C6D1 | 0.03 Unit on a scale | Standard Deviation 0.86 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C12D1 | -0.09 Unit on a scale | Standard Deviation 0.9 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C7D1 | 2.73 Unit on a scale | Standard Deviation 19.74 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C13D1 | 0.04 Unit on a scale | Standard Deviation 0.89 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C11D1 | 0.06 Unit on a scale | Standard Deviation 0.69 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C14D1 | -0.02 Unit on a scale | Standard Deviation 0.78 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C8D1 | 1.73 Unit on a scale | Standard Deviation 17.82 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C15D1 | 0.00 Unit on a scale | Standard Deviation 0.88 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C7D1 | 0.02 Unit on a scale | Standard Deviation 0.7 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C16D1 | -0.03 Unit on a scale | Standard Deviation 0.86 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C9D1 | 2.49 Unit on a scale | Standard Deviation 18.01 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C17D1 | 0.08 Unit on a scale | Standard Deviation 0.98 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C26D1 | 0.10 Unit on a scale | Standard Deviation 0.32 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C18D1 | 0.00 Unit on a scale | Standard Deviation 0.93 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C10D1 | 1.48 Unit on a scale | Standard Deviation 17.73 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C19D1 | -0.05 Unit on a scale | Standard Deviation 0.5 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C8D1 | 0.05 Unit on a scale | Standard Deviation 0.78 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C20D1 | -0.15 Unit on a scale | Standard Deviation 0.99 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C11D1 | 1.50 Unit on a scale | Standard Deviation 18.57 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C21D1 | -0.05 Unit on a scale | Standard Deviation 0.8 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care Baseline | 1.18 Unit on a scale | Standard Deviation 0.56 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C22D1 | -0.28 Unit on a scale | Standard Deviation 0.89 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C12D1 | 1.36 Unit on a scale | Standard Deviation 24.31 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C23D1 | -0.18 Unit on a scale | Standard Deviation 1.01 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C9D1 | 0.06 Unit on a scale | Standard Deviation 0.75 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C24D1 | 0.00 Unit on a scale | Standard Deviation 1.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C13D1 | 0.88 Unit on a scale | Standard Deviation 20.52 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C25D1 | 0.00 Unit on a scale | Standard Deviation 1.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C27D1 | -0.09 Unit on a scale | Standard Deviation 0.3 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C26D1 | 0.20 Unit on a scale | Standard Deviation 0.63 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C14D1 | 2.20 Unit on a scale | Standard Deviation 23.17 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C27D1 | 0.00 Unit on a scale | Standard Deviation 0.45 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C10D1 | 0.13 Unit on a scale | Standard Deviation 0.74 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C28D1 | 0.18 Unit on a scale | Standard Deviation 0.75 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C15D1 | -1.84 Unit on a scale | Standard Deviation 19.58 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort C29D1 | -0.08 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C15D1 | 0.05 Unit on a scale | Standard Deviation 0.52 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C16D1 | 3.44 Unit on a scale | Standard Deviation 25.37 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C11D1 | 0.15 Unit on a scale | Standard Deviation 0.87 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C17D1 | 2.35 Unit on a scale | Standard Deviation 13.65 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C28D1 | 0.09 Unit on a scale | Standard Deviation 0.3 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C18D1 | 4.59 Unit on a scale | Standard Deviation 12.68 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C12D1 | 0.02 Unit on a scale | Standard Deviation 0.66 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C19D1 | 5.95 Unit on a scale | Standard Deviation 10.28 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C2D1 | 0.07 Unit on a scale | Standard Deviation 0.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C20D1 | 4.15 Unit on a scale | Standard Deviation 14.14 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C13D1 | 0.10 Unit on a scale | Standard Deviation 0.85 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort 30 day follow up | 0.32 Unit on a scale | Standard Deviation 0.95 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C21D1 | 6.29 Unit on a scale | Standard Deviation 10.93 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Pain/Discomfort 90 day follow up | 0.10 Unit on a scale | Standard Deviation 0.94 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C29D1 | -0.08 Unit on a scale | Standard Deviation 0.51 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression Baseline | 1.64 Unit on a scale | Standard Deviation 0.77 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C22D1 | 3.28 Unit on a scale | Standard Deviation 13.4 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C2D1 | -0.11 Unit on a scale | Standard Deviation 0.79 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C14D1 | 0.11 Unit on a scale | Standard Deviation 0.53 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C3D1 | -0.01 Unit on a scale | Standard Deviation 0.88 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C23D1 | 4.12 Unit on a scale | Standard Deviation 16.03 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C4D1 | -0.08 Unit on a scale | Standard Deviation 0.89 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Self-Care C12D1 | 0.10 Unit on a scale | Standard Deviation 0.55 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C5D1 | -0.07 Unit on a scale | Standard Deviation 0.98 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Visual Analog Scale C24D1 | 6.85 Unit on a scale | Standard Deviation 14.15 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Anxiety/Depression C6D1 | 0.00 Unit on a scale | Standard Deviation 0.88 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire | Mobility C15D1 | 0.03 Unit on a scale | Standard Deviation 0.55 |
Secondary
Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire
OG25 evaluated gastric & gastroesophageal junction cancer-specific symptoms,had 25 items with 6 scales:dysphagia,eating restrictions,reflux,odynophagia,pain & discomfort,anxiety,and 10 single items:trouble with(taste, swallowing saliva, coughing, talking),eating in front of others,dry mouth,body image,choked when swallowing,weight loss and hair loss. STO22: gastric cancer quality of life questionnaire with 22 questions.For OG25 and STO22,items scored on(1:not at all; 2:a little, 3:quite a bit, 4:very much) and 1 question was yes or no for STO22.Linear transformation was used; score ranged from 0 to 100;higher score=better level of functioning or greater degree of symptoms. An item from STO22 instrument related to belching was used with OG25.
Time frame: Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up
Population: FAS with available data was analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C13D1 | -7.78 Unit on a scale | Standard Deviation 30.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C35D1 | -6.84 Unit on a scale | Standard Deviation 19.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia Baseline | 12.12 Unit on a scale | Standard Deviation 18.27 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions 30 day follow up | 0.15 Unit on a scale | Standard Deviation 27.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions 90 day follow up | -2.19 Unit on a scale | Standard Deviation 22.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux Baseline | 13.17 Unit on a scale | Standard Deviation 20.28 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C2D1 | -1.04 Unit on a scale | Standard Deviation 20.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C3D1 | -0.09 Unit on a scale | Standard Deviation 21.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C9D1 | -0.82 Unit on a scale | Standard Deviation 27.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C10D1 | -1.57 Unit on a scale | Standard Deviation 23.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C11D1 | -3.13 Unit on a scale | Standard Deviation 21.23 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C27D1 | -12.00 Unit on a scale | Standard Deviation 21.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety Baseline | 38.96 Unit on a scale | Standard Deviation 28.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C2D1 | -3.93 Unit on a scale | Standard Deviation 25.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C3D1 | -3.02 Unit on a scale | Standard Deviation 24.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C4D1 | -4.12 Unit on a scale | Standard Deviation 24.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C5D1 | -2.73 Unit on a scale | Standard Deviation 26.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C6D1 | -6.04 Unit on a scale | Standard Deviation 23.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C7D1 | -3.64 Unit on a scale | Standard Deviation 23.28 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C8D1 | -4.32 Unit on a scale | Standard Deviation 25.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C34D1 | -8.33 Unit on a scale | Standard Deviation 19.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C14D1 | -7.88 Unit on a scale | Standard Deviation 28.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C15D1 | -8.50 Unit on a scale | Standard Deviation 28.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C16D1 | -15.62 Unit on a scale | Standard Deviation 27.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C17D1 | -6.98 Unit on a scale | Standard Deviation 24.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C18D1 | -7.32 Unit on a scale | Standard Deviation 28.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C19D1 | -8.33 Unit on a scale | Standard Deviation 25.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C20D1 | -9.83 Unit on a scale | Standard Deviation 24.99 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C26D1 | -7.69 Unit on a scale | Standard Deviation 25.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C27D1 | -9.33 Unit on a scale | Standard Deviation 30.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C28D1 | -10.32 Unit on a scale | Standard Deviation 31.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C29D1 | -6.82 Unit on a scale | Standard Deviation 33.2 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C30D1 | -5.00 Unit on a scale | Standard Deviation 26.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C31D1 | -7.50 Unit on a scale | Standard Deviation 28.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C32D1 | -10.19 Unit on a scale | Standard Deviation 32.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C33D1 | -4.44 Unit on a scale | Standard Deviation 30.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C34D1 | -13.89 Unit on a scale | Standard Deviation 27.37 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C35D1 | -10.26 Unit on a scale | Standard Deviation 25.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C36D1 | -12.50 Unit on a scale | Standard Deviation 26.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C37D1 | -25.76 Unit on a scale | Standard Deviation 20.23 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C6D1 | -0.22 Unit on a scale | Standard Deviation 15.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C7D1 | -0.84 Unit on a scale | Standard Deviation 18.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C8D1 | -2.47 Unit on a scale | Standard Deviation 18.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C9D1 | -1.63 Unit on a scale | Standard Deviation 21.69 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C10D1 | -2.35 Unit on a scale | Standard Deviation 23.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C11D1 | -2.92 Unit on a scale | Standard Deviation 19.98 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C12D1 | -3.11 Unit on a scale | Standard Deviation 20.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C21D1 | -8.33 Unit on a scale | Standard Deviation 20.12 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C12D1 | -5.78 Unit on a scale | Standard Deviation 26.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C13D1 | -5.00 Unit on a scale | Standard Deviation 26.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C20D1 | -8.55 Unit on a scale | Standard Deviation 21.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C21D1 | -5.56 Unit on a scale | Standard Deviation 24.56 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C22D1 | -9.68 Unit on a scale | Standard Deviation 23.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C23D1 | -7.53 Unit on a scale | Standard Deviation 23.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C24D1 | -6.90 Unit on a scale | Standard Deviation 24.2 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C25D1 | -10.71 Unit on a scale | Standard Deviation 22.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C26D1 | -8.97 Unit on a scale | Standard Deviation 27.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C27D1 | -6.67 Unit on a scale | Standard Deviation 21.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth 30 day follow up | -4.68 Unit on a scale | Standard Deviation 26.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth 90 day follow up | 3.83 Unit on a scale | Standard Deviation 25.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste Baseline | 9.47 Unit on a scale | Standard Deviation 21.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C2D1 | 3.85 Unit on a scale | Standard Deviation 22.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C3D1 | 7.33 Unit on a scale | Standard Deviation 25.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C4D1 | 5.62 Unit on a scale | Standard Deviation 24.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C7D1 | 10.92 Unit on a scale | Standard Deviation 28.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C22D1 | -6.45 Unit on a scale | Standard Deviation 18.09 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C9D1 | 8.17 Unit on a scale | Standard Deviation 29.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C10D1 | 7.06 Unit on a scale | Standard Deviation 29.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C11D1 | 2.92 Unit on a scale | Standard Deviation 27.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C14D1 | 1.82 Unit on a scale | Standard Deviation 25.99 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C15D1 | 0.00 Unit on a scale | Standard Deviation 27.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C16D1 | 1.39 Unit on a scale | Standard Deviation 25.69 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C17D1 | 1.55 Unit on a scale | Standard Deviation 24.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C18D1 | 0.81 Unit on a scale | Standard Deviation 24.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C25D1 | -2.38 Unit on a scale | Standard Deviation 20.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C26D1 | -6.41 Unit on a scale | Standard Deviation 18.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C27D1 | -2.67 Unit on a scale | Standard Deviation 19.05 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C33D1 | -8.89 Unit on a scale | Standard Deviation 23.46 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C34D1 | -16.67 Unit on a scale | Standard Deviation 22.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C37D1 | -12.12 Unit on a scale | Standard Deviation 22.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C38D1 | -16.67 Unit on a scale | Standard Deviation 23.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C39D1 | -7.41 Unit on a scale | Standard Deviation 14.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others 90 day follow up | 3.28 Unit on a scale | Standard Deviation 18.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C3D1 | -0.55 Unit on a scale | Standard Deviation 23.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C7D1 | -0.28 Unit on a scale | Standard Deviation 27.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C6D1 | 0.89 Unit on a scale | Standard Deviation 27.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C8D1 | -1.85 Unit on a scale | Standard Deviation 25.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C10D1 | -5.88 Unit on a scale | Standard Deviation 28.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux 90 day follow up | 2.19 Unit on a scale | Standard Deviation 19.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C3D1 | -3.94 Unit on a scale | Standard Deviation 19.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C8D1 | -4.32 Unit on a scale | Standard Deviation 21.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C9D1 | -2.94 Unit on a scale | Standard Deviation 22.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C10D1 | -5.10 Unit on a scale | Standard Deviation 24.26 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C11D1 | -4.17 Unit on a scale | Standard Deviation 25.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C12D1 | -6.67 Unit on a scale | Standard Deviation 25.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C16D1 | -9.37 Unit on a scale | Standard Deviation 21.99 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C17D1 | -11.63 Unit on a scale | Standard Deviation 21.37 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C18D1 | -9.76 Unit on a scale | Standard Deviation 22.66 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C19D1 | -9.58 Unit on a scale | Standard Deviation 18.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C20D1 | -7.26 Unit on a scale | Standard Deviation 21.56 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C21D1 | -5.09 Unit on a scale | Standard Deviation 18.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C22D1 | -5.91 Unit on a scale | Standard Deviation 19.51 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C23D1 | -7.53 Unit on a scale | Standard Deviation 21.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C28D1 | -9.52 Unit on a scale | Standard Deviation 17.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C29D1 | -10.61 Unit on a scale | Standard Deviation 18.22 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C30D1 | -9.17 Unit on a scale | Standard Deviation 21.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C35D1 | -17.95 Unit on a scale | Standard Deviation 20.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C36D1 | -18.06 Unit on a scale | Standard Deviation 24.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C37D1 | -10.61 Unit on a scale | Standard Deviation 15.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C38D1 | -11.67 Unit on a scale | Standard Deviation 15.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C39D1 | -16.67 Unit on a scale | Standard Deviation 14.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia 30 day follow up | 1.75 Unit on a scale | Standard Deviation 29.66 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C4D1 | -7.33 Unit on a scale | Standard Deviation 24.99 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C5D1 | -7.44 Unit on a scale | Standard Deviation 20.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C6D1 | -5.82 Unit on a scale | Standard Deviation 25.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C9D1 | -5.07 Unit on a scale | Standard Deviation 24.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C10D1 | -8.24 Unit on a scale | Standard Deviation 26.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C11D1 | -7.71 Unit on a scale | Standard Deviation 30 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C16D1 | -12.15 Unit on a scale | Standard Deviation 24.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C17D1 | -9.69 Unit on a scale | Standard Deviation 25 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C26D1 | -1.28 Unit on a scale | Standard Deviation 17.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C27D1 | -4.00 Unit on a scale | Standard Deviation 17.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C28D1 | -1.59 Unit on a scale | Standard Deviation 12.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C29D1 | 3.03 Unit on a scale | Standard Deviation 22.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C36D1 | -5.56 Unit on a scale | Standard Deviation 12.97 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C37D1 | -6.06 Unit on a scale | Standard Deviation 13.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C38D1 | 0.00 Unit on a scale | Standard Deviation 15.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C39D1 | 3.70 Unit on a scale | Standard Deviation 11.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing 30 day follow up | 1.17 Unit on a scale | Standard Deviation 21.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing 90 day follow up | 2.19 Unit on a scale | Standard Deviation 15.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C6D1 | 0.67 Unit on a scale | Standard Deviation 13.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C7D1 | 0.84 Unit on a scale | Standard Deviation 15.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C8D1 | 0.93 Unit on a scale | Standard Deviation 12.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C9D1 | 0.65 Unit on a scale | Standard Deviation 15.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C10D1 | 0.39 Unit on a scale | Standard Deviation 14.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C11D1 | 0.42 Unit on a scale | Standard Deviation 12.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C16D1 | 0.00 Unit on a scale | Standard Deviation 16.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C17D1 | -4.65 Unit on a scale | Standard Deviation 13.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C18D1 | -3.25 Unit on a scale | Standard Deviation 12.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C19D1 | 0.00 Unit on a scale | Standard Deviation 15.1 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C20D1 | -2.56 Unit on a scale | Standard Deviation 14.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C21D1 | -0.93 Unit on a scale | Standard Deviation 18.66 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C22D1 | -3.23 Unit on a scale | Standard Deviation 13.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C23D1 | -1.08 Unit on a scale | Standard Deviation 13.56 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C24D1 | -2.30 Unit on a scale | Standard Deviation 12.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C25D1 | -1.19 Unit on a scale | Standard Deviation 14.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C26D1 | -1.28 Unit on a scale | Standard Deviation 14.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C27D1 | -2.67 Unit on a scale | Standard Deviation 13.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C28D1 | -3.17 Unit on a scale | Standard Deviation 14.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C29D1 | -1.52 Unit on a scale | Standard Deviation 16.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C30D1 | -1.67 Unit on a scale | Standard Deviation 17.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C31D1 | 0.00 Unit on a scale | Standard Deviation 18.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C32D1 | -1.85 Unit on a scale | Standard Deviation 17.98 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C33D1 | -4.44 Unit on a scale | Standard Deviation 17.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C34D1 | -5.56 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C35D1 | -5.13 Unit on a scale | Standard Deviation 18.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C36D1 | -5.56 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C37D1 | -6.06 Unit on a scale | Standard Deviation 20.1 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C38D1 | -6.67 Unit on a scale | Standard Deviation 21.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C39D1 | 0.00 Unit on a scale | Standard Deviation 0 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking 30 day follow up | 4.68 Unit on a scale | Standard Deviation 18.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking 90 day follow up | 3.83 Unit on a scale | Standard Deviation 10.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss Baseline | 23.05 Unit on a scale | Standard Deviation 27.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C2D1 | 0.16 Unit on a scale | Standard Deviation 23.28 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C3D1 | 0.92 Unit on a scale | Standard Deviation 26.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C4D1 | 0.00 Unit on a scale | Standard Deviation 28.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C5D1 | 2.52 Unit on a scale | Standard Deviation 32.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C6D1 | -0.45 Unit on a scale | Standard Deviation 25.99 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C7D1 | -2.52 Unit on a scale | Standard Deviation 27.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C8D1 | -2.47 Unit on a scale | Standard Deviation 26.46 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C9D1 | -5.88 Unit on a scale | Standard Deviation 29.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C10D1 | -7.06 Unit on a scale | Standard Deviation 32.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C11D1 | -9.58 Unit on a scale | Standard Deviation 30.56 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C12D1 | -10.22 Unit on a scale | Standard Deviation 30.5 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C13D1 | -11.67 Unit on a scale | Standard Deviation 28.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C14D1 | -13.94 Unit on a scale | Standard Deviation 26.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C15D1 | -12.42 Unit on a scale | Standard Deviation 26.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C16D1 | -15.97 Unit on a scale | Standard Deviation 22.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C17D1 | -14.73 Unit on a scale | Standard Deviation 19.66 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C18D1 | -11.38 Unit on a scale | Standard Deviation 25.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C19D1 | -16.67 Unit on a scale | Standard Deviation 22.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C20D1 | -10.26 Unit on a scale | Standard Deviation 21.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C21D1 | -12.96 Unit on a scale | Standard Deviation 22.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C22D1 | -12.90 Unit on a scale | Standard Deviation 23.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C23D1 | -10.75 Unit on a scale | Standard Deviation 19.98 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C24D1 | -10.34 Unit on a scale | Standard Deviation 26.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C25D1 | -10.71 Unit on a scale | Standard Deviation 20.39 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss 90 day follow up | -1.64 Unit on a scale | Standard Deviation 24.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss Baseline | 12.09 Unit on a scale | Standard Deviation 20.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C2D1 | -2.26 Unit on a scale | Standard Deviation 18.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C3D1 | -3.09 Unit on a scale | Standard Deviation 19.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C4D1 | -0.63 Unit on a scale | Standard Deviation 24.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C5D1 | -3.03 Unit on a scale | Standard Deviation 20.1 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C6D1 | 2.96 Unit on a scale | Standard Deviation 23.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C10D1 | -1.67 Unit on a scale | Standard Deviation 25.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C11D1 | -1.67 Unit on a scale | Standard Deviation 27.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C12D1 | -4.55 Unit on a scale | Standard Deviation 25.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss 30 day follow up | 8.33 Unit on a scale | Standard Deviation 23.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss 90 day follow up | 23.53 Unit on a scale | Standard Deviation 40.42 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching Baseline | 12.14 Unit on a scale | Standard Deviation 18.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C2D1 | -1.52 Unit on a scale | Standard Deviation 15.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C3D1 | 0.92 Unit on a scale | Standard Deviation 17.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C4D1 | 0.20 Unit on a scale | Standard Deviation 16.51 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C17D1 | -2.71 Unit on a scale | Standard Deviation 18.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C18D1 | -2.03 Unit on a scale | Standard Deviation 17.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C19D1 | 0.42 Unit on a scale | Standard Deviation 15.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C20D1 | 1.28 Unit on a scale | Standard Deviation 18.09 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C21D1 | -0.93 Unit on a scale | Standard Deviation 14.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C22D1 | -0.54 Unit on a scale | Standard Deviation 17.99 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C31D1 | 2.50 Unit on a scale | Standard Deviation 16.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C32D1 | 4.63 Unit on a scale | Standard Deviation 17.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C33D1 | -1.11 Unit on a scale | Standard Deviation 14.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C34D1 | 0.00 Unit on a scale | Standard Deviation 12.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C35D1 | 3.85 Unit on a scale | Standard Deviation 20.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C36D1 | 1.39 Unit on a scale | Standard Deviation 19.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C37D1 | 6.06 Unit on a scale | Standard Deviation 11.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C38D1 | 1.67 Unit on a scale | Standard Deviation 16.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C39D1 | 3.70 Unit on a scale | Standard Deviation 7.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching 30 day follow up | 3.22 Unit on a scale | Standard Deviation 21.23 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching 90 day follow up | -0.55 Unit on a scale | Standard Deviation 15.2 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C27D1 | 0.00 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C28D1 | 3.17 Unit on a scale | Standard Deviation 23.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C39D1 | 0.00 Unit on a scale | Standard Deviation 16.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste 30 day follow up | 4.09 Unit on a scale | Standard Deviation 23.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste 90 day follow up | 7.65 Unit on a scale | Standard Deviation 25.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image Baseline | 17.97 Unit on a scale | Standard Deviation 25.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C2D1 | -0.80 Unit on a scale | Standard Deviation 22.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C3D1 | 1.47 Unit on a scale | Standard Deviation 24.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C4D1 | 1.00 Unit on a scale | Standard Deviation 26.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C10D1 | -1.57 Unit on a scale | Standard Deviation 29.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C11D1 | -5.00 Unit on a scale | Standard Deviation 26.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C12D1 | -3.56 Unit on a scale | Standard Deviation 29.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C21D1 | -9.26 Unit on a scale | Standard Deviation 20.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C22D1 | -5.38 Unit on a scale | Standard Deviation 24.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C23D1 | -8.60 Unit on a scale | Standard Deviation 19.18 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C24D1 | -8.05 Unit on a scale | Standard Deviation 17.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C25D1 | -8.33 Unit on a scale | Standard Deviation 23.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C26D1 | -6.41 Unit on a scale | Standard Deviation 23.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C27D1 | -6.67 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C28D1 | -9.52 Unit on a scale | Standard Deviation 21.46 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C29D1 | -9.09 Unit on a scale | Standard Deviation 25.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C30D1 | -3.33 Unit on a scale | Standard Deviation 21.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image 90 day follow up | 7.10 Unit on a scale | Standard Deviation 20.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva Baseline | 3.84 Unit on a scale | Standard Deviation 12.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C2D1 | 0.48 Unit on a scale | Standard Deviation 13.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C3D1 | 0.00 Unit on a scale | Standard Deviation 13.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C11D1 | -0.42 Unit on a scale | Standard Deviation 13.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C12D1 | 0.00 Unit on a scale | Standard Deviation 10.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C13D1 | 0.00 Unit on a scale | Standard Deviation 12.27 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C14D1 | -1.21 Unit on a scale | Standard Deviation 11.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C15D1 | -1.96 Unit on a scale | Standard Deviation 14 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C16D1 | 0.00 Unit on a scale | Standard Deviation 16.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C21D1 | 0.00 Unit on a scale | Standard Deviation 17.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C22D1 | 0.00 Unit on a scale | Standard Deviation 12.17 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C23D1 | 0.00 Unit on a scale | Standard Deviation 12.17 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C24D1 | 0.00 Unit on a scale | Standard Deviation 12.6 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C25D1 | 1.19 Unit on a scale | Standard Deviation 14.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C26D1 | -1.28 Unit on a scale | Standard Deviation 11.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C36D1 | -2.78 Unit on a scale | Standard Deviation 9.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C37D1 | 0.00 Unit on a scale | Standard Deviation 14.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C38D1 | 0.00 Unit on a scale | Standard Deviation 15.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C39D1 | 0.00 Unit on a scale | Standard Deviation 0 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva 30 day follow up | 1.75 Unit on a scale | Standard Deviation 20.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva 90 day follow up | 1.64 Unit on a scale | Standard Deviation 16.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing Baseline | 5.35 Unit on a scale | Standard Deviation 14.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C2D1 | -1.60 Unit on a scale | Standard Deviation 13.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C3D1 | -1.10 Unit on a scale | Standard Deviation 12.09 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C4D1 | -2.01 Unit on a scale | Standard Deviation 14.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C5D1 | -1.68 Unit on a scale | Standard Deviation 15.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C10D1 | -1.96 Unit on a scale | Standard Deviation 14.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C12D1 | -2.22 Unit on a scale | Standard Deviation 14.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C13D1 | -3.33 Unit on a scale | Standard Deviation 14.65 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C16D1 | -2.08 Unit on a scale | Standard Deviation 12.69 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C18D1 | -0.81 Unit on a scale | Standard Deviation 11.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C20D1 | -2.56 Unit on a scale | Standard Deviation 11.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C22D1 | -2.15 Unit on a scale | Standard Deviation 11.97 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C23D1 | -2.15 Unit on a scale | Standard Deviation 14.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C25D1 | -3.57 Unit on a scale | Standard Deviation 13.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C27D1 | -1.33 Unit on a scale | Standard Deviation 17.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C30D1 | 3.33 Unit on a scale | Standard Deviation 18.42 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C32D1 | 0.00 Unit on a scale | Standard Deviation 19.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C33D1 | -2.22 Unit on a scale | Standard Deviation 15.26 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C35D1 | 2.56 Unit on a scale | Standard Deviation 21.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C36D1 | 2.78 Unit on a scale | Standard Deviation 17.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C39D1 | 0.00 Unit on a scale | Standard Deviation 16.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C7D1 | -2.24 Unit on a scale | Standard Deviation 19.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C8D1 | -0.31 Unit on a scale | Standard Deviation 17.94 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C9D1 | -3.92 Unit on a scale | Standard Deviation 20.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C10D1 | -3.53 Unit on a scale | Standard Deviation 22.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C15D1 | -7.19 Unit on a scale | Standard Deviation 20.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C16D1 | -4.17 Unit on a scale | Standard Deviation 23.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C17D1 | -7.75 Unit on a scale | Standard Deviation 22.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C18D1 | -6.50 Unit on a scale | Standard Deviation 21.37 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C19D1 | -5.00 Unit on a scale | Standard Deviation 17.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C20D1 | -3.42 Unit on a scale | Standard Deviation 19.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C21D1 | -4.63 Unit on a scale | Standard Deviation 19.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C22D1 | -5.38 Unit on a scale | Standard Deviation 17.42 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C23D1 | -4.30 Unit on a scale | Standard Deviation 18.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C24D1 | -3.45 Unit on a scale | Standard Deviation 18.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C2D1 | -0.37 Unit on a scale | Standard Deviation 17.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C3D1 | -0.92 Unit on a scale | Standard Deviation 15.22 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C4D1 | -2.68 Unit on a scale | Standard Deviation 17.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C5D1 | -1.05 Unit on a scale | Standard Deviation 20.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C36D1 | -9.26 Unit on a scale | Standard Deviation 19.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C37D1 | -8.08 Unit on a scale | Standard Deviation 14.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C12D1 | -4.44 Unit on a scale | Standard Deviation 22.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C38D1 | -6.67 Unit on a scale | Standard Deviation 16.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C39D1 | -4.94 Unit on a scale | Standard Deviation 12.56 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C13D1 | -3.33 Unit on a scale | Standard Deviation 28.26 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C14D1 | -1.82 Unit on a scale | Standard Deviation 22.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C15D1 | -3.92 Unit on a scale | Standard Deviation 18.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C16D1 | -3.13 Unit on a scale | Standard Deviation 23.23 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C17D1 | -5.81 Unit on a scale | Standard Deviation 22.09 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C18D1 | -3.25 Unit on a scale | Standard Deviation 23.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C19D1 | -2.92 Unit on a scale | Standard Deviation 22.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia 30 day follow up | 4.48 Unit on a scale | Standard Deviation 22.6 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia 90 day follow up | 0.36 Unit on a scale | Standard Deviation 12.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions Baseline | 22.67 Unit on a scale | Standard Deviation 25.2 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C2D1 | -1.24 Unit on a scale | Standard Deviation 21.39 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C20D1 | 0.00 Unit on a scale | Standard Deviation 20.94 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C21D1 | 0.46 Unit on a scale | Standard Deviation 24.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C22D1 | -5.38 Unit on a scale | Standard Deviation 17.94 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C23D1 | -4.30 Unit on a scale | Standard Deviation 18.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C24D1 | -2.30 Unit on a scale | Standard Deviation 19.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C29D1 | -3.03 Unit on a scale | Standard Deviation 14.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C30D1 | -0.83 Unit on a scale | Standard Deviation 13.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C31D1 | -1.67 Unit on a scale | Standard Deviation 16.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C32D1 | 0.00 Unit on a scale | Standard Deviation 18.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C34D1 | -4.17 Unit on a scale | Standard Deviation 18.97 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C35D1 | 1.28 Unit on a scale | Standard Deviation 19.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C36D1 | -4.17 Unit on a scale | Standard Deviation 21.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C37D1 | -4.55 Unit on a scale | Standard Deviation 18.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C38D1 | 0.00 Unit on a scale | Standard Deviation 20.79 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C39D1 | 7.41 Unit on a scale | Standard Deviation 12.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux 30 day follow up | 1.46 Unit on a scale | Standard Deviation 26.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C6D1 | -1.42 Unit on a scale | Standard Deviation 16.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C11D1 | -3.33 Unit on a scale | Standard Deviation 16.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C12D1 | -3.70 Unit on a scale | Standard Deviation 17.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C13D1 | -6.30 Unit on a scale | Standard Deviation 17.64 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C17D1 | -3.10 Unit on a scale | Standard Deviation 13.13 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C18D1 | -3.25 Unit on a scale | Standard Deviation 14.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C19D1 | -4.17 Unit on a scale | Standard Deviation 13.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C20D1 | -4.56 Unit on a scale | Standard Deviation 11.6 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C21D1 | -3.40 Unit on a scale | Standard Deviation 15.22 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C26D1 | -2.99 Unit on a scale | Standard Deviation 18.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C27D1 | -5.33 Unit on a scale | Standard Deviation 12.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C28D1 | -4.76 Unit on a scale | Standard Deviation 14.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C29D1 | -7.07 Unit on a scale | Standard Deviation 13.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C21D1 | -7.41 Unit on a scale | Standard Deviation 20.1 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C22D1 | -8.06 Unit on a scale | Standard Deviation 21.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C23D1 | -10.22 Unit on a scale | Standard Deviation 20.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C24D1 | -8.62 Unit on a scale | Standard Deviation 21.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C25D1 | -11.90 Unit on a scale | Standard Deviation 23.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C26D1 | -7.69 Unit on a scale | Standard Deviation 26.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C8D1 | -3.70 Unit on a scale | Standard Deviation 21.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C9D1 | -3.59 Unit on a scale | Standard Deviation 22.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C10D1 | -4.80 Unit on a scale | Standard Deviation 24.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C11D1 | -5.83 Unit on a scale | Standard Deviation 25.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C12D1 | -6.22 Unit on a scale | Standard Deviation 27.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C13D1 | -9.31 Unit on a scale | Standard Deviation 28.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C21D1 | -5.32 Unit on a scale | Standard Deviation 20.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C22D1 | -7.26 Unit on a scale | Standard Deviation 23.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C23D1 | -6.18 Unit on a scale | Standard Deviation 20.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C24D1 | -6.03 Unit on a scale | Standard Deviation 21.12 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C25D1 | -5.95 Unit on a scale | Standard Deviation 23.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C26D1 | -7.37 Unit on a scale | Standard Deviation 25.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C27D1 | -7.67 Unit on a scale | Standard Deviation 22.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C28D1 | -6.35 Unit on a scale | Standard Deviation 24.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C38D1 | -17.50 Unit on a scale | Standard Deviation 21.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C39D1 | -7.41 Unit on a scale | Standard Deviation 13.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C30D1 | 1.67 Unit on a scale | Standard Deviation 20.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C17D1 | -6.20 Unit on a scale | Standard Deviation 19.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C18D1 | -5.69 Unit on a scale | Standard Deviation 19.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C19D1 | -9.17 Unit on a scale | Standard Deviation 25.02 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C28D1 | -4.76 Unit on a scale | Standard Deviation 26.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C29D1 | -6.06 Unit on a scale | Standard Deviation 28.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C30D1 | -5.00 Unit on a scale | Standard Deviation 24.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C31D1 | -8.33 Unit on a scale | Standard Deviation 28.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C32D1 | -11.11 Unit on a scale | Standard Deviation 30.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C33D1 | -15.56 Unit on a scale | Standard Deviation 21.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C34D1 | -22.22 Unit on a scale | Standard Deviation 21.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C35D1 | -17.95 Unit on a scale | Standard Deviation 25.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C36D1 | -16.67 Unit on a scale | Standard Deviation 17.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C37D1 | -18.18 Unit on a scale | Standard Deviation 31.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C38D1 | -20.00 Unit on a scale | Standard Deviation 32.2 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C39D1 | -22.22 Unit on a scale | Standard Deviation 33.33 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C5D1 | 8.18 Unit on a scale | Standard Deviation 26.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C6D1 | 12.30 Unit on a scale | Standard Deviation 27.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C8D1 | 10.49 Unit on a scale | Standard Deviation 25.23 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C12D1 | 2.22 Unit on a scale | Standard Deviation 26.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C13D1 | 0.56 Unit on a scale | Standard Deviation 32.18 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C19D1 | 0.83 Unit on a scale | Standard Deviation 21.99 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C20D1 | 2.56 Unit on a scale | Standard Deviation 22.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C21D1 | -0.93 Unit on a scale | Standard Deviation 24.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C22D1 | -1.08 Unit on a scale | Standard Deviation 26.5 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C23D1 | 2.15 Unit on a scale | Standard Deviation 24.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C24D1 | 0.00 Unit on a scale | Standard Deviation 19.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C25D1 | 2.38 Unit on a scale | Standard Deviation 20.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C26D1 | -1.28 Unit on a scale | Standard Deviation 19.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C23D1 | -7.53 Unit on a scale | Standard Deviation 18.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C24D1 | -3.45 Unit on a scale | Standard Deviation 18.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C28D1 | -4.76 Unit on a scale | Standard Deviation 26.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C29D1 | -9.09 Unit on a scale | Standard Deviation 21.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C30D1 | -6.67 Unit on a scale | Standard Deviation 23.2 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C31D1 | -10.00 Unit on a scale | Standard Deviation 21.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C32D1 | -7.41 Unit on a scale | Standard Deviation 24.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C35D1 | -5.13 Unit on a scale | Standard Deviation 22.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C36D1 | -11.11 Unit on a scale | Standard Deviation 21.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others 30 day follow up | 2.92 Unit on a scale | Standard Deviation 23.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth Baseline | 19.20 Unit on a scale | Standard Deviation 24.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C2D1 | -0.32 Unit on a scale | Standard Deviation 23.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C4D1 | -2.01 Unit on a scale | Standard Deviation 25.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C5D1 | -1.05 Unit on a scale | Standard Deviation 26.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C9D1 | 0.00 Unit on a scale | Standard Deviation 28.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia Baseline | 15.64 Unit on a scale | Standard Deviation 22.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C2D1 | -2.80 Unit on a scale | Standard Deviation 21.46 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C4D1 | -5.22 Unit on a scale | Standard Deviation 21.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C5D1 | -4.19 Unit on a scale | Standard Deviation 22.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C6D1 | -2.80 Unit on a scale | Standard Deviation 20.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C7D1 | -3.92 Unit on a scale | Standard Deviation 19.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C13D1 | -8.06 Unit on a scale | Standard Deviation 26.66 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C14D1 | -7.58 Unit on a scale | Standard Deviation 24.18 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C15D1 | -7.84 Unit on a scale | Standard Deviation 23.18 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C24D1 | -6.90 Unit on a scale | Standard Deviation 21.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C25D1 | -7.14 Unit on a scale | Standard Deviation 18.39 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C26D1 | -7.69 Unit on a scale | Standard Deviation 23.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C27D1 | -7.33 Unit on a scale | Standard Deviation 18.05 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C31D1 | -12.50 Unit on a scale | Standard Deviation 19.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C32D1 | -11.11 Unit on a scale | Standard Deviation 19.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C33D1 | -10.00 Unit on a scale | Standard Deviation 15.17 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C34D1 | -16.67 Unit on a scale | Standard Deviation 20.1 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia 90 day follow up | -0.27 Unit on a scale | Standard Deviation 18.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort Baseline | 23.53 Unit on a scale | Standard Deviation 23.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C2D1 | -4.25 Unit on a scale | Standard Deviation 23.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C3D1 | -6.59 Unit on a scale | Standard Deviation 22.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C7D1 | -8.54 Unit on a scale | Standard Deviation 23.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C8D1 | -7.10 Unit on a scale | Standard Deviation 23.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C12D1 | -6.44 Unit on a scale | Standard Deviation 27.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C13D1 | -11.39 Unit on a scale | Standard Deviation 27.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C14D1 | -9.39 Unit on a scale | Standard Deviation 25.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C15D1 | -8.82 Unit on a scale | Standard Deviation 24.12 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C18D1 | -11.79 Unit on a scale | Standard Deviation 22.44 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C25D1 | -2.38 Unit on a scale | Standard Deviation 17.98 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C30D1 | 1.67 Unit on a scale | Standard Deviation 17.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C31D1 | 3.33 Unit on a scale | Standard Deviation 21.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C32D1 | 3.70 Unit on a scale | Standard Deviation 19.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C33D1 | -4.44 Unit on a scale | Standard Deviation 11.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C34D1 | 0.00 Unit on a scale | Standard Deviation 14.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C35D1 | -2.56 Unit on a scale | Standard Deviation 16.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking Baseline | 3.84 Unit on a scale | Standard Deviation 14.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C2D1 | 0.96 Unit on a scale | Standard Deviation 13.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C3D1 | -0.18 Unit on a scale | Standard Deviation 11.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C4D1 | -0.40 Unit on a scale | Standard Deviation 12.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C5D1 | 1.68 Unit on a scale | Standard Deviation 11.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C12D1 | -1.33 Unit on a scale | Standard Deviation 11.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C13D1 | -2.78 Unit on a scale | Standard Deviation 12.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C14D1 | -3.03 Unit on a scale | Standard Deviation 11.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C15D1 | -3.27 Unit on a scale | Standard Deviation 13.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C26D1 | -16.67 Unit on a scale | Standard Deviation 25.39 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C27D1 | -12.00 Unit on a scale | Standard Deviation 21.26 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C28D1 | -14.29 Unit on a scale | Standard Deviation 22.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C29D1 | -13.64 Unit on a scale | Standard Deviation 19.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C30D1 | -15.00 Unit on a scale | Standard Deviation 20.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C31D1 | -11.67 Unit on a scale | Standard Deviation 19.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C32D1 | -20.37 Unit on a scale | Standard Deviation 20.26 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C33D1 | -15.56 Unit on a scale | Standard Deviation 24.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C34D1 | -16.67 Unit on a scale | Standard Deviation 26.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C35D1 | -15.38 Unit on a scale | Standard Deviation 22.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C36D1 | -13.89 Unit on a scale | Standard Deviation 22.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C37D1 | -18.18 Unit on a scale | Standard Deviation 27.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C38D1 | -20.00 Unit on a scale | Standard Deviation 23.31 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C39D1 | -14.81 Unit on a scale | Standard Deviation 24.22 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss 30 day follow up | -1.75 Unit on a scale | Standard Deviation 30.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C7D1 | -3.33 Unit on a scale | Standard Deviation 22.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C8D1 | -5.71 Unit on a scale | Standard Deviation 27.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C9D1 | -2.22 Unit on a scale | Standard Deviation 26.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C13D1 | -5.26 Unit on a scale | Standard Deviation 29.94 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C14D1 | -11.11 Unit on a scale | Standard Deviation 29.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C15D1 | 6.06 Unit on a scale | Standard Deviation 25.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C16D1 | -2.56 Unit on a scale | Standard Deviation 16.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C17D1 | 0.00 Unit on a scale | Standard Deviation 21.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C18D1 | 0.00 Unit on a scale | Standard Deviation 22.22 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C19D1 | 0.00 Unit on a scale | Standard Deviation 17.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C20D1 | -3.33 Unit on a scale | Standard Deviation 18.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C21D1 | -3.33 Unit on a scale | Standard Deviation 18.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C22D1 | 0.00 Unit on a scale | Standard Deviation 17.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C23D1 | 0.00 Unit on a scale | Standard Deviation 21.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C24D1 | -4.76 Unit on a scale | Standard Deviation 23 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C25D1 | 0.00 Unit on a scale | Standard Deviation 21.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C5D1 | 1.68 Unit on a scale | Standard Deviation 17.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C6D1 | 0.00 Unit on a scale | Standard Deviation 16.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C7D1 | 0.28 Unit on a scale | Standard Deviation 17.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C8D1 | 1.54 Unit on a scale | Standard Deviation 20.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C9D1 | 1.31 Unit on a scale | Standard Deviation 18.27 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C10D1 | 0.39 Unit on a scale | Standard Deviation 18.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C11D1 | -2.08 Unit on a scale | Standard Deviation 17.26 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C12D1 | -1.78 Unit on a scale | Standard Deviation 16.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C13D1 | -0.28 Unit on a scale | Standard Deviation 20 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C14D1 | 0.00 Unit on a scale | Standard Deviation 17.27 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C15D1 | -1.31 Unit on a scale | Standard Deviation 16.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C16D1 | -2.78 Unit on a scale | Standard Deviation 18.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C23D1 | -3.23 Unit on a scale | Standard Deviation 16.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C24D1 | 0.00 Unit on a scale | Standard Deviation 16.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C25D1 | 0.60 Unit on a scale | Standard Deviation 17.26 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C26D1 | 1.92 Unit on a scale | Standard Deviation 17.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C27D1 | 0.00 Unit on a scale | Standard Deviation 15.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C28D1 | 3.97 Unit on a scale | Standard Deviation 13.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C29D1 | 0.00 Unit on a scale | Standard Deviation 15.43 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C30D1 | 0.83 Unit on a scale | Standard Deviation 14.78 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C29D1 | 4.55 Unit on a scale | Standard Deviation 21.32 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C25D1 | -1.19 Unit on a scale | Standard Deviation 19.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C31D1 | 1.67 Unit on a scale | Standard Deviation 22.88 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C32D1 | 0.00 Unit on a scale | Standard Deviation 22.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C33D1 | -2.22 Unit on a scale | Standard Deviation 23.46 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C34D1 | -8.33 Unit on a scale | Standard Deviation 20.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C35D1 | -2.56 Unit on a scale | Standard Deviation 21.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C36D1 | -2.78 Unit on a scale | Standard Deviation 22.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C37D1 | -3.03 Unit on a scale | Standard Deviation 27.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C38D1 | -3.33 Unit on a scale | Standard Deviation 29.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C5D1 | 2.52 Unit on a scale | Standard Deviation 28.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C6D1 | 3.58 Unit on a scale | Standard Deviation 24.55 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C7D1 | 0.28 Unit on a scale | Standard Deviation 25.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C8D1 | 2.78 Unit on a scale | Standard Deviation 26.62 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C9D1 | 1.31 Unit on a scale | Standard Deviation 24.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C13D1 | -7.22 Unit on a scale | Standard Deviation 30.12 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C14D1 | -6.06 Unit on a scale | Standard Deviation 27.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C15D1 | -5.88 Unit on a scale | Standard Deviation 28.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C16D1 | -7.64 Unit on a scale | Standard Deviation 27.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C17D1 | -6.20 Unit on a scale | Standard Deviation 27.46 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C18D1 | -8.13 Unit on a scale | Standard Deviation 25.58 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C19D1 | -6.67 Unit on a scale | Standard Deviation 24.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C20D1 | -3.42 Unit on a scale | Standard Deviation 23.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C31D1 | -10.00 Unit on a scale | Standard Deviation 21.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C32D1 | -11.11 Unit on a scale | Standard Deviation 22.87 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C33D1 | -15.56 Unit on a scale | Standard Deviation 24.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C34D1 | -13.89 Unit on a scale | Standard Deviation 17.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C35D1 | -10.26 Unit on a scale | Standard Deviation 16.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C36D1 | -11.11 Unit on a scale | Standard Deviation 16.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C37D1 | -15.15 Unit on a scale | Standard Deviation 17.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C38D1 | -16.67 Unit on a scale | Standard Deviation 17.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C39D1 | -11.11 Unit on a scale | Standard Deviation 16.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image 30 day follow up | 3.51 Unit on a scale | Standard Deviation 30 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C4D1 | 0.20 Unit on a scale | Standard Deviation 16.2 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C5D1 | 0.21 Unit on a scale | Standard Deviation 15.23 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C6D1 | 2.91 Unit on a scale | Standard Deviation 18.96 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C7D1 | 1.40 Unit on a scale | Standard Deviation 18.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C8D1 | -0.62 Unit on a scale | Standard Deviation 15.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C9D1 | 0.65 Unit on a scale | Standard Deviation 15.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C10D1 | 0.78 Unit on a scale | Standard Deviation 17.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C17D1 | -2.33 Unit on a scale | Standard Deviation 13.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C18D1 | -2.44 Unit on a scale | Standard Deviation 13.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C19D1 | -0.83 Unit on a scale | Standard Deviation 15.99 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C20D1 | -3.42 Unit on a scale | Standard Deviation 16.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C27D1 | 0.00 Unit on a scale | Standard Deviation 13.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C28D1 | 0.00 Unit on a scale | Standard Deviation 10.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C29D1 | 1.52 Unit on a scale | Standard Deviation 12.5 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C30D1 | 0.00 Unit on a scale | Standard Deviation 10.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C31D1 | 0.00 Unit on a scale | Standard Deviation 10.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C32D1 | -1.85 Unit on a scale | Standard Deviation 7.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C33D1 | -2.22 Unit on a scale | Standard Deviation 8.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C34D1 | 0.00 Unit on a scale | Standard Deviation 14.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C35D1 | 0.00 Unit on a scale | Standard Deviation 13.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C6D1 | -1.12 Unit on a scale | Standard Deviation 15.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C7D1 | 0.56 Unit on a scale | Standard Deviation 19.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C8D1 | -0.31 Unit on a scale | Standard Deviation 14.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C9D1 | -0.65 Unit on a scale | Standard Deviation 14.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C11D1 | -0.83 Unit on a scale | Standard Deviation 14.98 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C14D1 | -3.03 Unit on a scale | Standard Deviation 11.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C15D1 | -3.92 Unit on a scale | Standard Deviation 12.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C17D1 | -1.55 Unit on a scale | Standard Deviation 7.1 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C19D1 | -1.67 Unit on a scale | Standard Deviation 10.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C21D1 | -1.85 Unit on a scale | Standard Deviation 15.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C24D1 | -1.15 Unit on a scale | Standard Deviation 14.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C26D1 | -2.56 Unit on a scale | Standard Deviation 13.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C28D1 | 0.00 Unit on a scale | Standard Deviation 18.26 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C29D1 | 1.52 Unit on a scale | Standard Deviation 16.19 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C31D1 | 1.67 Unit on a scale | Standard Deviation 17.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C34D1 | 0.00 Unit on a scale | Standard Deviation 20.1 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C37D1 | -3.03 Unit on a scale | Standard Deviation 17.98 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C38D1 | -3.33 Unit on a scale | Standard Deviation 18.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing 30 day follow up | 4.09 Unit on a scale | Standard Deviation 21.89 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing 90 day follow up | 0.00 Unit on a scale | Standard Deviation 14.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing Baseline | 10.56 Unit on a scale | Standard Deviation 17.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C2D1 | -0.48 Unit on a scale | Standard Deviation 16.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C3D1 | -2.01 Unit on a scale | Standard Deviation 17.92 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C4D1 | -1.61 Unit on a scale | Standard Deviation 19 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C5D1 | 0.21 Unit on a scale | Standard Deviation 19.3 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C6D1 | 0.22 Unit on a scale | Standard Deviation 23.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C11D1 | -4.17 Unit on a scale | Standard Deviation 22.73 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C12D1 | -2.67 Unit on a scale | Standard Deviation 23.09 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C13D1 | -5.00 Unit on a scale | Standard Deviation 25.91 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C14D1 | -6.06 Unit on a scale | Standard Deviation 15.83 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C26D1 | -1.28 Unit on a scale | Standard Deviation 16.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C27D1 | -1.33 Unit on a scale | Standard Deviation 17.29 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C28D1 | 0.00 Unit on a scale | Standard Deviation 17.48 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C33D1 | -3.33 Unit on a scale | Standard Deviation 14.36 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C7D1 | -2.61 Unit on a scale | Standard Deviation 16.28 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C8D1 | -2.88 Unit on a scale | Standard Deviation 18.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C9D1 | -2.83 Unit on a scale | Standard Deviation 17.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C10D1 | -3.27 Unit on a scale | Standard Deviation 16.61 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C14D1 | -4.24 Unit on a scale | Standard Deviation 15.49 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C15D1 | -3.49 Unit on a scale | Standard Deviation 14.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C16D1 | -2.31 Unit on a scale | Standard Deviation 14.85 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C22D1 | -5.38 Unit on a scale | Standard Deviation 15.94 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C23D1 | -4.30 Unit on a scale | Standard Deviation 14.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C24D1 | -4.98 Unit on a scale | Standard Deviation 13.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C25D1 | -4.37 Unit on a scale | Standard Deviation 12.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C30D1 | -5.00 Unit on a scale | Standard Deviation 15.07 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C31D1 | -6.11 Unit on a scale | Standard Deviation 13.72 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C32D1 | -7.41 Unit on a scale | Standard Deviation 14.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C33D1 | -3.70 Unit on a scale | Standard Deviation 16.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C19D1 | -5.83 Unit on a scale | Standard Deviation 22.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C20D1 | -5.56 Unit on a scale | Standard Deviation 19.99 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C3D1 | -4.12 Unit on a scale | Standard Deviation 20.26 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C4D1 | -5.52 Unit on a scale | Standard Deviation 21.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C5D1 | -5.14 Unit on a scale | Standard Deviation 23.77 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C6D1 | -3.97 Unit on a scale | Standard Deviation 21.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C7D1 | -4.69 Unit on a scale | Standard Deviation 21.03 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C14D1 | -6.97 Unit on a scale | Standard Deviation 25.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C15D1 | -7.03 Unit on a scale | Standard Deviation 24.46 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C16D1 | -8.68 Unit on a scale | Standard Deviation 22.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C17D1 | -7.75 Unit on a scale | Standard Deviation 22.67 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C18D1 | -7.11 Unit on a scale | Standard Deviation 23.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C19D1 | -7.92 Unit on a scale | Standard Deviation 20.06 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C20D1 | -6.41 Unit on a scale | Standard Deviation 22.98 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C29D1 | -10.23 Unit on a scale | Standard Deviation 19.57 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C30D1 | -5.42 Unit on a scale | Standard Deviation 22.01 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C31D1 | -10.42 Unit on a scale | Standard Deviation 20.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C32D1 | -9.26 Unit on a scale | Standard Deviation 23.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C33D1 | -7.78 Unit on a scale | Standard Deviation 13.9 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C34D1 | -17.36 Unit on a scale | Standard Deviation 25.74 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C35D1 | -11.54 Unit on a scale | Standard Deviation 26.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C36D1 | -15.97 Unit on a scale | Standard Deviation 25.24 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C37D1 | -12.12 Unit on a scale | Standard Deviation 15.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C4D1 | -0.70 Unit on a scale | Standard Deviation 22.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C5D1 | -0.84 Unit on a scale | Standard Deviation 22.17 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C6D1 | -0.11 Unit on a scale | Standard Deviation 22.39 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C7D1 | -1.68 Unit on a scale | Standard Deviation 20.4 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C8D1 | -1.08 Unit on a scale | Standard Deviation 23.04 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C28D1 | -11.90 Unit on a scale | Standard Deviation 22.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C29D1 | -12.88 Unit on a scale | Standard Deviation 21.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C30D1 | -10.83 Unit on a scale | Standard Deviation 24.35 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C31D1 | -15.00 Unit on a scale | Standard Deviation 22.23 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C32D1 | -17.59 Unit on a scale | Standard Deviation 18.5 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C33D1 | -13.33 Unit on a scale | Standard Deviation 21.08 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C34D1 | -20.83 Unit on a scale | Standard Deviation 23.7 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C35D1 | -21.79 Unit on a scale | Standard Deviation 21.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C36D1 | -19.44 Unit on a scale | Standard Deviation 17.16 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C37D1 | -13.64 Unit on a scale | Standard Deviation 20.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C38D1 | -13.33 Unit on a scale | Standard Deviation 33.15 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C39D1 | -22.22 Unit on a scale | Standard Deviation 18.63 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort 30 day follow up | 0.88 Unit on a scale | Standard Deviation 29.45 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort 90 day follow up | -1.37 Unit on a scale | Standard Deviation 26.75 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C9D1 | -5.23 Unit on a scale | Standard Deviation 25.8 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C10D1 | -7.45 Unit on a scale | Standard Deviation 28.11 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C11D1 | -7.29 Unit on a scale | Standard Deviation 28.54 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C12D1 | -10.00 Unit on a scale | Standard Deviation 29.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C21D1 | -9.26 Unit on a scale | Standard Deviation 29.93 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C22D1 | -4.84 Unit on a scale | Standard Deviation 27.28 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C23D1 | -10.22 Unit on a scale | Standard Deviation 26.76 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C24D1 | -9.77 Unit on a scale | Standard Deviation 28 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C25D1 | -10.71 Unit on a scale | Standard Deviation 24.52 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C38D1 | -18.33 Unit on a scale | Standard Deviation 22.84 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C39D1 | -14.81 Unit on a scale | Standard Deviation 34.81 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety 30 day follow up | 2.34 Unit on a scale | Standard Deviation 31.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety 90 day follow up | 0.27 Unit on a scale | Standard Deviation 27.47 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others Baseline | 10.70 Unit on a scale | Standard Deviation 21.53 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C2D1 | -3.21 Unit on a scale | Standard Deviation 18.25 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C3D1 | -2.01 Unit on a scale | Standard Deviation 18.26 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C4D1 | -3.01 Unit on a scale | Standard Deviation 16.34 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C11D1 | -4.58 Unit on a scale | Standard Deviation 26.38 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C5D1 | -1.68 Unit on a scale | Standard Deviation 15.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C13D1 | -5.56 Unit on a scale | Standard Deviation 21.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C14D1 | -4.85 Unit on a scale | Standard Deviation 20.71 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C15D1 | -8.50 Unit on a scale | Standard Deviation 21.95 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C16D1 | -6.94 Unit on a scale | Standard Deviation 18.14 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C17D1 | -6.20 Unit on a scale | Standard Deviation 19.59 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C18D1 | -8.13 Unit on a scale | Standard Deviation 19.41 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C19D1 | -10.83 Unit on a scale | Standard Deviation 21.86 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C20D1 | -8.55 Unit on a scale | Standard Deviation 19.82 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C14D1 | -7.27 Unit on a scale | Standard Deviation 26.21 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C15D1 | -5.88 Unit on a scale | Standard Deviation 24.68 |
| CAPOX+ Zolbetuximab | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C16D1 | -7.64 Unit on a scale | Standard Deviation 25.02 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C25D1 | -4.17 Unit on a scale | Standard Deviation 25.75 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C4D1 | -0.99 Unit on a scale | Standard Deviation 20.39 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C26D1 | 3.70 Unit on a scale | Standard Deviation 18.22 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others 30 day follow up | 1.75 Unit on a scale | Standard Deviation 24.28 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C27D1 | 1.67 Unit on a scale | Standard Deviation 12.3 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C19D1 | -13.33 Unit on a scale | Standard Deviation 18.26 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth Baseline | 16.87 Unit on a scale | Standard Deviation 23.79 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C15D1 | -0.93 Unit on a scale | Standard Deviation 28.16 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C7D1 | -5.16 Unit on a scale | Standard Deviation 17.02 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C6D1 | 3.91 Unit on a scale | Standard Deviation 27.64 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C8D1 | -4.28 Unit on a scale | Standard Deviation 17.88 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C3D1 | 4.93 Unit on a scale | Standard Deviation 26.44 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C9D1 | -5.93 Unit on a scale | Standard Deviation 17.17 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C20D1 | 0.00 Unit on a scale | Standard Deviation 0 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C13D1 | -4.40 Unit on a scale | Standard Deviation 14.81 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C4D1 | 4.34 Unit on a scale | Standard Deviation 28.3 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C14D1 | -3.03 Unit on a scale | Standard Deviation 14.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C27D1 | -10.00 Unit on a scale | Standard Deviation 22.5 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C15D1 | -1.54 Unit on a scale | Standard Deviation 17.24 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C5D1 | 1.41 Unit on a scale | Standard Deviation 27.88 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C16D1 | 0.00 Unit on a scale | Standard Deviation 12.83 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C8D1 | 3.98 Unit on a scale | Standard Deviation 29.65 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C22D1 | -5.23 Unit on a scale | Standard Deviation 9.72 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C16D1 | 1.08 Unit on a scale | Standard Deviation 26.5 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C23D1 | -5.56 Unit on a scale | Standard Deviation 10.73 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C9D1 | 2.27 Unit on a scale | Standard Deviation 28.49 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C24D1 | -2.78 Unit on a scale | Standard Deviation 11.73 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing 30 day follow up | -3.07 Unit on a scale | Standard Deviation 19 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C29D1 | 1.85 Unit on a scale | Standard Deviation 13.26 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia Baseline | 17.29 Unit on a scale | Standard Deviation 24.69 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C17D1 | -2.67 Unit on a scale | Standard Deviation 23.41 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C28D1 | -9.09 Unit on a scale | Standard Deviation 21.56 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C4D1 | -8.19 Unit on a scale | Standard Deviation 21.14 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C18D1 | -6.35 Unit on a scale | Standard Deviation 28.61 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C18D1 | -4.76 Unit on a scale | Standard Deviation 26.43 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C19D1 | -5.00 Unit on a scale | Standard Deviation 17.18 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C5D1 | -7.58 Unit on a scale | Standard Deviation 23.75 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C20D1 | -7.02 Unit on a scale | Standard Deviation 26.83 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C26D1 | -1.85 Unit on a scale | Standard Deviation 28.19 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C5D1 | -5.35 Unit on a scale | Standard Deviation 18.59 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C3D1 | -6.08 Unit on a scale | Standard Deviation 20.52 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C6D1 | -5.98 Unit on a scale | Standard Deviation 22.96 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C4D1 | -8.19 Unit on a scale | Standard Deviation 21.18 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C19D1 | -1.67 Unit on a scale | Standard Deviation 7.45 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C5D1 | -7.22 Unit on a scale | Standard Deviation 22.12 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C7D1 | -5.33 Unit on a scale | Standard Deviation 24.19 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C6D1 | -6.03 Unit on a scale | Standard Deviation 23.04 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C6D1 | -4.02 Unit on a scale | Standard Deviation 20.53 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C13D1 | -7.99 Unit on a scale | Standard Deviation 25.5 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C14D1 | -7.39 Unit on a scale | Standard Deviation 22.17 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C19D1 | -1.67 Unit on a scale | Standard Deviation 13.13 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C15D1 | -6.25 Unit on a scale | Standard Deviation 21.02 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C14D1 | -5.68 Unit on a scale | Standard Deviation 24.1 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C16D1 | -6.72 Unit on a scale | Standard Deviation 20.23 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C7D1 | -5.07 Unit on a scale | Standard Deviation 20.66 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C17D1 | -3.33 Unit on a scale | Standard Deviation 21.52 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C17D1 | -2.67 Unit on a scale | Standard Deviation 24.38 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C18D1 | -10.32 Unit on a scale | Standard Deviation 21.23 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C29D1 | -8.33 Unit on a scale | Standard Deviation 20.72 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C19D1 | -9.17 Unit on a scale | Standard Deviation 14.02 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C24D1 | -11.11 Unit on a scale | Standard Deviation 29.59 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C28D1 | 2.27 Unit on a scale | Standard Deviation 7.54 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C8D1 | -5.05 Unit on a scale | Standard Deviation 21.46 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C29D1 | -3.47 Unit on a scale | Standard Deviation 19.29 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C25D1 | -9.72 Unit on a scale | Standard Deviation 30.53 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C13D1 | -6.94 Unit on a scale | Standard Deviation 22.76 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C26D1 | -1.85 Unit on a scale | Standard Deviation 13.03 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C9D1 | -9.39 Unit on a scale | Standard Deviation 20.44 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C27D1 | -1.67 Unit on a scale | Standard Deviation 14.59 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C21D1 | -5.00 Unit on a scale | Standard Deviation 16.31 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C10D1 | -7.38 Unit on a scale | Standard Deviation 19.93 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C23D1 | -4.17 Unit on a scale | Standard Deviation 20.64 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C3D1 | -4.17 Unit on a scale | Standard Deviation 18.36 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C11D1 | -9.62 Unit on a scale | Standard Deviation 21.21 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C4D1 | -5.82 Unit on a scale | Standard Deviation 21.53 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia 30 day follow up | 2.19 Unit on a scale | Standard Deviation 27.53 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C5D1 | -7.88 Unit on a scale | Standard Deviation 19.87 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing 90 day follow up | -1.69 Unit on a scale | Standard Deviation 21.94 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C6D1 | -7.01 Unit on a scale | Standard Deviation 20.57 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia 90 day follow up | -0.21 Unit on a scale | Standard Deviation 23.19 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C7D1 | -6.67 Unit on a scale | Standard Deviation 21.48 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C12D1 | -7.60 Unit on a scale | Standard Deviation 18.65 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C8D1 | -9.17 Unit on a scale | Standard Deviation 21.81 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort Baseline | 25.38 Unit on a scale | Standard Deviation 25.42 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C28D1 | 3.03 Unit on a scale | Standard Deviation 22.13 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C25D1 | -5.56 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C29D1 | -1.39 Unit on a scale | Standard Deviation 11.14 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C2D1 | -6.94 Unit on a scale | Standard Deviation 24.18 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C13D1 | -7.64 Unit on a scale | Standard Deviation 22.27 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C6D1 | -9.31 Unit on a scale | Standard Deviation 27.28 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C5D1 | -2.63 Unit on a scale | Standard Deviation 18.03 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C7D1 | -9.20 Unit on a scale | Standard Deviation 24.54 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C14D1 | -6.06 Unit on a scale | Standard Deviation 20.99 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C8D1 | -9.94 Unit on a scale | Standard Deviation 25.87 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C5D1 | -2.42 Unit on a scale | Standard Deviation 17.09 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C12D1 | -5.85 Unit on a scale | Standard Deviation 25.49 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C15D1 | -5.56 Unit on a scale | Standard Deviation 19.92 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C13D1 | -8.33 Unit on a scale | Standard Deviation 29.97 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort 30 day follow up | 1.32 Unit on a scale | Standard Deviation 27.99 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing Baseline | 9.82 Unit on a scale | Standard Deviation 19.49 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C8D1 | -8.87 Unit on a scale | Standard Deviation 29.79 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C14D1 | -3.79 Unit on a scale | Standard Deviation 27.81 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C9D1 | -6.96 Unit on a scale | Standard Deviation 26.04 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C16D1 | -5.91 Unit on a scale | Standard Deviation 22.17 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C10D1 | -11.60 Unit on a scale | Standard Deviation 32.4 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C17D1 | -6.00 Unit on a scale | Standard Deviation 28.41 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C11D1 | -8.69 Unit on a scale | Standard Deviation 31.35 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C6D1 | -1.84 Unit on a scale | Standard Deviation 18.33 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C12D1 | -8.19 Unit on a scale | Standard Deviation 31.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C23D1 | -9.38 Unit on a scale | Standard Deviation 23.55 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C21D1 | -11.67 Unit on a scale | Standard Deviation 35.91 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C29D1 | -2.78 Unit on a scale | Standard Deviation 17.16 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C22D1 | -7.84 Unit on a scale | Standard Deviation 40.45 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C28D1 | 0.00 Unit on a scale | Standard Deviation 0 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C23D1 | -10.42 Unit on a scale | Standard Deviation 35.42 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C24D1 | -5.56 Unit on a scale | Standard Deviation 32.05 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C24D1 | -9.72 Unit on a scale | Standard Deviation 41.72 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image 30 day follow up | 5.26 Unit on a scale | Standard Deviation 26.7 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C25D1 | -11.11 Unit on a scale | Standard Deviation 40.41 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C25D1 | -8.33 Unit on a scale | Standard Deviation 31.38 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C7D1 | -2.93 Unit on a scale | Standard Deviation 19.41 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C26D1 | 3.70 Unit on a scale | Standard Deviation 20.03 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety 30 day follow up | 3.51 Unit on a scale | Standard Deviation 26.15 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C4D1 | -0.59 Unit on a scale | Standard Deviation 16.05 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety 90 day follow up | -4.22 Unit on a scale | Standard Deviation 31.29 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking Baseline | 3.60 Unit on a scale | Standard Deviation 12.4 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others Baseline | 10.51 Unit on a scale | Standard Deviation 22.36 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C27D1 | 0.00 Unit on a scale | Standard Deviation 13.61 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C2D1 | -3.09 Unit on a scale | Standard Deviation 19.04 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C2D1 | -0.31 Unit on a scale | Standard Deviation 9.64 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C3D1 | -3.06 Unit on a scale | Standard Deviation 19.15 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C12D1 | -8.19 Unit on a scale | Standard Deviation 22.96 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C4D1 | -7.10 Unit on a scale | Standard Deviation 21.57 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C3D1 | -1.02 Unit on a scale | Standard Deviation 11.65 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C11D1 | -2.35 Unit on a scale | Standard Deviation 26.02 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C28D1 | 1.52 Unit on a scale | Standard Deviation 13.85 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C5D1 | -5.45 Unit on a scale | Standard Deviation 23.37 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C12D1 | -4.09 Unit on a scale | Standard Deviation 14.18 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C4D1 | 0.99 Unit on a scale | Standard Deviation 14.28 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C13D1 | 0.00 Unit on a scale | Standard Deviation 16.84 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C5D1 | -2.63 Unit on a scale | Standard Deviation 16.04 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C14D1 | -4.55 Unit on a scale | Standard Deviation 13.62 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C5D1 | -0.81 Unit on a scale | Standard Deviation 11.01 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C15D1 | -0.93 Unit on a scale | Standard Deviation 9.71 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C29D1 | -1.39 Unit on a scale | Standard Deviation 11.14 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C16D1 | -1.08 Unit on a scale | Standard Deviation 16.06 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C12D1 | 0.58 Unit on a scale | Standard Deviation 7.69 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C17D1 | 0.00 Unit on a scale | Standard Deviation 16.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C8D1 | -3.67 Unit on a scale | Standard Deviation 18.89 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C18D1 | -3.17 Unit on a scale | Standard Deviation 14.55 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C13D1 | -1.39 Unit on a scale | Standard Deviation 15.31 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C19D1 | -1.67 Unit on a scale | Standard Deviation 7.45 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C28D1 | 3.03 Unit on a scale | Standard Deviation 10.05 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C14D1 | 0.00 Unit on a scale | Standard Deviation 16.07 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C14D1 | -2.27 Unit on a scale | Standard Deviation 26.31 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C6D1 | 0.00 Unit on a scale | Standard Deviation 18.84 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C15D1 | 0.00 Unit on a scale | Standard Deviation 21.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C15D1 | -1.85 Unit on a scale | Standard Deviation 13.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C16D1 | 1.08 Unit on a scale | Standard Deviation 16.06 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C25D1 | -11.11 Unit on a scale | Standard Deviation 25.95 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C17D1 | 4.00 Unit on a scale | Standard Deviation 17.53 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C29D1 | 8.33 Unit on a scale | Standard Deviation 15.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C18D1 | 4.76 Unit on a scale | Standard Deviation 15.94 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C26D1 | -11.11 Unit on a scale | Standard Deviation 16.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C19D1 | 3.33 Unit on a scale | Standard Deviation 14.91 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C2D1 | -0.77 Unit on a scale | Standard Deviation 18.59 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C28D1 | 0.00 Unit on a scale | Standard Deviation 14.91 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C27D1 | -13.33 Unit on a scale | Standard Deviation 23.31 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C29D1 | -2.78 Unit on a scale | Standard Deviation 17.16 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C7D1 | -1.33 Unit on a scale | Standard Deviation 18.16 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C28D1 | -6.06 Unit on a scale | Standard Deviation 13.48 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C9D1 | -2.27 Unit on a scale | Standard Deviation 19.95 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C29D1 | -8.33 Unit on a scale | Standard Deviation 15.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C8D1 | -3.06 Unit on a scale | Standard Deviation 16.06 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C10D1 | -2.95 Unit on a scale | Standard Deviation 19.39 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C9D1 | -3.56 Unit on a scale | Standard Deviation 19.75 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C14D1 | -6.82 Unit on a scale | Standard Deviation 23.38 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C10D1 | -4.22 Unit on a scale | Standard Deviation 20.23 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C16D1 | -4.30 Unit on a scale | Standard Deviation 20.62 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C3D1 | 5.27 Unit on a scale | Standard Deviation 20.55 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C4D1 | 5.52 Unit on a scale | Standard Deviation 24.31 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C11D1 | -2.82 Unit on a scale | Standard Deviation 18.47 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C5D1 | 8.08 Unit on a scale | Standard Deviation 25.01 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C5D1 | 0.61 Unit on a scale | Standard Deviation 22.83 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C21D1 | -3.33 Unit on a scale | Standard Deviation 14.91 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C7D1 | 9.33 Unit on a scale | Standard Deviation 25.96 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C17D1 | -6.67 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C9D1 | 6.47 Unit on a scale | Standard Deviation 25.16 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C11D1 | 4.23 Unit on a scale | Standard Deviation 26.39 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C6D1 | -1.38 Unit on a scale | Standard Deviation 26.61 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C12D1 | 0.00 Unit on a scale | Standard Deviation 21.82 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C3D1 | -0.68 Unit on a scale | Standard Deviation 19.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C7D1 | -0.80 Unit on a scale | Standard Deviation 25.56 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C19D1 | 1.67 Unit on a scale | Standard Deviation 7.45 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C7D1 | -4.60 Unit on a scale | Standard Deviation 17.19 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C20D1 | 7.02 Unit on a scale | Standard Deviation 13.96 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C18D1 | -6.35 Unit on a scale | Standard Deviation 22.65 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C21D1 | 10.00 Unit on a scale | Standard Deviation 15.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C8D1 | -8.97 Unit on a scale | Standard Deviation 20.13 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C22D1 | 5.88 Unit on a scale | Standard Deviation 13.1 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C8D1 | 0.00 Unit on a scale | Standard Deviation 24.43 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C23D1 | 8.33 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C9D1 | -9.52 Unit on a scale | Standard Deviation 26.13 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C24D1 | 2.78 Unit on a scale | Standard Deviation 9.62 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C11D1 | -4.23 Unit on a scale | Standard Deviation 25.15 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C25D1 | 5.56 Unit on a scale | Standard Deviation 12.97 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C13D1 | -6.67 Unit on a scale | Standard Deviation 21.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C22D1 | -3.92 Unit on a scale | Standard Deviation 16.17 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C12D1 | -2.34 Unit on a scale | Standard Deviation 22.59 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C23D1 | -6.25 Unit on a scale | Standard Deviation 18.13 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C14D1 | 4.76 Unit on a scale | Standard Deviation 12.6 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C27D1 | 0.00 Unit on a scale | Standard Deviation 0 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C19D1 | -5.00 Unit on a scale | Standard Deviation 16.31 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C28D1 | -3.03 Unit on a scale | Standard Deviation 10.05 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C15D1 | -4.76 Unit on a scale | Standard Deviation 12.6 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C29D1 | 2.78 Unit on a scale | Standard Deviation 9.62 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C13D1 | 0.00 Unit on a scale | Standard Deviation 26.63 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C16D1 | -6.67 Unit on a scale | Standard Deviation 14.91 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C16D1 | 1.08 Unit on a scale | Standard Deviation 21.92 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C17D1 | 0.00 Unit on a scale | Standard Deviation 0 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C14D1 | -2.27 Unit on a scale | Standard Deviation 25.31 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia Baseline | 12.59 Unit on a scale | Standard Deviation 19.27 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C16D1 | 0.00 Unit on a scale | Standard Deviation 23.17 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C2D1 | -3.86 Unit on a scale | Standard Deviation 15.69 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss Baseline | 12.55 Unit on a scale | Standard Deviation 23.56 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C3D1 | -4.59 Unit on a scale | Standard Deviation 16.22 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C28D1 | 6.06 Unit on a scale | Standard Deviation 13.48 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C4D1 | -5.00 Unit on a scale | Standard Deviation 17.23 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C18D1 | -5.56 Unit on a scale | Standard Deviation 23.77 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C5D1 | -5.66 Unit on a scale | Standard Deviation 17.07 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C2D1 | -1.67 Unit on a scale | Standard Deviation 15.56 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C19D1 | -2.50 Unit on a scale | Standard Deviation 13.55 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C4D1 | -1.38 Unit on a scale | Standard Deviation 16.41 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C20D1 | -7.02 Unit on a scale | Standard Deviation 25.65 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C3D1 | -4.76 Unit on a scale | Standard Deviation 23.57 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C12D1 | -8.48 Unit on a scale | Standard Deviation 23.6 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C21D1 | -7.50 Unit on a scale | Standard Deviation 22.6 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C13D1 | -9.03 Unit on a scale | Standard Deviation 24.78 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C29D1 | 5.56 Unit on a scale | Standard Deviation 12.97 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C14D1 | -8.71 Unit on a scale | Standard Deviation 20.8 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C22D1 | -5.88 Unit on a scale | Standard Deviation 27.6 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C15D1 | -7.41 Unit on a scale | Standard Deviation 24.7 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C4D1 | 0.00 Unit on a scale | Standard Deviation 15.71 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C16D1 | -4.84 Unit on a scale | Standard Deviation 20.27 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C23D1 | -7.29 Unit on a scale | Standard Deviation 29.17 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C17D1 | -2.67 Unit on a scale | Standard Deviation 21.34 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C24D1 | -5.56 Unit on a scale | Standard Deviation 23.92 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C18D1 | -3.17 Unit on a scale | Standard Deviation 23.93 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C28D1 | -1.52 Unit on a scale | Standard Deviation 11.68 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C5D1 | -0.81 Unit on a scale | Standard Deviation 18.99 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia 30 day follow up | 0.73 Unit on a scale | Standard Deviation 24.63 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C29D1 | -1.39 Unit on a scale | Standard Deviation 8.58 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia 90 day follow up | -1.83 Unit on a scale | Standard Deviation 19.28 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C17D1 | 1.33 Unit on a scale | Standard Deviation 17.95 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions Baseline | 22.51 Unit on a scale | Standard Deviation 24.22 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C6D1 | -4.63 Unit on a scale | Standard Deviation 21.31 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C2D1 | -4.55 Unit on a scale | Standard Deviation 20.82 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C19D1 | -1.67 Unit on a scale | Standard Deviation 13.13 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image 90 day follow up | 6.75 Unit on a scale | Standard Deviation 29.42 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C20D1 | -4.39 Unit on a scale | Standard Deviation 24.75 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C10D1 | -8.33 Unit on a scale | Standard Deviation 28.54 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C21D1 | -2.50 Unit on a scale | Standard Deviation 27.72 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C6D1 | -1.38 Unit on a scale | Standard Deviation 16.61 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C22D1 | -1.96 Unit on a scale | Standard Deviation 26.93 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C11D1 | 3.03 Unit on a scale | Standard Deviation 17.98 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C23D1 | -4.17 Unit on a scale | Standard Deviation 24.72 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva Baseline | 5.26 Unit on a scale | Standard Deviation 15.52 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C24D1 | -6.94 Unit on a scale | Standard Deviation 26.07 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C28D1 | 3.03 Unit on a scale | Standard Deviation 16.36 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C3D1 | -8.25 Unit on a scale | Standard Deviation 21.97 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C29D1 | -1.39 Unit on a scale | Standard Deviation 8.58 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss C12D1 | 0.00 Unit on a scale | Standard Deviation 20.1 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C4D1 | -11.34 Unit on a scale | Standard Deviation 24.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C12D1 | -1.75 Unit on a scale | Standard Deviation 15.96 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C5D1 | -11.41 Unit on a scale | Standard Deviation 26.21 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss 30 day follow up | 2.38 Unit on a scale | Standard Deviation 30.56 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C2D1 | -1.85 Unit on a scale | Standard Deviation 14.62 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C9D1 | -8.09 Unit on a scale | Standard Deviation 26.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Hair Loss 90 day follow up | 15.15 Unit on a scale | Standard Deviation 26.68 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C10D1 | -8.23 Unit on a scale | Standard Deviation 28.48 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C21D1 | -1.67 Unit on a scale | Standard Deviation 20.16 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux 30 day follow up | 0.44 Unit on a scale | Standard Deviation 26.1 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C11D1 | -8.22 Unit on a scale | Standard Deviation 28.99 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C6D1 | -3.45 Unit on a scale | Standard Deviation 19 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C10D1 | -6.75 Unit on a scale | Standard Deviation 18.7 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C15D1 | -4.17 Unit on a scale | Standard Deviation 29.11 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C11D1 | -5.95 Unit on a scale | Standard Deviation 19.41 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching Baseline | 14.11 Unit on a scale | Standard Deviation 21.01 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C12D1 | -5.65 Unit on a scale | Standard Deviation 16.15 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C16D1 | -5.38 Unit on a scale | Standard Deviation 28.35 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C3D1 | -1.19 Unit on a scale | Standard Deviation 15.97 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C17D1 | -1.78 Unit on a scale | Standard Deviation 11.86 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C25D1 | -5.56 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C18D1 | -4.23 Unit on a scale | Standard Deviation 10.82 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C2D1 | -3.09 Unit on a scale | Standard Deviation 14.93 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C19D1 | -2.78 Unit on a scale | Standard Deviation 7.1 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C26D1 | -3.70 Unit on a scale | Standard Deviation 20.03 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C20D1 | -2.92 Unit on a scale | Standard Deviation 11.01 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C13D1 | -4.17 Unit on a scale | Standard Deviation 18.99 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C21D1 | -3.33 Unit on a scale | Standard Deviation 13.05 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C25D1 | -3.70 Unit on a scale | Standard Deviation 10.94 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C27D1 | -3.33 Unit on a scale | Standard Deviation 18.92 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C26D1 | 2.47 Unit on a scale | Standard Deviation 9.26 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C3D1 | -1.87 Unit on a scale | Standard Deviation 16.94 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C27D1 | 0.00 Unit on a scale | Standard Deviation 5.24 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C28D1 | 0.00 Unit on a scale | Standard Deviation 21.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dysphagia C28D1 | 1.01 Unit on a scale | Standard Deviation 5.99 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C11D1 | -4.69 Unit on a scale | Standard Deviation 18.94 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C4D1 | -3.16 Unit on a scale | Standard Deviation 18.81 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C21D1 | -10.00 Unit on a scale | Standard Deviation 23.82 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C14D1 | -1.52 Unit on a scale | Standard Deviation 21.51 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C22D1 | -5.88 Unit on a scale | Standard Deviation 31.7 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C17D1 | -5.33 Unit on a scale | Standard Deviation 22.42 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C23D1 | -8.33 Unit on a scale | Standard Deviation 29.81 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C12D1 | -4.68 Unit on a scale | Standard Deviation 19.35 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C24D1 | -8.33 Unit on a scale | Standard Deviation 29.73 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C18D1 | -3.17 Unit on a scale | Standard Deviation 27.19 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C25D1 | -9.72 Unit on a scale | Standard Deviation 32.14 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing 30 day follow up | 1.32 Unit on a scale | Standard Deviation 28.51 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C7D1 | -5.07 Unit on a scale | Standard Deviation 22.32 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C15D1 | 0.93 Unit on a scale | Standard Deviation 24.54 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C8D1 | -6.27 Unit on a scale | Standard Deviation 24.35 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing 90 day follow up | 1.27 Unit on a scale | Standard Deviation 25.29 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C9D1 | -7.52 Unit on a scale | Standard Deviation 22.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C19D1 | -2.50 Unit on a scale | Standard Deviation 11.18 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C10D1 | -8.54 Unit on a scale | Standard Deviation 26.75 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C6D1 | 0.46 Unit on a scale | Standard Deviation 11.78 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C11D1 | -9.39 Unit on a scale | Standard Deviation 27.17 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C13D1 | -2.78 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C12D1 | -9.36 Unit on a scale | Standard Deviation 22.33 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C7D1 | -0.53 Unit on a scale | Standard Deviation 11.19 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C13D1 | -10.59 Unit on a scale | Standard Deviation 21.59 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C20D1 | -9.21 Unit on a scale | Standard Deviation 20.95 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C20D1 | -7.02 Unit on a scale | Standard Deviation 21.74 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C21D1 | -10.00 Unit on a scale | Standard Deviation 19.61 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C8D1 | -1.22 Unit on a scale | Standard Deviation 13.55 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C22D1 | -12.25 Unit on a scale | Standard Deviation 22.46 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C7D1 | -1.87 Unit on a scale | Standard Deviation 19.54 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C23D1 | -12.50 Unit on a scale | Standard Deviation 19.95 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C9D1 | 0.32 Unit on a scale | Standard Deviation 13.6 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C24D1 | -6.25 Unit on a scale | Standard Deviation 20.45 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C21D1 | -5.00 Unit on a scale | Standard Deviation 23.63 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C25D1 | -8.33 Unit on a scale | Standard Deviation 18.46 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C10D1 | -1.27 Unit on a scale | Standard Deviation 15.51 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C26D1 | -2.78 Unit on a scale | Standard Deviation 17.68 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C14D1 | -3.79 Unit on a scale | Standard Deviation 25.13 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions C27D1 | -3.33 Unit on a scale | Standard Deviation 13.72 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C11D1 | -1.41 Unit on a scale | Standard Deviation 13.14 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching C22D1 | -4.90 Unit on a scale | Standard Deviation 28.73 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C16D1 | -1.08 Unit on a scale | Standard Deviation 16.06 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C17D1 | -4.00 Unit on a scale | Standard Deviation 22.19 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions 30 day follow up | 0.88 Unit on a scale | Standard Deviation 23.47 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C17D1 | 2.67 Unit on a scale | Standard Deviation 13.33 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating Restrictions 90 day follow up | -0.42 Unit on a scale | Standard Deviation 23.19 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C15D1 | -6.48 Unit on a scale | Standard Deviation 23.66 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux Baseline | 16.11 Unit on a scale | Standard Deviation 22.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C18D1 | 3.17 Unit on a scale | Standard Deviation 14.55 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C2D1 | -4.01 Unit on a scale | Standard Deviation 18.66 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C18D1 | -4.76 Unit on a scale | Standard Deviation 19.11 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C19D1 | 1.67 Unit on a scale | Standard Deviation 7.45 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C9D1 | -11.00 Unit on a scale | Standard Deviation 20.82 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C20D1 | -7.02 Unit on a scale | Standard Deviation 23.78 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C10D1 | -10.34 Unit on a scale | Standard Deviation 22.69 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C20D1 | 1.75 Unit on a scale | Standard Deviation 13.49 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux C11D1 | -11.03 Unit on a scale | Standard Deviation 24.23 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C10D1 | -2.11 Unit on a scale | Standard Deviation 27.39 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C18D1 | -3.17 Unit on a scale | Standard Deviation 17.97 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort C27D1 | -3.33 Unit on a scale | Standard Deviation 15.32 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Pain and Discomfort 90 day follow up | -2.95 Unit on a scale | Standard Deviation 23.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C21D1 | 3.33 Unit on a scale | Standard Deviation 18.42 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety Baseline | 42.05 Unit on a scale | Standard Deviation 28.3 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C21D1 | -5.00 Unit on a scale | Standard Deviation 27.09 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C2D1 | -7.02 Unit on a scale | Standard Deviation 25.23 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C22D1 | 0.00 Unit on a scale | Standard Deviation 20.41 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C3D1 | -6.04 Unit on a scale | Standard Deviation 25.63 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C8D1 | -1.22 Unit on a scale | Standard Deviation 20.75 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C4D1 | -7.20 Unit on a scale | Standard Deviation 26.96 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C23D1 | -2.08 Unit on a scale | Standard Deviation 19.12 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C5D1 | -6.77 Unit on a scale | Standard Deviation 27.66 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C22D1 | -5.88 Unit on a scale | Standard Deviation 24.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C6D1 | -8.51 Unit on a scale | Standard Deviation 29.14 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C24D1 | 0.00 Unit on a scale | Standard Deviation 24.62 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C7D1 | -8.80 Unit on a scale | Standard Deviation 26.23 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C20D1 | -3.51 Unit on a scale | Standard Deviation 18.9 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C25D1 | 2.78 Unit on a scale | Standard Deviation 17.16 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C13D1 | -6.60 Unit on a scale | Standard Deviation 31.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C23D1 | -10.42 Unit on a scale | Standard Deviation 23.47 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C14D1 | -5.68 Unit on a scale | Standard Deviation 31.53 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C26D1 | 3.70 Unit on a scale | Standard Deviation 11.11 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C15D1 | -6.02 Unit on a scale | Standard Deviation 33.13 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching 30 day follow up | 0.66 Unit on a scale | Standard Deviation 19.52 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C16D1 | -3.76 Unit on a scale | Standard Deviation 37.44 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C27D1 | 3.33 Unit on a scale | Standard Deviation 10.54 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C17D1 | -6.67 Unit on a scale | Standard Deviation 34.69 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C23D1 | -6.25 Unit on a scale | Standard Deviation 21.84 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C18D1 | -10.32 Unit on a scale | Standard Deviation 37.07 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C28D1 | 3.03 Unit on a scale | Standard Deviation 10.05 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C19D1 | -2.50 Unit on a scale | Standard Deviation 27.72 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Belching 90 day follow up | -1.90 Unit on a scale | Standard Deviation 17.5 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C20D1 | -8.77 Unit on a scale | Standard Deviation 35.73 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking C29D1 | 2.78 Unit on a scale | Standard Deviation 9.62 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C26D1 | 3.70 Unit on a scale | Standard Deviation 34.13 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C26D1 | 11.11 Unit on a scale | Standard Deviation 16.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C27D1 | 6.67 Unit on a scale | Standard Deviation 29.61 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C24D1 | -8.33 Unit on a scale | Standard Deviation 20.72 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C28D1 | 1.52 Unit on a scale | Standard Deviation 29.3 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C27D1 | 3.33 Unit on a scale | Standard Deviation 10.54 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Anxiety C29D1 | 1.39 Unit on a scale | Standard Deviation 37.24 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C22D1 | -3.92 Unit on a scale | Standard Deviation 20.01 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C25D1 | -13.89 Unit on a scale | Standard Deviation 26.43 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C9D1 | -2.91 Unit on a scale | Standard Deviation 21.44 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste 30 day follow up | 9.21 Unit on a scale | Standard Deviation 29.11 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva C26D1 | -11.11 Unit on a scale | Standard Deviation 23.57 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste 90 day follow up | 7.59 Unit on a scale | Standard Deviation 22.61 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C24D1 | -5.56 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image Baseline | 19.64 Unit on a scale | Standard Deviation 23.99 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking 30 day follow up | 2.19 Unit on a scale | Standard Deviation 15.72 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C6D1 | -4.83 Unit on a scale | Standard Deviation 21.51 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C19D1 | -1.67 Unit on a scale | Standard Deviation 7.45 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C7D1 | -4.53 Unit on a scale | Standard Deviation 20.45 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Talking 90 day follow up | 3.38 Unit on a scale | Standard Deviation 20.39 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C8D1 | -5.81 Unit on a scale | Standard Deviation 21.2 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C2D1 | -2.31 Unit on a scale | Standard Deviation 22.04 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C9D1 | -5.50 Unit on a scale | Standard Deviation 21.44 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss Baseline | 24.07 Unit on a scale | Standard Deviation 28.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C10D1 | -6.33 Unit on a scale | Standard Deviation 20.03 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C26D1 | 0.00 Unit on a scale | Standard Deviation 0 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C11D1 | -4.69 Unit on a scale | Standard Deviation 19.76 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C2D1 | 0.46 Unit on a scale | Standard Deviation 26.99 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C20D1 | 0.00 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C3D1 | -1.53 Unit on a scale | Standard Deviation 23.94 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C3D1 | 1.02 Unit on a scale | Standard Deviation 27.2 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C12D1 | 1.17 Unit on a scale | Standard Deviation 25.17 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C10D1 | -2.11 Unit on a scale | Standard Deviation 25.79 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C13D1 | -2.08 Unit on a scale | Standard Deviation 27.85 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C4D1 | -1.18 Unit on a scale | Standard Deviation 25.69 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C20D1 | 3.51 Unit on a scale | Standard Deviation 24.58 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C4D1 | -0.99 Unit on a scale | Standard Deviation 22.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C21D1 | 3.33 Unit on a scale | Standard Deviation 18.42 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C5D1 | -2.42 Unit on a scale | Standard Deviation 26.43 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C22D1 | 7.84 Unit on a scale | Standard Deviation 18.74 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C9D1 | -0.97 Unit on a scale | Standard Deviation 24.01 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C23D1 | 2.08 Unit on a scale | Standard Deviation 14.75 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C6D1 | -5.29 Unit on a scale | Standard Deviation 29.05 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C24D1 | 5.56 Unit on a scale | Standard Deviation 27.83 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C27D1 | 0.00 Unit on a scale | Standard Deviation 0 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C25D1 | 2.78 Unit on a scale | Standard Deviation 17.16 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C7D1 | -3.47 Unit on a scale | Standard Deviation 28.02 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C26D1 | 0.00 Unit on a scale | Standard Deviation 16.67 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C10D1 | -0.42 Unit on a scale | Standard Deviation 26.95 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C27D1 | 3.33 Unit on a scale | Standard Deviation 18.92 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C8D1 | -3.67 Unit on a scale | Standard Deviation 29.17 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth 30 day follow up | 5.70 Unit on a scale | Standard Deviation 26.88 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva 30 day follow up | -1.75 Unit on a scale | Standard Deviation 17.12 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth 90 day follow up | 6.75 Unit on a scale | Standard Deviation 28.43 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C9D1 | -7.12 Unit on a scale | Standard Deviation 29.76 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste Baseline | 7.47 Unit on a scale | Standard Deviation 18.5 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C11D1 | 0.94 Unit on a scale | Standard Deviation 26.41 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C2D1 | 2.47 Unit on a scale | Standard Deviation 20.69 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C10D1 | -5.91 Unit on a scale | Standard Deviation 28.12 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C29D1 | -2.78 Unit on a scale | Standard Deviation 9.62 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C6D1 | 11.72 Unit on a scale | Standard Deviation 27.65 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C11D1 | -8.45 Unit on a scale | Standard Deviation 25.65 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C8D1 | 10.40 Unit on a scale | Standard Deviation 28.58 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C20D1 | -3.51 Unit on a scale | Standard Deviation 29.18 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C12D1 | -10.53 Unit on a scale | Standard Deviation 24.53 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble Swallowing Saliva 90 day follow up | -2.95 Unit on a scale | Standard Deviation 21.48 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C10D1 | 2.95 Unit on a scale | Standard Deviation 26.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C13D1 | -10.42 Unit on a scale | Standard Deviation 25.87 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C13D1 | 3.47 Unit on a scale | Standard Deviation 19.74 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C21D1 | -8.33 Unit on a scale | Standard Deviation 23.88 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C14D1 | 1.52 Unit on a scale | Standard Deviation 22.68 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C14D1 | -6.82 Unit on a scale | Standard Deviation 23.38 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C15D1 | 1.85 Unit on a scale | Standard Deviation 23.83 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C22D1 | -5.88 Unit on a scale | Standard Deviation 21.2 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C16D1 | 3.23 Unit on a scale | Standard Deviation 15.76 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C15D1 | -8.33 Unit on a scale | Standard Deviation 30.21 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C17D1 | 8.00 Unit on a scale | Standard Deviation 14.53 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C22D1 | -3.92 Unit on a scale | Standard Deviation 30.92 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Taste C18D1 | 4.76 Unit on a scale | Standard Deviation 11.95 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C24D1 | -5.56 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C16D1 | -8.60 Unit on a scale | Standard Deviation 22.72 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C25D1 | -5.56 Unit on a scale | Standard Deviation 19.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing Baseline | 6.64 Unit on a scale | Standard Deviation 17 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others C26D1 | -3.70 Unit on a scale | Standard Deviation 11.11 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C17D1 | -13.33 Unit on a scale | Standard Deviation 21.52 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C23D1 | -8.33 Unit on a scale | Standard Deviation 28.54 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C18D1 | -14.29 Unit on a scale | Standard Deviation 27.02 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C15D1 | -7.41 Unit on a scale | Standard Deviation 21.25 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C19D1 | -11.67 Unit on a scale | Standard Deviation 16.31 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C24D1 | -5.56 Unit on a scale | Standard Deviation 34.33 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C20D1 | -12.28 Unit on a scale | Standard Deviation 25.36 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Eating in Front of Others 90 day follow up | 2.53 Unit on a scale | Standard Deviation 16.69 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C2D1 | 2.16 Unit on a scale | Standard Deviation 23.3 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C2D1 | -1.54 Unit on a scale | Standard Deviation 15 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C21D1 | -16.67 Unit on a scale | Standard Deviation 25.36 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C25D1 | -2.78 Unit on a scale | Standard Deviation 33.21 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Dry Mouth C7D1 | 0.53 Unit on a scale | Standard Deviation 28.08 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C22D1 | -17.65 Unit on a scale | Standard Deviation 26.66 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C20D1 | -5.26 Unit on a scale | Standard Deviation 22.94 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C23D1 | -22.92 Unit on a scale | Standard Deviation 29.11 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Reflux 90 day follow up | -1.69 Unit on a scale | Standard Deviation 21.28 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C2D1 | -4.63 Unit on a scale | Standard Deviation 22.2 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C26D1 | 3.70 Unit on a scale | Standard Deviation 11.11 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C3D1 | -6.04 Unit on a scale | Standard Deviation 20.37 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss C24D1 | -13.89 Unit on a scale | Standard Deviation 30.01 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C8D1 | -7.19 Unit on a scale | Standard Deviation 23.83 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Choked When Swallowing C3D1 | -1.87 Unit on a scale | Standard Deviation 17.92 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C9D1 | -7.93 Unit on a scale | Standard Deviation 24.35 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss 30 day follow up | 3.95 Unit on a scale | Standard Deviation 27.74 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C10D1 | -8.02 Unit on a scale | Standard Deviation 28.35 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Body Image C27D1 | 3.33 Unit on a scale | Standard Deviation 10.54 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C11D1 | -9.62 Unit on a scale | Standard Deviation 27.26 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Weight Loss 90 day follow up | 2.95 Unit on a scale | Standard Deviation 30.75 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C12D1 | -7.60 Unit on a scale | Standard Deviation 22.29 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Odynophagia C15D1 | -3.24 Unit on a scale | Standard Deviation 27.55 |
| CAPOX+ Placebo | Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire | Trouble with Coughing C16D1 | -8.60 Unit on a scale | Standard Deviation 19.18 |
Secondary
Duration Of Response (DOR)
DOR was defined as the time from the date of the first response (CR/PR) until the date of PD as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest.CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan-Meier estimates was used.
Time frame: From first response (CR/PR) until 61 months and 12 days
Population: FAS- All Objective Responders
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| CAPOX+ Zolbetuximab | Duration Of Response (DOR) | 6.28 Months |
| CAPOX+ Placebo | Duration Of Response (DOR) | 6.08 Months |
p-value: 0.082695% CI: [0.552, 1.105]Log Rank
Secondary
Number of Anti-drug Antibody (ADA) Positive Participants
Immunogenicity will be measured by the number of participants that are ADA positive.
Time frame: Predose on C1D1,C2D1,C5D1,C9D1,C13D1,C17D1, 30-day follow up, 90-day Follow up
Population: Participants who were Randomized to Zolbetuximab + CAPOX Arm with at least One Valid Result for ADA
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CAPOX+ Zolbetuximab | Number of Anti-drug Antibody (ADA) Positive Participants | C1D1 | 4 Participants |
| CAPOX+ Zolbetuximab | Number of Anti-drug Antibody (ADA) Positive Participants | C2D2 | 8 Participants |
| CAPOX+ Zolbetuximab | Number of Anti-drug Antibody (ADA) Positive Participants | C5D1 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Anti-drug Antibody (ADA) Positive Participants | C9D1 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Anti-drug Antibody (ADA) Positive Participants | C13D1 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Anti-drug Antibody (ADA) Positive Participants | C17D1 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Anti-drug Antibody (ADA) Positive Participants | 30 Day follow up | 5 Participants |
| CAPOX+ Zolbetuximab | Number of Anti-drug Antibody (ADA) Positive Participants | 90 Day follow up | 1 Participants |
Secondary
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An Adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.TEAE defined as an AE observed after starting administration of the study drug through 30 days after the last dose.
Time frame: From first dose until 61 months and 12 days
Population: FAS
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CAPOX+ Zolbetuximab | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 251 Participants |
| CAPOX+ Placebo | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 244 Participants |
Secondary
Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status
ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.
Time frame: Baseline, cycle (C) 1 day (D)1 through C60 D1
Population: FAS
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C60D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 0 | 108 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 1 | 34 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 0 | 23 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 1 | 27 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 2 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 0 | 22 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 1 | 24 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 2 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 0 | 26 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 1 | 21 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 0 | 22 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 1 | 21 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 0 | 24 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 1 | 19 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 0 | 23 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 1 | 17 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 0 | 17 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 1 | 15 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 2 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 0 | 20 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 1 | 14 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 0 | 19 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 1 | 13 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 0 | 17 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 1 | 14 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 0 | 19 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 1 | 11 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 0 | 17 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 1 | 11 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 0 | 17 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 1 | 7 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 0 | 17 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 1 | 7 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 0 | 15 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 1 | 7 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 0 | 15 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 1 | 7 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 0 | 13 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 1 | 6 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 0 | 11 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 1 | 5 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 0 | 11 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 1 | 3 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 0 | 10 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 1 | 5 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 0 | 10 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 1 | 6 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 0 | 9 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 1 | 5 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 0 | 8 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 1 | 5 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 0 | 8 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 1 | 3 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C40D1 Score 0 | 8 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C40D1 Score 1 | 3 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C40D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C40D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C40D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C40D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C41D1 Score 0 | 8 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C41D1 Score 1 | 3 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C41D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C41D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C41D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C41D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C42D1 Score 0 | 7 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C42D1 Score 1 | 3 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C42D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C42D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C42D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C43D1 Score 0 | 5 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C43D1 Score 1 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C43D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C43D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C43D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C43D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C44D1 Score 0 | 7 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C44D1 Score 1 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C44D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C44D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C44D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C45D1 Score 0 | 7 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C45D1 Score 1 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C45D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C45D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C45D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C45D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C46D1 Score 0 | 7 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C46D1 Score 1 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C46D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C46D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C46D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C46D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C47D1 Score 1 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C47D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C47D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C47D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C47D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C48D1 Score 0 | 5 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C48D1 Score 1 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C48D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C48D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C48D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C48D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C49D1 Score 0 | 3 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C49D1 Score 1 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C49D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C49D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C49D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C49D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C50D1 Score 0 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C50D1 Score 1 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C50D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C50D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C50D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C50D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C51D1 Score 0 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C51D1 Score 1 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C51D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C51D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C51D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C51D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C52D1 Score 0 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C52D1 Score 1 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C52D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C52D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C52D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C52D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C53D1 Score 0 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C53D1 Score 1 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C53D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C53D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C53D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C53D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C54D1 Score 0 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C54D1 Score 1 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C54D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C54D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C54D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C54D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C55D1 Score 0 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C55D1 Score 1 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C55D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C55D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C55D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C55D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C56D1 Score 0 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C56D1 Score 1 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C56D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C56D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C56D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C56D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C57D1 Score 0 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C57D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C57D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C57D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C57D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C58D1 Score 0 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C58D1 Score 1 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C58D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C58D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C58D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C58D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C59D1 Score 0 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C59D1 Score 1 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C59D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C59D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C59D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C60D1 Score 0 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C60D1 Score 1 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C60D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C60D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 1 | 145 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 0 | 85 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 0 | 80 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 1 | 116 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 0 | 68 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 0 | 71 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 1 | 86 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 2 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 3 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 2 | 1 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 1 | 57 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 2 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 0 | 39 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 1 | 47 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 2 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 0 | 41 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 1 | 45 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 0 | 39 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 0 | 24 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 1 | 30 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C42D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C44D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C47D1 Score 0 | 6 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C57D1 Score 1 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C59D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C60D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 1 | 129 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 2 | 5 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 0 | 74 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 1 | 106 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 1 | 98 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 2 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 2 | 2 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 0 | 52 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 1 | 67 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 0 | 49 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 1 | 63 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 0 | 47 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 1 | 38 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 3 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 4 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 5 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 0 | 32 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 1 | 32 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 2 | 0 Participants |
| CAPOX+ Zolbetuximab | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 0 | 33 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 0 | 108 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C45D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 1 | 142 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 0 | 14 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C43D1 Score 1 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 0 | 97 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 1 | 4 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 0 | 91 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 1 | 117 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C40D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 1 | 98 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 0 | 75 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C23D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C44D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 0 | 72 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 0 | 11 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 3 | 1 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 0 | 3 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 1 | 5 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C40D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 1 | 3 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C43D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 1 | 59 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C40D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 0 | 11 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 1 | 5 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 0 | 40 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C45D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 1 | 44 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C40D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C10D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 0 | 34 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C35D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 1 | 43 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C25D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C43D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 0 | 29 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 1 | 36 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 0 | 8 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 0 | 1 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 1 | 4 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C41D1 Score 0 | 1 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 0 | 16 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 1 | 25 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 1 | 3 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C44D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C45D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C26D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C41D1 Score 1 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 0 | 8 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 1 | 126 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 1 | 4 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 2 | 2 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C43D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C3D1 Score 2 | 2 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C36D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 0 | 79 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C41D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 2 | 2 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C2D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C4D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C27D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 0 | 3 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 1 | 98 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 0 | 8 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 2 | 2 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C41D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 1 | 4 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C5D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 1 | 80 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 1 | 1 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 2 | 3 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C43D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C6D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 0 | 60 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C7D1 Score 1 | 76 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 0 | 44 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C41D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 1 | 70 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C28D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C8D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 0 | 8 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C9D1 Score 0 | 47 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C45D1 Score 0 | 1 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 1 | 4 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C11D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C41D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C12D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C37D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C44D1 Score 0 | 1 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C29D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 0 | 20 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 0 | 2 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 1 | 28 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 0 | 4 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C42D1 Score 0 | 1 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 0 | 24 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 1 | 4 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 1 | 30 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 1 | 1 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C13D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C45D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C14D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 0 | 18 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C42D1 Score 1 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C30D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C15D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 1 | 17 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 0 | 3 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C44D1 Score 1 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 1 | 4 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C16D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 0 | 17 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C42D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 1 | 12 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C38D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C44D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C17D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C31D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 0 | 16 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 0 | 1 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 1 | 8 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 0 | 4 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C40D1 Score 1 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 1 | 4 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C42D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C18D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 0 | 14 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 1 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 1 | 8 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C42D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C19D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C32D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 0 | 15 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C45D1 Score 1 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 1 | 6 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 0 | 4 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 1 | 3 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C42D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C20D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 0 | 15 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 1 | 7 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C44D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C39D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C21D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C33D1 Score 5 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 0 | 12 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C43D1 Score 0 | 1 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 1 | 5 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 0 | 4 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 2 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C40D1 Score 0 | 1 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 3 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C34D1 Score 1 | 3 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C24D1 Score 4 | 0 Participants |
| CAPOX+ Placebo | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | C22D1 Score 4 | 0 Participants |
Secondary
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as was assessed by IRC per RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.
Time frame: From the date of randomization until 61 months and 12 days
Population: FAS
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CAPOX+ Zolbetuximab | Objective Response Rate (ORR) | 42.5 Percentage of Participants |
| CAPOX+ Placebo | Objective Response Rate (ORR) | 39.1 Percentage of Participants |
p-value: 0.2219Cochran-Mantel-Haenszel
Secondary
Overall Survival (OS)
OS was defined as the time from the date of randomization until the date of death from any cause. Kaplan-Meier estimates was used.
Time frame: From the date of randomization until 61 months and 12 days
Population: FAS
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| CAPOX+ Zolbetuximab | Overall Survival (OS) | 14.32 Months |
| CAPOX+ Placebo | Overall Survival (OS) | 12.16 Months |
p-value: 0.004795% CI: [0.622, 0.936]Log Rank
Secondary
Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough)
Ctrough was defined as the predose concentration at the end of dosing interval.
Time frame: Predose on C2D1,C5D1,C9D1,C13D1,C17D1
Population: Pharmakokinetic analysis set (PKAS) consisted of the subset of the SAF for which at least 1 zolbetuximab concentration measurement was available. Participants with available data at each timepoint were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAPOX+ Zolbetuximab | Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough) | C2D1 | 38.6 micrograms/mililiter (ug/mL) | Standard Deviation 31.3 |
| CAPOX+ Zolbetuximab | Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough) | C5D1 | 74.1 micrograms/mililiter (ug/mL) | Standard Deviation 51.6 |
| CAPOX+ Zolbetuximab | Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough) | C9D1 | 99.6 micrograms/mililiter (ug/mL) | Standard Deviation 58.2 |
| CAPOX+ Zolbetuximab | Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough) | C13D1 | 119.0 micrograms/mililiter (ug/mL) | Standard Deviation 55.6 |
| CAPOX+ Zolbetuximab | Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough) | C17D1 | 147.0 micrograms/mililiter (ug/mL) | Standard Deviation 70.5 |
Secondary
Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30
TTCD: time from randomization to first CMFD that was confirmed at the next scheduled visit.The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status/QoL, which are scored 1 (very poor) to 7 (excellent). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. Clinically meaningful deterioration was defined if a participant's CFB exceeded a pre-specified threshold (as per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used.
Time frame: From the date of randomization until 61 months and 12 days
Population: FAS
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| CAPOX+ Zolbetuximab | Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30 | 9.40 Months |
| CAPOX+ Placebo | Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30 | 7.49 Months |
p-value: 0.16795% CI: [0.655, 1.153]Log Rank
Secondary
Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching Subscale
TTCD:time from randomization to first CMFD confirmed at next scheduled visit.OG25 evaluated gastric & gastroesophageal junction cancer-specific symptoms,had 25 items with 6 scales:dysphagia,eating restrictions,reflux,odynophagia,pain, discomfort,anxiety,and 10 single items:trouble with(taste, swallowing saliva, coughing, talking),eating in front of others,dry mouth,body image,choked when swallowing,weight loss and hair loss. STO22: gastric cancer quality of life questionnaire with 22 questions.For OG25 and STO22,items scored on(1:not at all; 2:a little, 3:quite a bit, 4:very much) and 1 question was yes or no for STO22.Linear transformation was used; score ranged from 0 to 100; higher score=better level of functioning or greater degree of symptoms. An item from STO22 instrument related to belching was used with OG25. CMFD: if participant's CFB exceeded pre-specified threshold (per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used
Time frame: From the date of randomization until 61 months and 12 days
Population: FAS
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| CAPOX+ Zolbetuximab | Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching Subscale | NA Months |
| CAPOX+ Placebo | Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching Subscale | 25.82 Months |
p-value: 0.447895% CI: [0.673, 1.577]Log Rank
Secondary
Time to Confirmed Deterioration (TTCD) Using Physical Functioning as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)
TTCD: time from randomization to first clinically meaning full deterioration (CMFD) that was confirmed at the next scheduled visit. The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status which are scored 1 ('very poor') to 7 ('excellent'). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. Clinically meaningful deterioration was defined if a participant's change from baseline (CFB) exceeded a pre-specified threshold (as per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used.
Time frame: From the date of randomization until 61 months and 12 days
Population: FAS
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| CAPOX+ Zolbetuximab | Time to Confirmed Deterioration (TTCD) Using Physical Functioning as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) | 7.95 Months |
| CAPOX+ Placebo | Time to Confirmed Deterioration (TTCD) Using Physical Functioning as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) | 7.92 Months |
p-value: 0.465495% CI: [0.772, 1.328]Log Rank